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General introduction 
Chapter 1 
2 
Overview 
 
Sexually transmitted human papillomavirus (HPV) is usually asymptomatic but can cause 
anogenital warts (AGWs) and various anogenital and head-and-neck cancers in both men 
and women. The most important types causing cancer are HPV16 and HPV18 and the most 
important types causing AGWs are HPV6 and HPV11. To prevent HPV infection and 
associated diseases, prophylactic vaccines have been developed. In the Netherlands, free 
of charge HPV vaccination was introduced in 2009 for girls only, using the bivalent HPV 
vaccine that targets HPV16 and HPV18. The program started with a catch-up campaign for 
12- to 16-year-old girls born in 1993-1996. From 2010 onwards, HPV vaccination was 
offered to girls in the year they turn 13 years old. After implementation of vaccines in 
national immunization programs, post-implementation studies are important to assess the 
(long-term) effects of vaccination. Multiple vaccine effects can be distinguished, like the 
direct vaccine effectiveness and the impact of the vaccination program in the population. 
Because vaccination changes the force of infection, evaluation of these vaccine effects 
needs to take some methodological challenges into account. 
The goal of this thesis is to measure effects of the bivalent HPV vaccine and the HPV 
vaccination program in the Netherlands. Because it takes decades for HPV infections to 
cause cancer, we focus on the surrogate end-point HPV positivity and AGWs for which it 
takes less time to assess vaccine effects. Focusing on HPV infections will also provide unique 
insights into the HPV infection dynamics after vaccine introduction. In the following sections 
of this introductory chapter we will give a brief introduction to HPV, HPV-related diseases, 
the available HPV vaccines, and the implementation of HPV vaccination in the Netherlands. 
Moreover, we will describe the different effects of vaccination that can be distinguished 
and how these effects can be measured using a theoretical framework. We will end with 
the outline of this thesis. 
 
HPV and HPV-related diseases 
 
HPV is a small, double-stranded, non-enveloped, circular DNA virus with 8 protein-coding 
genes (6 early genes E1, E2, E4, E5, E6, and E7 that encode proteins involved in replication, 
transcription, and immune suppression; and 2 late genes L1 and L2 that encode capsid 
proteins) and a noncoding, regulatory long control region (LCR) [1]. Currently, there are over 
200 different HPV types identified, divided into the genera alpha, beta, gamma, mu, and nu. 
We will focus on the HPV types of the alpha genus that can infect the mucosal epithelia and 
are transmitted through sexual contact. There are about 50 different mucosal αHPV types, 
which differ by definition 10-30% in the L1 gene sequence [2-5]. The HPV types are generally 
classified as high-risk (hr) or low-risk (lr) HPV types based on their oncogenic potential [6]. 
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People get exposed to sexually transmitted HPV via an infected partner. Knowledge of 
the life-cycle of HPV infections is mostly based on research on cervical HPV16 infection and 
proceeds as follows [5]. Via micro-abrasions in the mucosa the virus can reach the basal cell 
layer and infect undifferentiated basal epithelial cells. Using host replication machinery, 
HPV replicates while the basal cells differentiate. When infected cells reach the epithelial 
surface the lifecycle of HPV is completed and viral particles are shed. This is called a 
productive infection [7-9]. In 80%-90% of incident infections, HPV will become undetectable 
within a few years after acquisition, with longer time to become undetectable for HPV16 
compared to other hrHPV types [10-14]. It is unknown if the virus is then truly cleared or 
present in low copy numbers at an undetectable level (latent infection) [15, 16]. In case an 
infection with a hrHPV type is not cleared, a subset of the infections can become a 
transforming infection, meaning that the E6 and E7 genes become deregulated and 
expressed in dividing basal cells. By interfering with the host cell-cycle, a transforming 
infection can drive cell proliferation, leading to uncontrolled cell growth (neoplasia) and 
ultimately invasive cancer, a process that can take decades [17, 18]. HPV-related cancers 
are preceded by precancerous lesions. For squamous cell cancers, these so called 
intraepithelial neoplasia’s are divided into stages based on the severity of the dysplasia. For 
example cervical intraepithelial neoplasia (CIN) are graded from CIN1 (low-grade lesions) to 
CIN3 (high-grade lesions). Progression and regression to and from each stage is possible, 
with lower chances to regress with higher grade lesions [19]. It has been estimated that 
CIN1, CIN2, and CIN3 will progress to cervical cancer in about 1%, 5%, and 12%-30% of the 
cases without treatment respectively [20, 21]. Progression to cancer at other anatomical 
sites is less well studied, but seems to be comparable to the cervix. Data suggest that high-
grade anal lesions progress to anal cancer in about 9%-13% of the cases within 5 years [22]. 
The life-cycle of lrHPV types is much less studied, but thought to be broadly comparable to 
the life-cycle of hrHPV types, with the exception for viral gene expression to become 
deregulated and the ability to drive cell proliferation in the basal cell layer [5]. Therefore 
lrHPV types rarely cause neoplasia or invasive cancers. Instead these types, especially lrHPV 
types 6 and 11, are more often associated with the development of AGWs and the rare 
condition recurrent respiratory papillomatosis [23, 24]. The incubation period of AGWs is 
much shorter compared to cancer and estimated to be between 3-18 months with a median 
of 6-10 months [25]. 
HPV is very prevalent and highly transmissible; it is estimated that about 80% of the 
sexually active population will acquire a sexually transmitted HPV infection at least once 
during lifetime [26]. Like other sexually transmitted infections (STIs), the main risk factors 
to acquire HPV are related to sexual risk behavior, such as the number of vaginal, anal, and 
oral sex partners. Other risk factors for an HPV infection include factors like smoking 
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behavior, oral contraceptive use, and concurrent STIs [27]. Condom use is only partially 
effective in preventing transmission and most HPV infections occur soon after sexual debut 
[28-31]. While among women in industrialized countries the peak of genital infection is 
before the mid-twenties, this is less so the case among men [12, 32-34]. 
Cancers with an established HPV etiology are cervical, vaginal, vulvar, penile, anal, and 
oropharyngeal cancer [35]. Almost all cervical cancers are caused by HPV infections and HPV 
is postulated to be a necessary cause in the cervical cancer development [36, 37]. The HPV 
attributable fraction for the other cancer sites is lower and depends on the study population 
and diagnostic measures used [37, 38]. Worldwide, the HPV attributable fraction is 
estimated to be 25% for vulvar and up to 88% for anal cancer (Table 1.1). The hrHPV types 
16 and 18 are the most import types causing cancer. About 71% of the cervical cancers are 
associated with HPV16/18. Other hrHPV types in cervical cancer, in descending order of 
importance are: 45, 33, 31, 52, 58, 35, 39, 51, 59, and 56 [39]. Together the relative 
attribution of HPV31/33/45/52/58 in cervical cancer is 18% [40]. The relative attribution of 
HPV16/18 for other cancers sites is estimated to be 64% for HPV-related vaginal cancer and 
up to 87% and 90% for HPV-related anal and oropharyngeal cancer respectively (Table 1.1) 
[40]. AGWs are most commonly caused by lrHPV types 6 and 11 that are estimated to cause 
90% of the cases [24]. 
 
Table 1.1. The global HPV attributable fraction and the relative contribution of specific HPV types 
in HPV-related cancer, per cancer site. 
 
Cancer site HPV attributable 
fraction (%) [37] 
Relative attribution of 
HPV16/18 in HPV-
related cancer (%) [40] 
Relative attribution of 
HPV31/33/45/52/58 in HPV-
related cancer (%) [40] 
Cervix 100 71 18 
Anus 88 87 8 
Oropharynx 31 90 5 
Vagina 78 64 21 
Vulva  25 79 14 
Penis 50 77 11 
 
Because HPV is very prevalent, the HPV-related disease burden is high. Worldwide, 570,000 
women were diagnosed with cervical cancer in 2018, making cervical cancer the most 
important HPV-related cancer and the 4th most common cancer in women globally (Figure 
1.1) [41]. There were much less, but still a substantial number of HPV-related anal (43,000), 
oropharyngeal (29,000), vaginal (14,000), vulvar (11,000), and penile (17,000) cancer 
diagnoses. Oropharyngeal cancer is more often observed in men, while anal cancer is 
slightly more often observed in women. Among men, having sex with another men is a 
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major risk factor for especially anal cancer and to a lesser extent oropharyngeal cancer [42]. 
Many industrialized countries have observed increases in anal, vulvar, and oropharyngeal 
cancers in recent years, which has been associated with changes in sexual risk behavior in 
recent decades [43-45]. For AGWs a reliable number of worldwide diagnoses is lacking. For 
Europe, the annual number of new AGW diagnoses was estimated to be between 380,000 
and 510,000 among women and between 340,000 and 460,000 among men [46]. 
 
 
Figure 1.1. Global estimated number of HPV-related cancer diagnoses in 2018 by cancer site and sex.  
Note: To come to these numbers the HPV attributable fraction and male-female distribution per cancer site were adapted from De 
Martel et al. 2017 [37] and projected on the number of world-wide new cancers in 2018 retrieved from Globocan 2018 [41]. 
Numbers are rounded to 2 significant digits. 
 
Also in the Netherlands the HPV-related disease burden is high and higher compared to 
other infectious diseases. The annual HPV-related disease burden was 13,900 disability-
adjusted life-year (DALY) in the period 2011-2014 [47]. In comparison, disease burden due 
to influenza was about 10,500 DALY in the period 2013-2017 [48]. In the cervical screening 
program, women are screened for precancerous lesions and early detection of cervical 
cancer, and treated if necessary. Since the introduction of screening, the incidence of 
cervical cancer and the mortality due to the disease have decreased substantially, from 12 
to 3.6/100,000 woman-years and from 5.4 to 1.1/100,000 women-years in the period 1970-
2003, respectively [49]. Despite screening, an increase in the incidence of cervical cancer 
has been observed in recent years, from 600-750 diagnoses in the period 2000-2010 to over 
800 diagnoses in 2018-2019. The yearly number of women who die due to cervical cancer 
has been stable since 2002 at 200 [50]. For the other cancer sites there is no screening 
program. Over the period 2008-2017, the total estimated yearly number of cancer 
diagnoses attributable to HPV in the Netherlands was above 1,200 and in 2017-2018 the 
estimated yearly number of AGW diagnoses was above 43,000 [51, 52]. 
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HPV vaccines 
 
To prevent HPV infection and subsequently HPV-associated diseases, prophylactic vaccines 
that target HPV have been developed. To date, 3 vaccines have been licensed in Europe; a 
bivalent (2vHPV) vaccine Cervarix®, a quadrivalent (4vHPV) vaccine Gardasil®, and a 
nonavalent (9vHPV) vaccine Gardasil9® [53-55] (Table 1.2).  
 
Table 1.2. Overview of the 3 currently available prophylactic HPV vaccines. 
 
 Bivalent HPV vaccine 
(Cervarix®) [53] 
Quadrivalent HPV vaccine 
(Gardasil®) [54] 
Nonavalent HPV vaccine 
(Gardasil9®) [55] 
Composition 
per 1 dose 
(0.5ml) 
Virus-like particle of L1 
protein of: 
Virus-like particle of L1 
protein of: 
Virus-like particle of L1 
protein of: 
HPV16  
HPV18  
20 μg 
20 μg 
HPV6 
HPV11 
HPV16  
HPV18  
20 μg 
40 μg 
40 μg 
20 μg 
HPV6 
HPV11 
HPV16  
HPV18 
HPV31 
HPV33 
HPV45 
HPV52 
HPV58 
30 μg 
40 μg 
60 μg 
40 μg 
20 μg 
20 μg 
20 μg 
20 μg 
20 μg 
Adjuvant 50 μg AS04 (3-O-desacyl-4’- 
monophosphoryl lipid A 
plus aluminum hydroxide) 
225 μg AAHS (amorphous 
aluminum 
hydroxyphosphate sulfate) 
500 μg AAHS (amorphous 
aluminum 
hydroxyphosphate sulfate)  
Target 
population 
Males and females ≥9 years 
of age 
Males and females ≥9 years 
of age 
Males and females ≥9 years 
of age 
Vaccination 
scheme 
Intramuscular 
9- to 14-year-olds: 2 doses, 
at 0,6 monthsa 
≥15-year-olds: 3 doses, at 
0,1,6 monthsb 
Intramuscular 
9- to 13-year-olds: 2 doses, 
at 0,6 months 
≥14-year-olds: 3 doses, at 
0,2,6 monthsc 
Intramuscular 
9- to 14-year-olds: 2 doses, 
at 0,6-12 monthsd 
≥15-year-olds: 3 doses, at 
0,2,6 monthse 
Indications Protection against HPV-
related: 
- Precancerous cervical, 
vulvar, vaginal, and anal 
lesions; 
- Cervical and anal cancers 
 
Protection against HPV-
related: 
- Precancerous cervical, 
vulvar, vaginal, and anal 
lesions; 
- Cervical and anal cancers; 
- Genital warts  
Protection against HPV-
related: 
- Precancerous cervical, 
vulvar, vaginal, and anal 
lesions; 
- Cervical, vulvar, vaginal, 
and anal cancers; 
- Genital warts  
Notes a. 2nd dose can be given 
between 5-13 months. 
b. 2nd dose can be given 
between 1-2.5 months after 1st 
dose. 3th dose can be given 
between 5-12 months after 1st 
dose. 
c. 2nd dose should be given >1 
month after 1st dose. 3th dose 
should be given >3 months after 
the 2nd dose and <12 months 
after 1st dose. 
d. 2nd dose can be given between 
5-13 months . 
e. 2nd dose should be given >1 
month after 1st dose. 3th dose 
should be given >3 months after 
the 2nd dose and <12 months 
after 1st dose. 
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All 3 vaccines contain virus-like particles (VLPs) of the major capsid L1 protein of several 
HPV types. Since VLPs contain no viral DNA the vaccines cannot infect cells, reproduce, or 
cause disease. The number of HPV types that are targeted, differs per vaccine; all 3 vaccines 
contain VLPs of the most oncogenic types 16 and 18; the 4vHPV and 9vHPV vaccine also 
contain VLPs of the lrHPV types 6 and 11; the 9vHPV vaccine additionally contains VLPs of 
the hrHPV types 31, 33, 45, 52, and 58. The 3 vaccines are licensed for males and females 
from the age of 9 years and indicated to prevent anogenital (pre)cancers caused by vaccine 
types. The 4vHPV and 9vHPV vaccine are also indicated to prevent AGWs. For 9- to 13/14-
year-olds, vaccination is given in a 2-dose schedule, while 3 doses of vaccine are required 
for those who are older at the moment of vaccination. All 3 vaccines have acceptable safety 
profiles [53-57]. 
Generally the efficacy of vaccines is measured in double blinded randomized controlled 
trials (RCTs), where participants are randomly allocated to receive the vaccine under study 
(intervention arm) or a placebo (control arm). In a trial setting with successful 
randomization, there will be no differences between the intervention and control arm that 
could confound the effects of vaccination. Moreover blinding to the vaccine will neutralize 
possible placebo effects. In an RCT it is therefore assumed that differences in disease 
occurrence between arms can only be attributed to the effect of the vaccine of interest. 
RCTs often use different analyses to evaluate the vaccine efficacy; intention-to-treat (ITT), 
per-protocol (PP), or a variant of these two. ITT analysis generally means evaluation of all 
participants according to the allocated arm, independent of the actual (number of) vaccine 
doses they received. PP analysis generally means evaluation of the participants without 
protocol violations, usually only including those who actually received the vaccine they were 
allocated to with the correct dosing schedule [58]. For HPV, the distinction between ITT and 
PP was also based on the HPV DNA and HPV antibody status at the moment of vaccination. 
The ITT cohorts included those with and without evidence of prior HPV exposure, while the 
PP cohorts were restricted those HPV DNA negative and HPV seronegative (as a proxy for 
absence of prior exposure). 
RCTs to study the HPV vaccine efficacy have mainly focused on 15- to 26-year-old 
women using a 3-dose schedule and on protection against cervical HPV. The RCTs were not 
conducted in the eventual target population of (pre)adolescents because of practical 
reasons. Trials in this age group would have required follow-up for a really long time, due 
to the age of sexual activity and the long time to develop clinical disease after acquiring an 
infection. Because cancer development can take decades, the HPV vaccine efficacy was 
measured against HPV (persistent) infections and precancerous lesions as surrogate 
endpoints for cancer. This is also the reason why the vaccines are not indicated to prevent 
oropharyngeal cancer; due to the absence of well-defined precancerous lesions for 
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oropharyngeal cancer, studying the vaccine efficacy against this disease is very time-
consuming. For the 4vHPV vaccine the efficacy was also measured against AGWs. In the 
evaluation of vaccine efficacy, several subpopulations have been made according to the 
HPV DNA and HPV antibody status at the moment of vaccination. The population being HPV 
DNA negative and HPV seronegative at the moment of vaccination was assumed to be the 
best approximation for the target population of (pre)adolescents before sexual debut [59]. 
However, it is important to note that HPV DNA and serologic measures will underestimate 
the true level of (prior) HPV exposure, as people could have a latent infection, not all people 
seroconvert after an infection, and antibodies may wane over time [60, 61]. 
Most RCTs and with the longest follow-up were those with the 2vHPV and 4vHPV vaccine 
and most vaccine efficacy measures come from these trials. The trails have shown high 
vaccine efficacy against persistent infections, AGWs in the case of the 4vHPV vaccine, and 
precancerous cervical lesions with the HPV vaccine types, especially in those who were HPV 
DNA negative and HPV seronegative (generally well over 90%) [56, 62]. The trials showed 
that vaccination is not effective against HPV infections prevalent at the time of vaccination, 
meaning that vaccination does not speed up clearance. However among women with HPV 
DNA of 1 vaccine type present, the vaccine was still effective in preventing infections with 
the other type(s) [63]. The vaccine efficacy among women who were HPV seropositive when 
vaccinated was less but still substantial (>66% against persistent cervical infection with the 
vaccine types) [64, 65]. These results demonstrate the prophylactic nature of the vaccines 
and the importance of vaccination before HPV exposure. Although the vaccines do not have 
a therapeutic effect on prevalent infections, vaccination might still prevent future infections 
but this is not well studied. Next to the high vaccine efficacy against the vaccine types, the 
RCTs of the 2vHPV and the 4vHPV vaccines also hinted towards cross-protection against 
non-vaccine types, with generally higher and broader signs of cross-protection for the 
2vHPV compared to the 4vHPV vaccine. However, the results of type-specific cross-
protection were less conclusive and dependent on the population and outcome studied. 
Moreover, the duration of the cross-protection has been questioned [66]. 
There are less RCTs that studied the vaccine efficacy for other anatomical sites. In studies 
of the 4vHPV vaccine, vaccine efficacy was high against low-grade vulvar and vaginal lesions 
among women without evidence of prior exposure (>90%) [67]. In post-hoc analyses of a 
2vHPV vaccine trial, vaccine efficacy was estimated against one-time detection of vulvar, 
anal, and oral HPV infection among women, which were comparable to estimates against 
cervical infection [68-70]. 
There are also much less RCTs among males [71]. In 2 trials, both using the 4vHPV 
vaccine, the vaccine efficacy has been studied among 16- to 26-year-old men. Results of 
these trials were comparable to the results among women, with high vaccine efficacy 
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against HPV vaccine-type related penile and anal persistent infections and external penile 
and anal lesions, among those who were HPV DNA negative and seronegative (vaccine 
efficacy ranging between 78% and 100%) [72-74]. 
The RCTs have shown that all 3 HPV vaccines induce high antibody responses against the 
vaccine types, demonstrating that the vaccines are highly immunogenic [59, 75]. 
Immunobridging studies were used to extrapolate the vaccine efficacy as measured in the 
RCTs to other target populations or vaccine schedules. Assuming the antibody 
concentration is an indicator for protection, the rationale behind immunobridging is that an 
equally high antibody concentration means an equally high vaccine efficacy. For example, if 
the antibody concentration after vaccination in (pre)adolescent females is non-inferior to 
the antibody concentration in 15- to 26-year-old women among whom vaccine efficacy had 
been demonstrated, comparable vaccine efficacy is inferred. Using this principle, vaccine 
efficacy was extrapolated to younger target populations [76-78], males [77-81], and a 2-
dose schedule [81-83]. Immunobridging was also used to infer the vaccine efficacy of the 
9vHPV vaccine against the 4vHPV types 6, 11, 16, and 18 [75]. 
 
HPV vaccination program in the Netherlands 
 
In the Netherlands, free of charge 2vHPV vaccination was introduced in 2009 for girls only, 
with the main aim to prevent cervical cancer [84]. It started in 2009 with a catch-up program 
for 12- to 16-year-old girls born in 1993-1996. From 2010 onwards, HPV vaccination was 
offered to girls in the year they turn 13 years old [85, 86]. At first, vaccination was given in 
a 3-dose schedule (given at 0, 1, 6 months). In 2014, the vaccination schedule was changed 
to a 2-dose schedule (given at 0, 6 months) for girls under the age of 15 years, based on the 
results of immunobridging studies showing that that a 2-dose schedule given before 15 
years of age was as immunogenic as a 3-dose schedule among 15- to 26-year-old women 
[76]. For girls older than 15, the 3-dose schedule still applied [87]. The vaccination coverage 
of complete dosing varied between 45.5% and 61% depending on the birth cohort (Figure 
1.2) [88, 89]. Preliminary data from January 2020 showed an increased vaccination coverage 
of the first dose of 72% among girls born in 2006, who were offered vaccination in 2019 
[90]. 
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Figure 1.2. HPV vaccination coverage in the Netherlands by birth cohort. 
Note: Preliminary data showed an increased vaccination coverage of the first dose of HPV vaccine among girls born in 2005 (59%) 
and 2006 (72%) [90]. Source: Immunization coverage and annual reports national immunization program in the Netherlands [88, 
89]. 
 
HPV vaccine safety has been studied extensively worldwide and in the Netherlands. Based 
on these studies HPV vaccines are considered safe [91, 92]. Local reactions (like pain and 
redness at the injection site), acute reactions (like fainting), and transient systemic reactions 
(like headaches and muscle strain) are frequently reported among HPV vaccinated 
individuals. However, based on many studies, including those of the Netherlands, a 
statistically significant relation between HPV vaccination and severe side effects (like 
chronic fatigue or auto-immune diseases) have not been found [85, 93]. 
 
Measuring vaccine effects 
 
After implementation of vaccines in national immunization programs, observational studies 
are required to assess the (long-term) effects of vaccination on the occurrence of the 
infection in a population at large. Because vaccination will lower the force of infection (rate 
at which susceptible individuals acquire an infection), the evaluation of the effects of 
vaccination needs to take into account some methodological challenges [94]. To measure 
different vaccine effects that can be distinguished, we will follow the theoretical framework 
as proposed Halloran et al. [94] and adapted by Hanquet et al. [95] and focus on the direct 
vaccine effectiveness and impact of vaccination (Figure 1.3). Direct vaccine effectiveness is 
related to the direct protection of the vaccine itself (individual-level effect), while the 
impact is related to the effects of a vaccination program in the total population (population-
level effects) [95]. A more detailed description of the direct vaccine effectiveness and 
impact of vaccination and how they can be measured is provided below. 
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Figure 1.3. Theoretical framework to distinguish and measure different type of vaccine effects, 
adapted from Halloran et al. [94] and Hanquet et al. [95]. 
Note: The control population constitutes a population without an established vaccination program, while the intervention 
population constitutes a population with an established vaccination program. Abbreviation: VE= direct vaccine effectiveness. 
Rc=Rcu= measure of infection risk in the control population (all unvaccinated). Ri= measure of infection risk in the intervention 
population (mix between vaccinated and unvaccinated individuals). Riu= measure of infection risk among those unvaccinated in 
the intervention population. Riv= measure of infection risk among those vaccinated in the intervention population. 
 
Direct vaccine effectiveness 
The direct vaccine effectiveness is also referred to as the direct effect of vaccination under 
field conditions or field efficacy. We will refer to the direct vaccine effectiveness as VE. It 
reflects the protection of individuals vaccinated in routine practice [95, 96]. VE differs from 
vaccine efficacy in the sense that it is measured under field conditions while vaccine efficacy 
is measured in an RCT under controlled conditions and in a strict study population [96]. In 
real-life settings, the cold chain, vaccine storage, and vaccination schedules can be 
suboptimal. These conditions could possibly affect the VE, making the evaluation of VE in 
post-implementation studies important. In the case of HPV, the VE can also deviate from 
the vaccine efficacy, since the RCTs that measured vaccine efficacy included a different 
study population (15- to 26-year-old women) than the target population of HPV vaccination 
programs (preadolescent girls) [59]. Because vaccine efficacy was not directly measured in 
the target population, the evaluation of the HPV VE is even more important. 
The VE can be measured by comparing infections among vaccinated individuals with 
infections among unvaccinated individuals, in a population with an established vaccination 
program (intervention population in Figure 1.3). Usually, it is estimated as 1 minus some 
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measure of risk of infection in vaccinated relative to unvaccinated individuals (i.e. VE=1–
relative risk). Depending on the study design, this relative risk can be for instance a risk 
ratio, odds ratio, or prevalence ratio [95, 97]. In the evaluation of VE, both vaccinated and 
unvaccinated individuals should have an equal exposure to the infection and equal 
susceptibility independent of vaccination. Therefore it is important that both vaccinated 
and unvaccinated individuals belong to the same source population and are exposed to the 
same vaccination program [95]. Still, in observational studies these assumptions are 
frequently violated. For example, in studies conducted in the Netherlands there are 
differences with respect to demographics and risk behavior between women who are 
vaccinated against HPV and women who are not, either because these differences exist in 
the general population or because of selective participation in studies [98-100]. These 
differences could affect the susceptibility or risk of exposure and should therefore be taken 
into account in the VE estimation, either by controlling for it during the design or analyses 
phase or during the interpretation of the results [101]. 
 
Impact of vaccination 
The impact of a vaccination program is also referred to as the overall effect of vaccination 
in the entire population or population vaccine effectiveness [95, 102]. It reflects the 
difference in infection risk between a population with an established vaccination program 
and the infection risk in the same population without a vaccination program, i.e. the 
counterfactual. The impact captures the changes in the transmission dynamics in a 
population due to vaccination, which is usually not the case in traditional pre-licensure RCTs 
that are designed to measure the vaccine efficacy only [101]. Therefore, post-
implementation observational studies are important and needed to measure the eventual 
population-level effects of a vaccination program. The impact of a vaccination program 
consists of the weighted sum of 2 more types of vaccine effects, namely the indirect effects 
of vaccination on unvaccinated individuals and the total effects of vaccination on vaccinated 
individuals [95]. 
Indirect effects of vaccination result from reduced circulation of the vaccine-targeted 
infection, thereby reducing the risk of infection in the entire population including 
unvaccinated individuals. This indirect effect is called herd protection [103]. In case of 
sexually transmitted HPV, the sexual partners of vaccinated individuals will also benefit 
from vaccination. Because the majority of the people identify themselves as heterosexual 
[104, 105], the benefits from vaccination could extend to both sexes even in a girls-only 
vaccination program [106]. The indirect effects can be measured by comparing infections in 
unvaccinated individuals in a population with an established vaccination program, with 
infections in unvaccinated individuals in a control population without a vaccination program 
as a proxy of the counterfactual (Figure 1.3) [95, 97]. 
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The total effects of vaccination for vaccinated individuals include both direct and indirect 
effects. It reflects the combined benefits of being vaccinated (lower probability of infection 
given exposure) and being in a population with a vaccination program (lower exposure). The 
total effects can be measured by comparing infections in vaccinated individuals in a 
population with a vaccination program with infections in unvaccinated individuals in a 
control population (Figure 1.3) [95, 97]. 
The need for an intervention population with a vaccination program and a control 
population without a vaccination program is methodologically challenging. This is because 
the populations should be comparable to each other with respect to baseline force of 
infection and population characteristics, but separated to make transmission between 
these populations impossible. To overcome the latter, in many studies the control 
population constitutes a population before a vaccination program has been established and 
the intervention population constitutes a similar population after a vaccination program has 
been established. A major assumption in using such a design is that the pre-vaccination 
population is a valid post-vaccination counterfactual condition and that all relevant factors, 
other than the vaccination program, remain constant over time. This assumption is violated 
for example if there are secular trends in the target infection or if risk factors change over 
time. Another design to measure the impact of vaccination is a cluster RCT, in which clusters 
or communities are randomized to a vaccination program or not. A major assumption of 
this design is that the transmission between clusters is not possible, which is not the case 
when individuals migrate from a control cluster to an intervention cluster or conversely [95, 
97]. Moreover, the intervention and control clusters need to be comparable with respect to 
baseline force of infection and population characteristics, which is often difficult to achieve 
by randomization because of the limited number of clusters that are usually included in such 
trials. 
The magnitude of the impact of a vaccination program is influenced by a lot of factors. 
Among the most important are the VE, transmissibility of the infection, mixing patterns 
(sexual mixing in the case of HPV), vaccination coverage, and the distribution of the 
vaccination coverage in the population according to risk factors [103]. The transmission 
potential of an infection can be expressed by the basic reproduction number R0, which is 
the average number of secondary cases caused by an infected individual if all contacts are 
with susceptibles. Simply said, the higher the R0 the higher the vaccination coverage needs 
to be to eliminate the infection, classically quantified as 1–1/R0. However, this simple 
threshold theory assumes random vaccine uptake and homogenous mixing, which is often 
not the case, and need not apply in sex-specific immunization for STIs [107]. The vaccination 
coverage among risk groups and mixing patterns within and between risk groups all 
influence the impact of vaccination [108]. For example for HPV, assortative sexual mixing 
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among individuals with high sexual risk behavior can lead to maintained transmission of 
HPV and lower herd effects. In these populations, the vaccination coverage will need to be 
higher to realize a large impact of vaccination [108-110]. 
Not all effects of vaccination programs are favorable. For multi-type pathogens like HPV, 
types not targeted by the vaccine could take over the ecological nice left vacant by 
elimination of the vaccine-targeted types. This phenomenon is called type-replacement. For 
type-replacement to occur, there needs to be some sort of competition between types 
during natural infection or transmission, so that a decreasing prevalence of a vaccine type 
after vaccination implementation can lead to an increasing prevalence of a competitive non-
vaccine type [111, 112]. For HPV, type-replacement could play a role, as there are many 
different HPV types and the available vaccines only target a subset. While some believe the 
risk of HPV type-replacement is low, it cannot be excluded [113-115]. Possible type-
replacement is part of the overall impact of a vaccination program. It can be measured using 
the above described methods comparing the risk of infection between an intervention and 
control population, focusing on non-vaccine types. 
 
Aim and outline of this thesis 
 
The aim of this thesis is to measure the individual- and population-level effects of 2vHPV 
vaccination. More specifically the aim is to measure the VE of 2vHPV vaccination against 
HPV positivity and AGWs and to measure the impact of the girls-only 2vHPV vaccination 
program on the HPV prevalence in the Netherlands. 
To measure the individual- and population-level effects of 2vHPV vaccination on HPV, 
the PASSYON (PApillomavirus Surveillance among STI clinic YOungsters in the Netherlands) 
study was set-up in 2009 [116, 117]. In this repeated cross-sectional study, 16- to 24-year-
old men and women visiting sexual health centers (SHCs) throughout the Netherlands were 
tested for type-specific HPV positivity. SHCs (previously called STI clinics) in the Netherlands 
provide free STI testing and care for people at high risk for STIs, including youth up to 24 
years of age [118]. As a consequence, people visiting SHCs are generally at higher risk for 
HPV infections compared to the general population [119]. The PASSYON study started in 
2009 and was repeated every other year using the same study protocol. The first study 
round in 2009 was before HPV vaccination was implemented in the Netherlands and can be 
seen as the control population in Figure 1.3. Each subsequent study round was in the post-
vaccination era and can be seen as an intervention population in Figure 1.3, with a part of 
the population vaccinated and a part unvaccinated. Using the PASSYON study data and 
above mentioned theoretical framework, different effects of vaccination can be measured. 
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The first part of this thesis focusses on the VE of 2vHPV vaccination against HPV positivity 
among women who had been eligible for HPV vaccination in the Netherlands, i.e. women 
born in 1993 or later. We focus on the VE against the vaccine types HPV16 and HPV18 and 
on the VE against non-vaccine types to study possible cross-protection in the target 
population. In Chapter 2 the VE against genital type-specific hrHPV positivity is provided 
using data up to 6 years post-vaccination. In Chapter 3, we update the measures of VE 
against genital HPV using data up to 8 years post-vaccination and including lrHPV types. 
Moreover, to substantiate cross-protection reported across the RCTs, the VE against non-
vaccine HPV types is related to the phylogenetic distance of these types towards the vaccine 
types. Chapter 4 assesses the VE against type-specific anal HPV positivity among women. 
The second part of this thesis focusses on the impact of the HPV vaccination program in 
the Netherlands on the HPV prevalence in the population. The impact of a vaccination 
program cannot be captured in an RCT, highlighting the importance of post-implementation 
observational studies. In Chapter 5 trends in the HPV16 and HPV18 prevalence among 
female and heterosexual male visitors of SHCs are provided from pre-vaccination up to 6 
years post-vaccination with the main aim to study herd effects. In Chapter 6, the aim is to 
study herd effects for vaccine and cross-protective HPV types and possible type-
replacement. We provide trends in the type-specific HPV prevalence for hrHPV as well as 
lrHPV types from pre-vaccination up to 8 years post-vaccination among women and 
heterosexual men. In Chapter 7, we studied the impact of the girls-only vaccination program 
on the HPV prevalence among men who have sex with men (MSM) up to 8 years post-
vaccination. Moreover to study prior HPV exposure, we assessed the proportion of MSM 
who were HPV DNA and HPV seronegative when visiting the SHC, which informs the 
opportunities for targeted vaccination in this high-risk group. 
Although the 2vHPV vaccine is not indicated to prevent HPV6 or HPV11 infections, there 
are indications the 2vHPV vaccine might provide protection against AGWs. However results 
regarding this protection have been inconclusive. The third part of this theses focusses on 
the VE of 2vHPV vaccination against AGWs among women who had been eligible for HPV 
vaccination in the Netherlands. In Chapter 8, we calculate the effect of HPV vaccination on 
the occurrence of AGWs diagnosed at the SHC using data from the PASSYON study. In this 
chapter, we also calculate the effect of HPV vaccination on the most important types 
causing AGWs, HPV6/11 positivity. Because most AGWs are diagnoses by general 
practitioners, in Chapter 9 we assess the VE of 2vHPV vaccination against AGWs, using data 
from general practitioners linked to the vaccination registry. 
Last, in Chapter 10 the main findings of this thesis are summarized and discussed. Future 
perspectives are given for measuring the effects of HPV vaccination. 
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Abstract 
 
Introduction: Observational post-marketing studies are important to assess vaccine 
effectiveness (VE). We estimated VE from the bivalent human papillomavirus (HPV) vaccine 
against HPV positivity of vaccine and non-vaccine types in a high-risk population. 
 
Methods: We included all vaccine-eligible women from the PASSYON study, a biennial 
cross-sectional survey in Dutch sexually transmitted infection clinics. Cervicovaginal swabs 
were analyzed using a polymerase chain reaction-based assay (SPF10-LiPA25) able to detect 
the 12 high-risk HPV (hrHPV) types 16/18/31/33/35/39/45/51/52/56/58/59. We compared 
hrHPV positivity between self-reported vaccinated (≥1 dose) and unvaccinated women, and 
estimated VE by a logistic mixed model. 
 
Results: We included 1,087 women of which 53% were hrHPV positive and 60% reported to 
be vaccinated. The adjusted pooled VE against HPV16/18 was 89.9% (95% confidence 
interval 81.7%-94.4%). Moreover, we calculated significant VE against non-vaccine types 
HPV45 (91%), HPV35 (57%), HPV31 (50%), and HPV52 (37%). Among women who were 
offered vaccination 5/6 years ago, we estimated similar VE against HPV16/18 (92%) and all 
hrHPV types (35%) compared to women who were offered vaccination <5 years ago (83% 
and 33%, respectively). 
 
Discussion: We demonstrated high VE of the bivalent vaccine against HPV16/18 and cross-
protection against HPV45/35/31/52. Protection against HPV16/18 was sustained up to 6 
years post-vaccination. 
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Introduction 
 
Human papillomavirus (HPV) is a sexually transmitted virus that is considered a necessary 
factor in the development of cervical cancer [1]. Many different HPV types have been 
identified and classified as high-risk HPV (hrHPV) or low-risk HPV (lrHPV) based on their 
oncogenic potential [2]. HrHPV types 16 and 18 are associated with approximately 71% of 
all cervical cancer cases. Other hrHPV types frequently identified in cervical cancers 
(together in approximately 21% of the cancers) are 31, 33, 35, 45, 52, and 58 [3]. Prevention 
of infection with HPV16/18 and other hrHPV by means of prophylactic vaccination provides 
a tremendous opportunity to prevent cancer [4]. 
To date, 3 vaccines have been licensed for the prevention of HPV-related cancer, 
providing direct protection against 2, 4, or 9 HPV types. The national immunization program 
(NIP) of the Netherlands uses the bivalent HPV (2vHPV) vaccine Cervarix®, which was 
licensed in 2007 and targets HPV types 16 and 18 [5]. The Dutch HPV vaccination program 
started in 2009 with a catch-up campaign for girls born in 1993-1996 (12-16 years old). From 
2010 onwards, girls are offered vaccination in the year they turn 13 years old, starting with 
birth cohort 1997 [6]. 
The 2vHPV vaccine trials invariably showed high efficacy against persistent HPV16/18 
infection and associated precancer lesions of over 90% [7]. Moreover, some level of cross-
protection against non-vaccine hrHPV types was shown in the vaccine trials, but results are 
less conclusive and dependent on the population and outcome studied [7-10]. 
Observational studies after the implementation of large-scale immunization programs 
are important to assess the vaccine effectiveness (VE) against both the vaccine and non-
vaccine types in the population at large. Direct effectiveness measures of the 2vHPV vaccine 
from observational studies are becoming available in the Netherlands [11, 12], as well as 
other countries [13-16]. These studies showed high VE from a 3-dose schedule against the 
vaccine types, ranging between 73% and 100% [12-15]. There are also indications for cross-
protection of the 2vHPV vaccine from observational studies; in a recently published paper, 
high VE against HPV31, HPV33, and HPV45 was observed among women attending their 
first cervical screening in Scotland [15]. However, type-specific estimates of VE against 
hrHPV types other than HPV16/18/31/33/45 are not yet available in a population-based 
setting. 
Knowledge about the cross-protective VE is important to understand the overall VE and 
potential clinical impact of the 2vHPV vaccination program. It is also important for vaccine 
comparisons in health economic assessments [17, 18], especially in view of the more 
recently licensed nonavalent HPV (9vHPV) vaccine that targets 5 additional hrHPV types 
associated with about 19% of all cervical cancer cases (HPV31/33/45/52/58) [19]. Here, we 
provide direct VE estimates from the 2vHPV vaccine against hrHPV DNA positivity using 
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cross-sectional data from a biennial survey in Dutch sexually transmitted infection (STI) 
clinics (PASSYON study). We present the VE against type-specific HPV DNA positivity as well 
as pooled estimates of VE. 
 
Methods 
 
Study design and population 
The PASSYON (PApillomavirus Surveillance among STI clinic YOungsters in the Netherlands) 
study is a biennial cross-sectional survey among 16- to 24-year-old STI clinic visitors that 
started in 2009, when HPV vaccination was implemented in the Netherlands (Figure 2.1). 
The study design is described in detail elsewhere [20]. Briefly, additional to the routine STI 
consultation, participants were asked to provide a self-collected genital swab for HPV 
testing and to fill in a questionnaire including self-reported vaccination status. From 
participants who provided blood for routine syphilis and HIV testing at the STI clinic, serum 
was collected for HPV serology. Initially, all people attending the STI clinic provided blood, 
but due to policy changes from 2013 onwards, only specific groups at high risk for syphilis 
or HIV provided blood. The Medical Ethical Committee of the University of Utrecht, the 
Netherlands approved this study (protocol number 08/397). Data were obtained using a 
unique code per person and all participants gave informed consent. 
To calculate the VE, we included from the PASSYON study years 2011-2015 all women 
who had been eligible for vaccination in the Netherlands (i.e. women born in 1993 or later 
[6]), who reported their vaccination status, and who provided a cervicovaginal swab. 
 
 
Figure 2.1. HPV vaccination in the Netherlands, the PASSYON study design, and the study population 
selection. 
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Laboratory methods 
Swabs were stored at −20°C until analyses. DNA was extracted using the MagnaPure 
platform (Total Nucleic Acid Isolation Kit, Roche, the Netherlands) and eluted in 100-
microliter elution buffer. HPV DNA was amplified using the SPF10 primer set. Subsequently, 
HPV-specific amplicons were detected using the DNA enzyme linked immunoassay (HPV-
DEIA, DDL Diagnostics Laboratory, the Netherlands). Amplicons of positive samples were 
genotyped with the Line probe assay (HPV-LiPA25, DDL Diagnostics Laboratory, the 
Netherlands), which is able to detect the 12 hrHPV types 16/18/31/33/35/39/45/51/52/56/ 
58/59 [20]. 
Serum samples were stored at −80°C until analyses [21]. HPV antibodies against L1 virus-
like particles for types 16 and 18 were assessed using a multiplex immunoassay. Cut-off 
levels for seropositivity were 9 Luminex Units (LU)/mL for HPV16 and 13 LU/mL for HPV18 
[22]. 
 
Validation of self-reported vaccination status 
We used serology to validate the self-reported vaccination status among those who 
provided blood. We compared the HPV16 and HPV18 seropositivity rates and antibody 
concentrations between self-reported vaccinated (≥1 dose) and unvaccinated women. To 
check the discriminative ability of antibody concentrations with respect to self-reported 
vaccination status, we calculated the area under the curve (AUC) of a receiver operating 
characteristic (ROC). 
 
Statistical analyses 
We checked for differences in potential confounders between vaccinated and unvaccinated 
women using χ2 tests. We included the demographic variables age, migration background, 
and education level. Migration background was based on (parental) country of birth. A 
woman was defined as native Dutch if both parents were born in the Netherlands [23]. 
Education level was self-reported and categorized as high and low/middle. We also included 
the number of sex partners in the past 6 months, number of lifetime sex partners, age at 
sexual debut (defined as vaginal or anal intercourse), history of STIs, condom use with casual 
partners in the past 6 months, hormonal contraceptives use, and current genital chlamydia 
or gonorrhea infection. Chlamydia and gonorrhea infection were diagnosed during the 
routine STI consultation. The other variables were self-reported and categorized (Table 2.1). 
Cervicovaginal hrHPV DNA positivity was compared between women who reported to 
be vaccinated (≥1 dose) and women who reported to be unvaccinated. Outcomes were 
type-specific hrHPV positivity, the vaccine types HPV16/18 (pooled), the hrHPV types 
included in the 9vHPV vaccine (HPV16/18/31/33/45/52/58, pooled), and all hrHPV types 
(HPV16/18/31/33/35/39/45/51/52/56/58/59, pooled). We used odds ratios (ORs) to 
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estimate the VE, which is suggested to be a suitable measure for the relative reduction in 
HPV positivity (the combination of incidence and duration of an HPV infection) from cross-
sectional data [24]. Because we were interested in the VE on an individual level to give the 
best approximation of the trial efficacy estimates, we calculated the ORs using a logistic 
mixed model, incorporating all hrHPV types and a random intercept to account for residual 
dependence between type-specific infections within individuals. This is an efficient method 
compared to standard logistic regression, because the covariates’ coefficients are estimated 
from all HPV types simultaneously and the measurement of VE against multiple HPV types 
(pooled outcomes) is specified as a weighted average [25]. All analyses were adjusted for 
the variables that were associated with vaccination status (P<.1). VE was calculated as 1 
minus the adjusted OR times 100% [26]. 
Because vaccine efficacy is reduced when recipients are HPV positive at vaccination [5, 
27], we calculated the VE against the pooled outcomes separately among women who were 
(possibly) sexually active when vaccination was offered and among women who were not 
yet sexually active when vaccination was offered. For the catch-up birth cohorts (1993-
1996), vaccination of the first dose was offered on 1 March 2009 and for the birth cohorts 
from 1997 onwards, vaccination of the first dose was offered on 1 March in the year they 
turned 13 years old [28]. We compared the self-reported age of sexual debut with the age 
when vaccination was offered, and categorized women into either not sexually active if the 
age when vaccination was offered preceded sexual debut, or (possibly) sexually active 
otherwise (including women who reported the same age of sexual debut as the age when 
vaccination was offered). Moreover, as cross-protection has been suggested to wane over 
time [29], we calculated the VE against the pooled outcomes separately among women who 
were offered vaccination <5 years ago and among women who were offered vaccination 
5/6 years ago. This categorization was chosen to have more or less equal numbers in each 
subgroup. The stratified analyses were adjusted for the variables that were associated with 
vaccination status (P<.1) as well as the age at which the women were offered vaccination. 
All analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC), using 
proc glimmix with adaptive Gauss-Hermite quadrature approximation of the maximum 
likelihood. We used a significance level of p<.05. The records with missing data were 
excluded from the analyses, as these represented less than 5% of the study population. 
 
Sensitivity analyses 
In sensitivity analyses, we calculated the type-specific and pooled estimates of VE for 
women who reported to be vaccinated with 3 doses. Moreover, we repeated the stratified 
analyses, assuming catch-up cohorts were offered vaccination 3 months later, on 31 May 
2009 because there was variation in the dates that vaccination was offered during the catch-
up campaign [28]. 
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Table 2.1. Characteristics of the study population and a comparison between vaccinated and 
unvaccinated women. 
 
 Total 
N (%) 
Unvaccinated 
N (%) 
Vaccinated (≥1 dose) 
N (%) 
 
p valuea 
Total 1087 438 649  
Age    0.50 
  16-18 years 325 (29.9) 136 (31.1) 189 (29.1)  
  19-22 years 762 (70.1) 302 (68.9) 460 (70.9)  
Migration background    <.01 
  Native Dutch 854 (78.9) 311 (71.3) 543 (83.9)  
  Not native Dutch 229 (21.1) 125 (28.7) 104 (16.1)  
Education levelb    <.01 
  Low/middle 344 (31.7) 171 (39.0) 173 (26.7)  
  High 742 (68.3) 267 (61.0) 475 (73.3)  
No. of sex partners, past 6 months   0.02 
  0-1 partners 310 (28.5) 145 (33.1) 165 (25.4)  
  2-3 partners 538 (49.5) 206 (47.0) 332 (51.2)  
  ≥4 partners 239 (22.0) 87 (19.9) 152 (23.4)  
No. of sex partners, lifetime   0.24 
  ≤3 partners 288 (26.9) 127 (29.5) 161 (25.1)  
  4-6 partners 346 (32.3) 137 (31.9) 209 (32.6)  
  ≥7 partners 438 (40.9) 166 (38.6) 272 (42.4)  
Age at sexual debutc    0.06 
  ≤14 years 192 (17.8) 91 (21.0) 101 (15.7)  
  15-16 years 558 (51.8) 221 (51.0) 337 (52.3)  
  ≥17 years 327 (30.4) 121 (27.9) 206 (32.0)  
History of any STI   0.03 
  No 575 (53.1) 213 (48.9) 362 (56.0)  
  Yes 241 (22.3) 113 (25.9) 128 (19.8)  
  Never tested 267 (24.7) 110 (25.2) 157 (24.3)  
Current genital chlamydia/gonorrhea infection  0.90 
  No  889 (82.1) 357 (82.3) 532 (82.0)  
  Yes 194 (17.9) 77 (17.7) 117 (18.0)  
Condom use with casual partners, past 6 monthsd  0.32 
  Inconsistent 510 (47.0) 199 (45.5) 311 (48.1)  
  Consistent 336 (31.0) 132 (30.2) 204 (31.5)  
  No casual partners  238 (22.0) 106 (24.3) 132 (20.4)  
History of using hormonal contraceptives   <.01 
  No 43 (4.0) 26 (6.0) 17 (2.6)  
  Yes 1029 (96.0) 404 (94.0) 625 (97.4)  
Totals vary because of missing values. 
a. Comparing women vaccinated at least once with unvaccinated women. 
b. High educational level included school of higher general secondary education, pre-university education, university of applied 
sciences, and university. Low/middle educational level included all other forms of education. 
c. Vaginal or anal intercourse. 
d. Inconsistent included reporting never, rarely and “sometimes I do, sometimes I do not” condom use. Consistent included 
reporting often or always condom use. 
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Results 
 
Study population 
In the PASSYON study years 2011-2015, 1,198 women had been eligible for HPV vaccination, 
of which 1,087 women reported their vaccination status and provided a cervicovaginal swab 
(Figure 2.1). Of these 1,087 women, 649 (60%) reported to be vaccinated and 438 (40%) 
reported to be unvaccinated. Of the women who reported to be vaccinated, 70% (n=456) 
reported to be vaccinated with 3 doses, 11% (n=72) reported <3 doses, and 19% (n=121) 
reported to not know the number of doses. Of the women who reported to be vaccinated, 
94% belonged to the catch-up cohorts (birth cohort 1993-1996). 
The characteristics of the study population, stratified by vaccination status, are 
presented in Table 2.1. Vaccinated women were more often native Dutch and highly 
educated. They had more partners in the past 6 months, were older at sexual debut, 
reported less often a history of STIs, and used hormonal contraceptives more often.   
 
Validation of self-reported vaccination status 
In total, 43% of the study population had serum available for antibody testing. Of the self-
reported vaccinated women, 96% were seropositive for both HPV16 and HPV18. Only 11 
self-reported vaccinated women (4.2%) were seronegative for HPV16 or HPV18 or both 
(Supplementary Figure 2.1). Of these 11 women, 8 reported 3 doses, 2 <3 doses, and 1 
reported not to know the number of doses. The HPV16 and HPV18 antibody concentrations 
agreed well with the self-reported vaccination status (AUC 92.3%). 
 
HPV prevalence 
 
 
Figure 2.2. High-risk HPV prevalence by vaccination status. 
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Overall, 53% tested positive for ≥1 hrHPV type. Of the vaccinated women, 49% were positive 
for an hrHPV type compared to 59% of the unvaccinated women. HPV51 was the most 
prevalent type followed by HPV52. For most hrHPV types, the prevalence was lower for 
vaccinated compared to unvaccinated women (Figure 2.2). 
 
Vaccine effectiveness estimates 
The pooled VE against the 2 vaccine types was 89.9%; 92.3% against HPV16 and 85.5% 
against HPV18 (Figure 2.3). Moreover, we calculated significant VE against the non-vaccine 
types HPV45, HPV35, HPV31, and HPV52. Although borderline non-significant, the VE 
against HPV59 was negative (−89%). The pooled VE against the hrHPV types included in the 
9vHPV vaccine was 60.5% and against all 12 hrHPV types 32.9%. 
 
 
Figure 2.3. VE for at least 1 dose against, A) type-specific hrHPV positivity and B) pooled estimates. 
Note: The hr nonavalent HPV types included: HPV16/18/31/33/45/52/58. All hrHPV types included: HPV16/18/31/33/35/39/45/ 
51/52/56/58/59. VE was corrected for: migration background, education level, number of sex partners in the past 6 months, age 
at sexual debut, history of any STI, and history of hormonal contraceptives use. 
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Results from the stratified analyses are presented in Table 2.2. Among women who were 
not sexually active when vaccination was offered, the adjusted pooled VE against the 
vaccine types (92.2%) was higher than among women who were (possibly) sexually active 
when vaccination was offered (81.1%). Among women who were offered vaccination 5/6 
years ago, we observed similar or higher VE against HPV16/18 (92.4%), the hrHPV types 
included in the 9vHPV vaccine (65.5%), and all hrHPV types (34.6%) compared to women 
who were offered vaccination <5 years ago (83.2%, 50.7%, and 33.0%, respectively). 
 
Table 2.2. VE against pooled estimates, stratified by sexual activity when vaccination was offered 
and time since vaccination was offered. 
 
 
 
VE (95% CI)a 
 N (%) HPV16/18 Hr nonavalent 
typesb 
All hrHPVc 
Women not sexually active when vaccination was offered   
  Unvaccinated 303 (37.7)    
  Vaccinated (≥1 dose) 501 (62.3) 92.2 (83.2 - 96.4) 60.1 (47.1 - 70.0) 29.6 (13.4 - 42.7) 
Women (possibly) sexually active when vaccination was offeredd  
  Unvaccinated 119 (47.6)    
  Vaccinated (≥1 dose) 131 (52.4) 81.1 (52.1 - 92.5) 60.2 (36.2 - 75.2) 39.9 (16.3 - 56.8) 
Women offered vaccination <5 years ago   
  Unvaccinated 178 (43.1)    
  Vaccinated (≥1 dose) 235 (56.9) 83.2 (57.9 - 93.3) 50.7 (23.9 - 68.1) 33.0 (10.4 - 49.8) 
Women offered vaccination 5/6 years ago   
  Unvaccinated 244 (38.1)    
  Vaccinated (≥1 dose) 397 (61.9) 92.4 (83.6 - 96.5) 65.5 (53.9 - 74.1) 34.6 (19.0 - 47.2) 
For the catch-up cohorts, vaccination was offered on 1 March 2009. For the cohorts vaccinated in the NIP, vaccination was 
offered on 1 March in the year they turn 13 years old. 
a. VE was corrected for: migration background, education level, number of sex partners in the past 6 months, age at sexual 
debut, history of any STI, history of hormonal contraceptives use, and age vaccination was offered. 
b. Including HPV types HPV16/18/31/33/45/52/58. 
c. Including HPV types HPV16/18/31/33/35/39/45/51/52/56/58/59. 
d. Includes women who reported the same age (in years) of sexual debut as the age they were offered vaccination. 
 
Sensitivity Analyses  
The VE estimates according to vaccination with 3 doses are presented in Supplementary 
Figure 2.2. Overall, results were comparable to the main analysis. The pooled VE against the 
vaccine types was somewhat higher; 94.7%. The negative VE against HPV59 became 
borderline statistically significant (−107.2%, 95% confidence interval [CI] −307.1 to −5.4). 
Assuming vaccination for the catch-up cohorts was offered 3 months later did not lead to 
different results in the stratified analyses (Supplementary Table 2.1). 
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Discussion 
 
We demonstrated high VE from the 2vHPV vaccine against the vaccine types HPV16/18 and 
significant cross-protection against the hrHPV types 45, 35, 31, and 52. Together, these 
cross-protective types are associated with approximately an additional 15% of all cervical 
cancers [3]. To our knowledge, this is the first observational study reporting VE against 
hrHPV positivity on a type-specific level for the 2vHPV vaccine. The cross-protective VE from 
the 2vHPV vaccine suggests that the impact of HPV vaccination will be greater than 
anticipated upon introduction [30]. 
The high HPV prevalence among STI clinic visitors and sensitive diagnostics to measure 
infection status, enabled us to measure the type-specific VE against HPV positivity from 
cross-sectional data. The usefulness of using data from high-risk populations to infer VE in 
an early stage after the introduction of mass vaccination has been shown by Australian 
studies; 2 years after HPV vaccination was implemented in Australia, a decline was observed 
in genital warts among young women and heterosexual men visiting sexual health services 
[31]. This declining trend was later confirmed in other settings more representative for the 
general population [32, 33]. 
We do acknowledge some limitations. First, we used self-reported vaccination status, 
which is prone to recall bias. The vaccination coverage in our study population was 
comparable to the vaccination coverage in the total Dutch population: 52% of the catch-up 
cohorts received 3 doses and this increased to 59% for birth cohort 1999; an additional 3.8% 
received <3 doses [34-36]. We showed reliable reporting of vaccination status in our study, 
but we could only validate self-reported vaccination status among women with serum 
available. Due to the recent policy changes for syphilis and HIV testing at the STI clinic 
towards high-risk individuals, women with serum available could be biased towards having 
higher antibody concentrations [37], complicating the distinction between vaccinated and 
unvaccinated women. Nevertheless, antibody concentrations performed well in 
discriminating self-reported vaccination status. Moreover, misclassification according to 
self-reported vaccination status would lead to conservative estimates of VE. Second, 
because our study population consisted mainly of women who were vaccinated during the 
catch-up campaign, some women were probably HPV infected at vaccination, leading to 
lower VE compared to an HPV-naive population [5, 27]. Indeed, we showed a higher VE 
against the vaccine types among women with a reported sexual debut after vaccination was 
offered, in line with results from the vaccine trials. Last, most women in our study were 
vaccinated according to the 3-dose schedule as this was the guideline prevailing at the time 
of vaccination, so our results might not be generalizable to the current 2-dose schedule. In 
our study, the VE against the vaccine types was higher for 3 doses compared to ≥1 dose, 
indicating a lower VE among women who did not know the number of doses or who 
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reported <3 doses. Because of a limited number of women who reported having received 2 
doses and because we did not known the interval between doses, we were unable to 
evaluate the current 2-dose schedule with 6 months between doses. 
Our results agree well with the literature. Overall, the VE that we calculated against 
HPV16/18 positivity and against cross-protective types, are in line with data from the 2vHPV 
vaccine trials [7]. In the PATRICIA trial, the largest phase III trial, cross-protection has been 
described against persistent HPV31, 33, 45, 51, and 52 infections and against incident 
HPV35 infection [8, 9]. In contrast to the PATRICIA trial, we did not find statistically 
significant cross-protection against HPV33 or HPV51. In the Costa Rica Vaccine Trial, the 
efficacy against HPV33 was, like ours, not statistically significant (32%, 95% CI −41% to 68%, 
against 6-month persistent infection) and against HPV51 negative (−56%, 95% CI −114% to 
−14%, against 6-month persistent infection) [10]. We found no effect on HPV51. Effect 
estimates from observational studies against non-vaccine HPV types are still limited. Trend 
studies found that the HPV31/33/45 prevalence decreased in post-vaccination periods 
compared to pre-vaccination periods, suggestive of cross-protection [38-40]. Among 
women who underwent their first cervical screening in Scotland, vaccine effectiveness was 
observed against HPV31, 33, and 45 [15]. 
In our study, the VE against the pooled outcomes was similar or even higher among 
women who were offered vaccination 5 or 6 years ago compared to women who were 
offered vaccination more recently. These analyses were adjusted for sexual behavior and 
age when vaccination was offered. These findings are in line with those from Scotland, 
where high VE against the vaccine types HPV16/18 and against HPV types 31, 33, and 45 
was observed up to 7 years after vaccination [15]. Due to low numbers in the stratified 
analyses, we were unable to calculate the type-specific VE by time since vaccination was 
offered. As the PASSYON study continues, we will repeat the analyses to investigate the 
duration of protection further. 
We observed a negative VE against HPV59, which was just statistically significant in 
sensitivity analysis restricted to women who reported 3 doses versus no vaccination. The 
SPF10-LiPA25 assay that we used in the current study is very sensitive, but the detection 
limit for HPV59 is much higher than for the other hrHPV types, which could lead to an 
underestimation of the HPV59 prevalence [41, 42]. Moreover, this assay is a broad-
spectrum polymerase chain reaction (PCR) in which some competition between types in the 
same sample can occur [43]. Possibly due to the reduced occurrence of vaccine and cross-
protection types, HPV59 was more often detected in vaccinated compared to unvaccinated 
women, which would lead to an artificial negative VE. This phenomenon of increased 
detection is referred to as unmasking [44]. Another possible explanation for a negative VE 
is type-replacement. This means that an HPV type is taking over the vacated ecological niche 
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of the vaccine and cross-protective types [44]. In post-hoc analyses of the PATRICIA trial, an 
alternative HPV DNA testing algorithm was used including a type-specific test that is not 
affected by competition between types. Using this type-specific test next to the SPF10-
LiPA25, the number of HPV59 cases roughly doubled, but the vaccine efficacy against HPV59 
remained (non-significantly) negative for 12-month persistent infection (−29.2%) [9]. 
Because the sensitivity of the SPF10-LiPA25 for HPV59 is limited and because the confidence 
intervals were large, the negative VE against HPV59 in our study should be interpreted with 
caution. Further research is necessary to investigate what is causing this negative VE 
estimate. 
To conclude, we showed high VE of the 2vHPV vaccine against HPV16/18 positivity and 
significant cross-protection against HPV45, HPV35, HPV31, and HPV52 in a Dutch high-risk 
population. We observed cross-protection against 3 of the 5 additional hrHPV types 
included in the 9vHPV vaccine. As the cross-protective types HPV45, HPV35, HPV31, and 
HPV52 are associated with an additional 15% of all cervical cancer cases, cross-protection 
of the 2vHPV vaccine can have a major impact on cancer prevention. 
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Supplementary information to Chapter 2 
 
 
 
Supplementary Figure 2.1. Log HPV16 and log HPV18 antibody concentration by self-reported 
vaccination status, among women with serum available.  
Note: The dashed lines represent the cut-off levels for seropositivity for HPV16 and HPV18. 
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Supplementary Figure 2.2. Sensitivity analyses: VE for 3 doses against, A) type-specific hrHPV 
positivity and B) pooled estimates. 
Note: The hr nonavalent HPV types included: HPV16/18/31/33/45/52/58. All hrHPV types included: HPV16/18/31/33/35/39/45/ 
51/52/56/58/59. VE was corrected for: migration background, education level, number of sex partners in the past 6 months, age 
at sexual debut, history of any STI, and history of hormonal contraceptives use. 
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Supplementary Table 2.1. Sensitivity analyses: VE against pooled estimates, stratified by sexual 
activity when vaccination was offered and time since vaccination was offered, assuming catch-up 
cohorts were offered vaccination on 31 May 2009. 
 
 
 
VE (95% CI)a 
 N (%) HPV16/18 Hr nonavalent typesb All hrHPVc 
Women not sexually active when vaccination was offered   
  Unvaccinated 283 (37.7)    
  Vaccinated (≥1 dose) 468 (62.3) 92.6 (83.3 - 96.7) 59.0 (45.2 - 69.3) 29.0 (12.3 - 42.6) 
Women (possibly) sexually active when vaccination was offeredd  
  Unvaccinated 139 (45.9)    
  Vaccinated (≥1 dose) 164 (54.1) 81.9 (57.0 - 92.4) 62.7 (41.8 - 76.1) 39.3 (16.9 - 55.7) 
Women offered vaccination <5 years ago   
  Unvaccinated 178 (43.1)    
  Vaccinated (≥1 dose) 235 (56.9) 83.3 (58.3 - 93.3) 51.2 (24.8 - 68.4) 33.6 (11.5 - 50.3) 
Women offered vaccination 5/6 years ago   
  Unvaccinated 244 (38.1)    
  Vaccinated (≥1 dose) 397 (61.9) 92.5 (83.7 - 96.5) 65.7 (54.2 - 74.3) 35.0 (19.5 - 47.5) 
For the catch-up cohorts, we assumed vaccination was offered on 31 May 2009. For the cohorts vaccinated in the NIP, 
vaccination was offered on 1 March in the year they turn 13 years old. 
a. VE was corrected for: migration background, education level, number of sex partners in the past 6 months, age at sexual 
debut, history of any STI, history of hormonal contraceptives use, and age vaccination was offered. 
b. Including HPV types HPV16/18/31/33/45/52/58. 
c. Including HPV types HPV16/18/31/33/35/39/45/51/52/56/58/59. 
d. Includes women who reported the same age (in years) of sexual debut as the age they were offered vaccination. 
 
 
 
 
 
 
 
  
  
 
 
Chapter 3 
Bivalent human papillomavirus (HPV) vaccine 
effectiveness correlates with phylogenetic distance 
from HPV vaccine types 16 and 18 
Johannes A. Bogaards 
Pascal van der Weele 
Petra J. Woestenberg 
Birgit H. B. van Benthem 
Audrey J. King 
The contents of this chapter have been published in The Journal of Infectious Diseases 
J Infect Dis. 2019; 220:1141-6 
Chapter 3 
46 
Abstract 
 
To substantiate cross-protection reported across AS04-adjuvanted bivalent human 
papillomavirus (HPV) vaccine (2vHPV) studies, we re-evaluated vaccine effectiveness 
against type-specific HPV positivity as a function of phylogenetic distance to vaccine target 
types HPV16 and 18. We provide evidence of sustained cross-protection up to 8 years post-
vaccination in a high-risk population in the Netherlands. Moreover, our findings suggest that 
genomic distance better explains cross-protection than distance measures based on capsid 
antigens only. Taken together, 2vHPV is predicted to provide partial cross-protection 
against HPV31, 33, 35, 45, 52, and possibly 58, that is, acknowledged oncogenic types with 
close phylogenetic relationships to HPV16 or 18. 
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Introduction 
 
The sexually transmitted human papillomavirus (HPV) is considered a necessary factor for 
development of cervical cancer and is linked to other anogenital and oropharyngeal cancer 
[1]. Papillomaviruses are characterized by genotype, defined as >10% DNA sequence 
divergence from other known genotypes (generally termed “types”) in the L1 capsid gene 
[2]. Most HPV-related malignancies are attributable to types 16 and 18. Consequently, first-
generation vaccines, based on recombinant expression of L1 in systems yielding virus-like 
particles (VLPs), focused on HPV16 and 18, with the quadrivalent (4vHPV) vaccine also 
containing L1 VLPs of HPV6 and 11, primarily associated with anogenital warts. As up to 30% 
of cervical cancer is attributed to oncogenic types other than 16 or 18, achieving broader 
protection through cross-reactivity or expansion of the range of VLP types is desirable. 
Endeavors to expand the range of VLP types have resulted in the second-generation 
nonavalent HPV (9vHPV) vaccine, containing L1 VLPs from those already contained in the 
4vHPV vaccine plus the 5 next most common types in cervical cancer: HPV types 31, 33, 45, 
52, and 58. Alternatively, the minor capsid protein L2, though less immunogenic than L1, is 
potentially an effective target for prophylaxis, as several subdominant protective epitopes 
of L2 are well conserved between types and broadly cross-protective in animal models. By 
contrast, the protection elicited by L1 VLPs is generally taken to be type-restricted (i.e. 
reactive with the homologous type) [1]. 
First-generation HPV vaccines have shown durable type-specific protection for at least 
a decade [3]. Importantly, this protection is not absolutely type-restricted, because 
significant cross-protection has been observed against several non-vaccine types, 
particularly for the AS04-adjuvanted bivalent (2vHPV) vaccine containing L1 VLPs of HPV16 
and 18 only. In the largest phase III trial of the 2vHPV vaccine, cross-protection was 
described against persistent HPV6, 31, 33, 45, 51, and 52 infections, and against incident 
HPV35 infection. However, findings with regard to non-vaccine types are equivocal, as the 
2vHPV vaccine trial from Costa Rica reported significant protection against HPV31, 45, and 
52, insignificant protection against HPV33, and no effect on HPV51 [4]. 
Recent population-based studies from the United Kingdom and the Netherlands confirm 
some cross-protection from 2vHPV in post-vaccine surveillance. In Scotland, a decrease in 
the prevalence of HPV31, 33, and 45 was observed among women who underwent their 
first cervical screening within 7 years after initiating a 2vHPV vaccination program [5]. In the 
Netherlands, significant cross-protection was estimated against HPV31, 35, 45, and 52 
among female visitors to sexually transmitted infection (STI) clinics who reported to be 
vaccinated, relative to vaccine-eligible controls [6]. Cross-protection from 2vHPV against 
HPV6 or 11 has not been replicated in post-vaccine surveillance, neither in England [7] nor 
in the Netherlands [8]. 
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To reconcile the inconsistencies in cross-protection reported across 2vHPV vaccine 
studies and to assess the type-restricted nature of the protection elicited by L1 VLPs, we re-
evaluated vaccine effectiveness (VE) against type-specific HPV positivity among STI clinic 
visitors up to 8 years after vaccination as a function of phylogenetic distance to L1 capsid 
antigens contained in the 2vHPV vaccine. 
 
Methods 
 
We estimated VE from the PASSYON study, a biennial cross-sectional survey in the 
Netherlands, as described before [6], but now with an extra study round and including all 
genotypes in the SPF10-LiPA25 assay (DDL Diagnostics Laboratory). In brief, women aged 
16-24 years, who had been eligible for HPV vaccination and visited the STI clinic between 
2011 and 2017, provided a cervicovaginal swab that was analyzed using a polymerase chain 
reaction (PCR-) based assay able to detect 25 HPV types, including 12 acknowledged and 3 
possibly oncogenic types (Table 3.1). We compared type-specific HPV positivity between 
1,305 self-reported vaccinated (≥1 dose) and 799 unvaccinated women. The self-reported 
vaccination status was validated by serology among those who also provided blood. 
Phylogenetic distance of each genotype to the 2vHPV types used for construction of 
VLPs was calculated from reference DNA sequences obtained via the papillomavirus 
episteme, a database of curated papillomavirus genomic sequences [9]. We performed a 
phylogenetic analysis on L1 amino acid (AA) composition using a general Dayhoff matrix for 
evolutionary change in L1 protein with standard codon model and multiple sequence 
alignment (www.ebi.ac.uk/Tools/msa/muscle/). In addition, we constructed phylogenetic 
trees directly from DNA sequences on the basis of L1 capsid gene, and on the basis of whole-
genome sequences (WGS). Unrooted evolutionary trees from L1 protein or DNA sequences 
were constructed by maximum likelihood with substitution model selection using IQ-TREE 
version 1.6.0 software (www.iqtree.org/). Phylogenetic distance was calculated from the 
consensus tree constructed from 1000 ultra-fast bootstrap trees [10]. Finally, we compared 
dependence on phylogenetic distance to the Hamming distance from aligned L1 sequences, 
that is, the number of positions at which the corresponding L1 proteins of reference types 
are different from the AA expressed by VLPs in 2vHPV. 
We assessed VE as a function of minimum distance to VLP AA composition in L1 protein 
analysis and as a function of minimum distance to HPV16 or 18 reference sequences in DNA 
analyses. Because the LiPA25 assay cannot distinguish between types 68/73/97, we omitted 
these types from statistical analysis. We also omitted HPV59, as the estimate of cross-
protection against this type is potentially hampered by technical issues in the assay [6]. For 
the remaining types, we fitted a penalized regression spline to the estimates from the 
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logistic mixed model, weighted by the square root of the number of positives used in VE 
estimation (Table 3.1), as a function of phylogenetic distance. The smoothness of the 
function was determined by general cross-validation, and confidence intervals (CIs) were 
obtained through Bayesian approximation. In addition, we performed weighted covariance 
analyses on the rank values of the various distance measures, stratified by (putative) 
oncogenicity of HPV types. Statistical analyses were performed with R version 3.5.1. 
 
Table 3.1. Bivalent HPV VE against type-specific HPV positivity. 
 
HPV typea  VE (95% CI)b  N (n vaccinated / 
n nonvaccinated)c 
Reference genomed Hamming 
distancee 
High-risk      
  16 0.92 (0.86 - 0.96)  100 (13/87)  gi|333031|lcl|HPV16REF.1  37  
  18 0.89 (0.7 - 80.94)  63 (11/52)  gi|60975|lcl|HPV18REF.1  41  
  31 0.66 (0.51 - 0.77)  129 (50/79)  gi|333048|lcl|HPV31REF.1  102  
  33 0.41 (0.05 - 0.63)  73 (37/36)  gi|333049|lcl|HPV33REF.1  111  
  35 0.40 (−0.03 - 0.65)  55 (28/27)  gi|396997|lcl|HPV35REF.1  105  
  39 0.15 (−0.19 - 0.39)  165 (98/67)  gi|333245|lcl|HPV39REF.1  128  
  45 0.81 (0.55 - 0.92)  28 (7/21)  gi|397022|lcl|HPV45REF.1  91  
  51 −0.24 (−0.54 - 0.01)  522 (345/177)  gi|333087|lcl|HPV51REF.1  180  
  52 0.36 (0.19 - 0.50)  342 (185/157)  gi|397038|lcl|HPV52REF.1  117  
  56 −0.17 (−0.59 - 0.14)  220 (145/75)  gi|397053|lcl|HPV56REF.1  173  
  58 0.30 (−0.06 - 0.54)  95 (52/43)  gi|222386|lcl|HPV58REF.1  113  
  59 −0.95 (−2.17 to −0.20)  96 (73/23)  gi|557236|lcl|HPV59REF.1  125  
Probable high-risk     
  53 0.26 (0.05 - 0.43)  332 (189/143)  gi|9627377|lcl|HPV53REF.1  173  
  66 0.02 (−0.26 - 0.24)  340 (212/128)  gi|1020290|lcl|HPV66REF.1  174  
  68/73/97 −0.08 (−0.63 - 0.28)  110 (71/39)  gi|71726685|lcl|HPV68REF.1  
gi|1491692|lcl|HPV73REF.1  
gi|71726694|lcl|HPV97REF.1  
139  
150  
89  
Low-risk      
  6 −0.15 (−0.52 - 0.14)  263 (172/91)  gi|60955|lcl|HPV6REF.1  161  
  11 −0.07 (−1.00 - 0.42)  45 (29/16)  gi|333026|lcl|HPV11REF.1  162  
  34 0.00 (−1.57 - 0.61)  19 (12/7)  gi|9627334|lcl|HPV34REF.1  154  
  40 0.08 (−0.68 - 0.50)  46 (28/18)  gi|397014|lcl|HPV40REF.1  163  
  42 −1.27 (−3.34 to −0.19)  57 (45/12)  gi|333211|lcl|HPV42REF.1  160  
  43 −0.78 (−2.13 to −0.01)  67 (50/17)  gi|40804474|lcl|HPV43REF.1  176  
  44 −0.32 (−1.30 - 0.24)  61 (42/19)  gi|1020242|lcl|HPV44REF.1  162  
  54 −0.34 (−0.95 - 0.08)  141 (97/44)  gi|9628437|lcl|HPV54REF.1  143  
  70 0.02 (−1.03 - 0.52)  32 (20/12)  gi|1173493|lcl|HPV70REF.1  126  
  74 0.26 (−0.19 - 0.54)  75 (42/33)  gi|27462483|lcl|HPV74REF.1  168  
a. HPV genotypes in the SPF10-LiPA25 assay, with 68 being indistinguishable from 73 and 97. 
b. VE (with 95% CI) was calculated as 1 minus the adjusted odds ratio from a logistic mixed model described in [6]. 
c. No. of positive test results (among 1305 vaccinated; 799 non-vaccinated women) used in VE estimation. 
d. Whole-genome reference DNA sequences obtained from the papillomavirus genome database (https://pave.niaid.nih.gov/). 
e. Minimum number of different amino acids between aligned L1 sequences of reference types and VLPs in bivalent vaccine. 
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Results 
 
Type-specific VE estimates are provided in Table 3.1. The pooled VE against the 2 vaccine 
types was 91.0% (95% CI, 86.0%-94.2%). Pooled VE against all (possibly) oncogenic types 
was 25.8% (95% CI, 17.7%-33.2%), whereas the pooled VE against non-oncogenic types 
included in the assay was −4.9% (95% CI, −20.7% to 8.8%). We found no indications for 
dependency of VE on time since vaccination in stratified analyses, comparing women who 
were offered vaccination <5 years ago, 5-6 years ago, or 7-8 years ago (Supplementary Table 
3.1). 
Overall, there was a clear relationship between VE and phylogenetic distance in L1 
protein analysis (Figure 3.1A). The consistently high cross-protection reported for HPV45 is 
due to its close relationship to HPV18 (Figure 3.1B). The cross-protection of around 50% 
against HPV31 and 35 fits their almost equidistant relationship to HPV16. Likewise, the 
cross-protection of around 35% against HPV33, 52, and 58 is in line with these types having 
approximately similar phylogenetic distance to HPV16. Our analysis further supports the 
notion that the estimate of VE against HPV59 appears to be an outlier.  
 
A) VE as a function of phylogenetic distance 
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B) Phylogenetic tree 
 
 
Figure 3.1. A) Bivalent HPV VE as a function of phylogenetic distance to L1 VLPs and B) phylogenetic 
tree based on L1 protein.  
Note: The VE was calculated from cross-sectional prevalence data [6] for all genotypes in the SPF10-LiPA25 assay. Phylogenetic 
distance to L1 VLPs was calculated from reference DNA sequences, using the Dayhoff model for evolutionary change in L1 protein. 
Substitution rate heterogeneity among alignment sites was incorporated by assuming γ-distributed rates plus a fraction of 
invariable sites. A) Red data points denote (possibly) oncogenic types, with HPV68 being indistinguishable from HPV73 and 97 (in 
gray). The size of each data point is plotted proportional to the number of positive test results (n) used in VE estimation. Spearman 
rank correlation (with 95% confidence limits in brackets) was calculated from all data points weighted by √n, excluding HPV59 and 
68/73/97 (open circles). The estimated spline function (in blue) is shown with 95% credible intervals (dotted lines). B) Phylogenetic 
tree based on L1 protein, with blue tips denoting reference sequences used for construction of L1 VLPs in the bivalent HPV vaccine 
and red tips denoting (possibly) oncogenic types in the SPF10-LiPA25 assay. The yellow and purple clades highlight types that are 
close enough to L1 VLPs to benefit (in principle) from cross-protection, according to predictions with 95% confidence from the 
weighted penalized regression spline in A). 
 
Of the acknowledged oncogenic types, HPV51, 56, and 66 are most distantly related to 
either L1 VLP and least likely to be affected by cross-neutralizing antibodies induced by the 
2vHPV vaccine (Supplementary Figure 3.1A). The significant rank correlation (ρ= −0.70 [95% 
CI, −0.83 to −0.51) between VE and phylogenetic distance to L1 VLP in protein analysis was 
entirely explained by oncogenic types (ρ= −0.93 [95% CI, −0.95 to −0.89]), as no significant 
correlation was observed for non-oncogenic types (Supplementary Figure 3.1B). 
Chapter 3 
52 
Analysis based on Hamming distance toward L1 VLPs yielded similar results as L1 
phylogenetic analysis (Supplementary Figure 3.2A). Phylogenetic analysis based on the L1 
capsid gene and WGS yielded slightly different depictions but was still comparable to those 
for L1 protein (Supplementary Figure 3.2B and 3.2C). To express the specific association 
between VE and each phylogenetic distance while controlling for the effect of other 
measures, we computed their partial rank correlations from the inverse weighted 
covariance matrix. Apparently, WGS phylogenetic distance to HPV16 or 18 was the 
strongest independent determinant of VE (ρpartial= −0.53, p<.01), with HPV51, 53, 56, and 66 
located around the threshold genomic distance still informative for VE. The non-oncogenic 
types were further distanced from vaccine target types in WGS analysis than in analyses 
based on capsid antigen only, and the partial rank correlations between VE and L1 distance 
measures were no longer significant when corrected for genomic distance (Supplementary 
Table 3.2). 
 
Discussion 
 
This study provides evidence of sustained cross-protection from the 2vHPV vaccine up to 8 
years post-vaccination in a high-risk population. Taken together, the 2vHPV vaccine is 
predicted to provide partial cross-protection against HPV types 31, 33, 35, 45, 52, and 
possibly 58, that is, high-risk types belonging to HPV α-7 (including HPV18) or α-9 (including 
HPV16) species [2]. Of those, HPV35 and 58 are not frequently reported among the cross-
protective types, which may be due to their relative rarity as compared to other cross-
protective types. Likewise, VE against HPV35 and 58 was not significantly different from 
zero in this study, and regression analyses based on phylogenetic distance predicted only 
small to moderate effect size. Of the other (possibly) oncogenic types, cross-protection may 
extend to HPV39 but is unlikely for HPV51, 53, 56, and 66 (i.e. high-risk types belonging to 
HPV α-5 or α-10 species) [2]. Similarly, cross-protection against low-risk types was not 
observed in our study [8] and is not to be expected on the basis of phylogenetic analyses. 
Although there has been concern about the durability of cross-reactivity, so far there is 
no evidence for the waning of cross-protection from the 2vHPV vaccine in women who have 
been vaccinated 3 times, as per initial recommendation [5, 6, 11]. Moreover, although we 
have previously shown reliable reporting of vaccination status in our study [6], our VE 
estimates and their relation with phylogenetic distance may be underestimated by 
nondifferential misclassification with regard to self-reported vaccination status. It remains 
to be seen whether cross-reactivity of the 2vHPV vaccine following vaccination with <3 
doses induces similar, long-lasting cross-protection. Analysis of the impact of 2vHPV 
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vaccination among female teenagers in the United Kingdom shows evidence of type-specific 
protection, but not cross-protection following a single dose of vaccine [12]. 
One possibility as to why cross-protection is better explained by genomic distance than 
by measures based on the L1 capsid protein is that L1 VLP may induce cross-neutralizing 
antibodies to L2 that are critical in preventing viral entry into the host cell [1]. Moreover, 
the adjuvant AS04 in the 2vHPV vaccine has been suggested to induce a T-cell response that 
enhances local innate control and provides help for subsequent adaptive immunity [13]. 
Although the mechanisms of adaptive immunity are still ambiguous, it is worthwhile to 
point out that 2vHPV vaccination results not only in reduced incidence rates, but also in 
reduced viral load in breakthrough infections [14], suggesting that VE extends to control of 
infection post-acquisition. AS04 is particularly effective in activating antigen-presenting 
cells, inducing cytokines and a T-helper 1-type response, leading to inhibition of viral 
transcription or translation [1]. Such features could contribute to cross-protective humoral 
and cellular control of HPV infections, and may be boosted by natural exposure to non-
vaccine HPV types. 
Cross-protection can be expected to mitigate the potential for type-replacement by 
acting as a substitute of latent competitive pressures induced by vaccine types. Thus, 
oncogenic types that do not benefit from cross-reactivity should be considered foremost in 
evaluating type-replacement in the wake of vaccination. In this context, the negative VE 
against HPV59 might stem from differential sensitivity of the SPF10-LiPA25 assay in 
vaccinees relative to non-vaccinated controls [6], and not from type-replacement. A Finnish 
community randomized trial on the population effects of 2vHPV vaccination, using a 
different PCR-based assay than ours, found no indications for type-replacement by HPV59 
[15]. Instead, HPV39 and HPV51 were marked as potential culprits for an increased post-
vaccination occurrence. 
To summarize, our analysis indicates that cross-protection from the 2vHPV vaccine is 
sustained up to 8 years post-vaccination and that the level of protection correlates with 
genomic distance to HPV16 or 18. This suggests that the benefits of 2vHPV vaccination may 
extend to clinically relevant non-vaccine types, given that oncogenic potential of 
papillomaviruses itself has a phylogenetic basis [1-3]. Further studies will reveal to what 
extent cross-protection induced by the 2vHPV vaccine will contribute to HPV-related 
disease prevention. 
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Supplementary information to Chapter 3 
 
Supplementary Table 3.1. Bivalent HPV VE against pooled estimates.  
 
 N (%) VE (95% CI)a 
  HPV16/18 (possibly) oncogenic 
typesb 
non-oncogenic 
typesc 
All women 
  Unvaccinated 799 (38.0) 
91.0 (86.0 - 94.2) 25.8 (17.7 - 33.2) −4.9 (−20.7 - 8.8) 
  Vaccinated (≥1 dose) 1305 (62.0) 
Women offered vaccination <5 years agod 
  Unvaccinated 185 (42.5) 
85.4 (60.9 - 94.5) 20.6 (−2.3 - 38.4) 5.9 (−31.3 - 32.6) 
  Vaccinated (≥1 dose) 250 (57.5) 
Women offered vaccination 5/6 years ago 
  Unvaccinated 306 (37.7) 
92.1 (83.9 - 96.2) 30.6 (18.3 - 41.3) −14.2 (−42.8 - 8.6) 
  Vaccinated (≥1 dose) 505 (62.3) 
Women offered vaccination 7/8 years ago 
  Unvaccinated 308 (35.9) 
91.7 (83.4 - 95.8) 24.5 (11.4 - 35.7) −0.4 (−24.4 - 18.9) 
  Vaccinated (≥1 dose) 550 (64.1) 
a. VE was corrected for: age, migration background, education level, no. of sex partners in past 6 months, no. of lifetime sex 
partners, age at sexual debut, history of any STI, history of hormonal contraceptives use, STI-related symptoms, and age 
vaccination was offered. 
b. Including HPV types HPV16/18/31/33/35/39/45/51/52/56/58/59/66/68 (73/97). 
c. Including HPV types HPV6/11/34/40/42/43/44/53/54/70/74. 
d. Time since vaccination offered was calculated from the date of sampling relative to the scheduled date of vaccination, 
according to year of birth and the official schedule of HPV immunization in the Netherlands. For the catch-up cohorts, 
vaccination was offered on 1 March 2009. For the cohorts vaccinated routinely in the national immunization program, 
vaccination was offered on 1 March in the year they turn 13 years old. 
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A) (Possibly) oncogenic types 
 
B) Non-oncogenic types 
 
Supplementary Figure 3.1. Bivalent HPV VE versus phylogenetic distance to L1 VLP, by oncogenicity. 
Note: Data points in A) and B) are similar to those in Figure 3.1A but include 95% CIs for VE. Spearman’s rank correlation (with 95% 
confidence limits in brackets) in A) applies to (possibly) oncogenic types, excluding HPV59 and 68, whereas the correlation in B) 
applies to non-oncogenic types, excluding HPV73 and 97. The correlation in A) was ρ= −0.88 (95% CI: −0.93; −0.78) when also 
excluding HPV16 and 18 (i.e. for non-vaccine types only).  
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A) Hamming distance 
 
B) L1 capsid genes 
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C) Whole genome sequences 
 
Supplementary Figure 3.2. Bivalent HPV VE as a function of alternative distance measures from HPV16 
and 18.  
Note: In all panels, the size of each data point is plotted proportional to the number of positive test results n used in VE estimation, 
and Spearman’s rank correlations (with 95% confidence limits in brackets) were calculated from all data points weighted by √n, 
excluding HPV59 and 68/73/97 (open circles). Red data points denote (possibly) oncogenic types in the SPF10-LiPA25 assay (Table 
3.1), with HPV68 being indistinguishable from HPV73 and 97 (in grey). Hamming distance in A) expresses the number of positions 
at which the L1 proteins of reference types have different amino acids than the VLPs in 2vHPV. Phylogenetic distance on L1 capsid 
genes in B) was calculated from reference DNA sequences, using the transversion model (AG=CT) and unequal base frequencies 
counted from the data [9]. Substitution rate heterogeneity among alignment sites was incorporated by assuming Gamma-
distributed rates plus a fraction of invariable sites. Phylogenetic distance on whole genome sequences (WGS) in C) was calculated 
from reference DNA sequences, using the transversion model with AG=CT and empirical base frequencies [9]. Substitution rate 
heterogeneity among alignment sites was incorporated via a free rate model with 5 categories. The estimated spline functions (in 
blue) are shown with 95% credible intervals (dotted lines). 
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Supplementary Table 3.2. Rank correlation analysis between bivalent HPV VE and various distance 
measures. 
 
Correlation 
coefficient  Measure 
  
Hamminga AAb L1c WGSd 
Spearman’s ρe VE  -0.713  
(p<.001)  
-0.703  
(p<.001)  
-0.680  
(p<.001)  
-0.753  
(p<.001)  
  Hamming ±   0.963  0.957  0.744  
  AA    0.959  0.712  
  L1     0.765  
Spearman’s ρpartial f VE  -0.158  
(p=0.50)  
-0.290  
(p=0.20)  
0.320  
(p=0.15)  
-0.512  
(p=0.012)  
  Hamming   0.429  0.414  0.046  
  AA    0.571  -0.324  
  L1     0.478  
Spearman’s ρpartial  VE  (omitted)  -0.401  
(p=0.063)  
0.284  
(p=0.21)  
-0.526  
(p=0.0087)  
  AA    0.910  -0.337  
  L1     0.546  
a. Minimum Hamming distance between aligned L1 AA sequences of reference types and virus-like particles in 2vHPV vaccine. 
b. Minimum phylogenetic distance between aligned L1 AA sequences of reference types and 2vHPV vaccine types, HPV16 and 
18. 
c. Minimum phylogenetic distance between aligned DNA sequences on the L1 capsid gene of reference types and 2vHPV vaccine 
types, HPV16 and 18. 
d. Minimum phylogenetic distance between aligned DNA sequences on the whole viral genome of reference types and 2vHPV 
vaccine types, HPV16 and 18. 
e. All correlation coefficients are weighted for the number of positive test results used in VE estimation (see Table 3.1). 
f. Partial correlation coefficients are obtained from the inverse weighted covariance matrix. 
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Abstract 
 
Human papillomavirus (HPV) vaccines are indicated for anal cancer prevention, but 
evidence for vaccine effectiveness (VE) against anal HPV infections among women is limited. 
We estimated the VE (≥1 dose) against anal HPV positivity of the bivalent vaccine, whose 
target types HPV16/18 are associated with approximately 90% of HPV-related anal cancers. 
Among 548 female sexually transmitted infection (STI) clinic visitors 16-24 years old who 
provided an anal swab sample as part of a repeated cross-sectional survey, VE against 
HPV16/18 was 89.9% (95% confidence interval, 63.0%-97.2%). Type-specific VE correlated 
well with VE against cervicovaginal HPV (Spearman’s ρ = 0.76), suggesting comparable 
effectiveness of HPV16/18 vaccination against genital and anal infections. 
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Introduction 
 
The sexually transmitted human papillomavirus (HPV) plays a causal role in the 
development of cervical, vaginal, vulvar, penile, oropharyngeal, and anal cancers. Anal 
cancer is more prevalent among women than among men and is responsible for the second 
largest HPV-related disease burden among women after cervical cancer [1]. The share of 
anal cancer in the total HPV-related disease burden is steadily increasing in many countries, 
owing to rising incidence trends and a current lack of effective screening opportunities [2]. 
Worldwide, over 20,000 women are affected by anal cancer each year, of which 
approximately 88% are caused by oncogenic HPV infections, mainly HPV16/18 [1]. 
HPV vaccines hold promise for anal cancer control. However, though the high vaccine 
effectiveness (VE) of prophylactic HPV vaccines against cervicovaginal HPV infections has 
been widely documented in both randomized controlled trials (RCTs) and post-marketing 
studies, data on VE against anal HPV infections are scarce, especially among women. In 1 
RCT of the bivalent (2vHPV) vaccine, post-hoc analyses demonstrated strong protection 
against anal positivity with vaccine types HPV16/18 (vaccine efficacy, 83.6% in the per-
protocol population) and significant cross-protection against HPV31 and HPV45 [3]. 
In 2 other RCTs of the quadrivalent (4vHPV) vaccine, vaccine efficacy against anal HPV 
infections was estimated among men. In the per-protocol populations, vaccination afforded 
strong protection against anal persistent HPV16/18 infection (vaccine efficacy, >95%) [4, 5]. 
In addition, efficacy against high-grade anal intraepithelial neoplasia was demonstrated 
among men who have sex with men (vaccine efficacy, 74.9%) [4]. Based on the latter study, 
the HPV vaccines received an indication for the prevention of anal cancer. One 
observational study of the 4vHPV vaccine explored the association between vaccination and 
anal HPV positivity among high-risk women and found a 64% reduction in the detection of 
anal HPV6/11/16/18 infections [6]. So far, post-marketing evidence on protection against 
anal HPV infection by the v2HPV vaccine has not become available. 
The Netherlands has consistently used the 2vHPV vaccine (Cervarix; GSK) in the national 
immunization program (NIP). Largescale vaccination started in 2009 with a catch-up 
campaign for girls born in 1993-1996. Routine HPV vaccination was introduced in 2010 for 
girls in the year they turn 13 years old. We previously reported on type-specific VE of the 
2vHPV vaccine against cervicovaginal HPV positivity [7]. In the current study, we evaluated 
VE against anal HPV positivity among female visitors to sexually transmitted infection (STI) 
clinics in the Netherlands. 
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Methods 
 
We used the same methods to estimate the VE against anal HPV positivity as previously 
used to estimate VE against cervicovaginal HPV positivity [7]. In short, we used data from 
the papillomavirus surveillance among STI clinic youngsters in the Netherlands (PASSYON) 
study. In this biennial cross-sectional study that started in 2009, 16- to 24-year-old visitors 
to STI clinics in the Netherlands were asked to provide a self-collected genital swab sample 
and to fill-in a questionnaire, including self-reported HPV vaccination status. A random 
subset of women were also asked to provide a self-collected anal swab sample on a 
voluntary basis. Because of financial constraints, not all women were asked for an anal swab 
sample; in the PASSYON study years 2015 and 2017, we aimed to obtain anal swab samples 
from a convenience sample of about 30% of the women, irrespective of self-reported 
vaccination status or sexual risk behavior. 
Women who agreed to provide an anal swab sample were instructed to insert a swab 
about 3 cm into the anus and circle it around for 5-10 seconds. Swab samples were tested 
using the SPF10-DEIA-LiPA25 assay (DDL Diagnostics Laboratory). This broad-spectrum 
polymerase chain reaction assay can detect DNA of several HPV types, including the high-
risk HPV (hrHPV) types 16/18/31/33/35/39/45/51/52/56/58/59 and the low-risk HPV 
(lrHPV) types HPV6/11. All participants provided informed consent. 
For the current research question, we included women who had been eligible for HPV 
vaccination in the Netherlands (i.e. women born since 1993), reported their vaccination 
status, and provided an anal swab sample. We included data from the PASSYON study years 
2011-2017. 
Anal HPV positivity was compared between women who reported being vaccinated (≥1 
dose) and those who reported not being vaccinated. To estimate the VE against anal HPV 
positivity, we used logistic mixed models with a random intercept, incorporating all clinically 
relevant HPV types (hrHPV and HPV6/11). Outcomes were type-specific HPV positivity, 
positivity for the vaccine types (HPV16/18, pooled), for the HPV types included in the 
nonavalent (9v) vaccine (HPV6/11/16/18/31/33/45/52/58, pooled), and for all 
acknowledged hrHPV types (HPV16/18/31/33/35/39/45/51/52/56/58/59, pooled). The 
pooled estimates were obtained as weighted averages of type-specific estimates. The 
analyses were adjusted for age and the variables that were found with χ2 tests to be 
associated with vaccination status (at a p<.1 level). VE was estimated as (1 − adjusted odds 
ratio) × 100%. 
Next, we assessed the Spearman’s correlation between the type-specific anal and 
cervicovaginal VE estimates. The VE against cervicovaginal HPV positivity was estimated 
using the same study population and method used for estimating VE against anal HPV 
positivity. 
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As sensitivity analyses, we estimated the VE against anal HPV positivity restricted to 
women who reported any history of anal sex (i.e., those considered at increased risk for 
anal cancer [8]) or restricted to women who were offered vaccination ≥5 years ago, 
comparable to previous analyses [7]. All analyses were performed using SAS version 9.4 (SAS 
Institute Inc., Cary, NC), with a significance level of p<.05. Records with missing data were 
excluded from the analyses, because these represented <5% of the study population. 
 
Results 
 
In the PASSYON study (years 2011-2017), a total of 2,413 women were eligible for HPV 
vaccination in the Dutch NIP, of whom 2,246 reported their vaccination status. Of these 
women, 548 (24%) provided an anal swab sample (Supplementary Figure 4.1). 
Demographics and sexual risk behavior differed between women who provided an anal 
swab sample and those who did not, possibly related to the willingness of women to collect 
the sample. For example, anal swab samples were available for 51% of the women who 
reported anal sex in the past 6 months, compared with 19% of those who reported no 
history of anal sex. Whether or not women provided an anal swab sample also differed by 
vaccination status. For instance, among women who reported no history of anal sex, 
vaccinated women were more likely than unvaccinated women to provide a sample (21% 
vs 15%, respectively) (Supplementary Table 4.1). 
Of the 548 women who did provide an anal swab and were included in the analyses, 357 
(65%) reported being vaccinated with ≥1 dose (43 women reported incomplete dosing). 
Vaccinated women were more likely to report a high education level, no history of anal sex, 
more sex partners in the past 6 months, no STI-related symptoms, and a history of using 
hormonal contraceptive (Table 4.1). The VE measures were adjusted for all these variables. 
 
Table 4.1. Characteristics of the study population used to estimate VE against anal HPV positivity. 
 
 Total (N=548); 
N (%) 
 Unvaccinateda 
(n=191); N (%) 
Vaccinateda (≥1 
dose, n=357); N (%) 
p value 
(χ2 test) 
Age     0.36 
  16-18 years 72 (13.1)  29 (15.2) 43 (12.0)  
  19-21 years 330 (60.2)  117 (61.3) 213 (59.7)  
  22-24 years 146 (26.6)  45 (23.6) 101 (28.3)  
Migration backgroundb     0.10 
  Native Dutch 420 (76.8)  139 (72.8) 281 (78.9)  
  Not native Dutch 127 (23.2)  52 (27.2) 75 (21.1)  
Education levelc     <.01 
  Low/middle 115 (21.0)  55 (28.8) 60 (16.8)  
  High 433 (79.0)  136 (71.2) 297 (83.2)  
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Table 4.1. (Continued). 
 
 Total (N=548); 
N (%) 
 Unvaccinateda 
(n=191); N (%) 
Vaccinateda (≥1 
dose, n=357); N (%) 
p value 
(χ2 test) 
History of anal sex     0.02 
  No 295 (54.0)  91 (47.9) 204 (57.3)  
  Yes, past 6 months 142 (26.0)  63 (33.2) 79 (22.2)  
  Yes, ever 109 (20.0)  36 (18.9) 73 (20.5)  
No. of sex partners, past 6 monthsd    0.05 
  0-1 partners 133 (24.3)  55 (28.9) 78 (21.8)  
  2-3 partners 263 (48.1)  93 (48.9) 170 (47.6)  
  ≥4 partners 151 (27.6)  42 (22.1) 109 (30.5)  
No. of sex partners, lifetimed    0.18 
  ≤3 partners 110 (20.4)  46 (24.7) 64 (18.1)  
  4-6 partners 142 (26.3)  48 (25.8) 94 (26.6)  
  ≥7 partners 288 (53.3)  92 (49.5) 196 (55.4)  
Age at sexual debutd    0.96 
  ≤14 years 75 (13.8)  25 (13.4) 50 (14.1)  
  15-16 years 283 (52.2)  99 (52.9) 184 (51.8)  
  ≥17 years 184 (33.9)  63 (33.7) 121 (34.1)  
History of any STI    0.60 
  No 291 (53.1)  97 (50.8) 194 (54.3)  
  Yes 155 (28.3)  59 (30.9) 96 (26.9)  
  Never tested 102 (18.6)  35 (18.3) 67 (18.8)  
Current anal chlamydia/gonorrhoea infection  0.28 
  No  173 (31.6)  68 (35.6) 105 (29.4)  
  Yes 32 (5.8)  12 (6.3) 20 (5.6)  
  Not tested 343 (62.6)  111 (58.1) 232 (65.0)  
Notified for STIs     0.59 
  No 468 (85.4)  161 (84.3) 307 (86.0)  
  Yes 80 (14.6)  30 (15.7) 50 (14.0)  
STI-related symptoms     0.05 
  No 411 (75.1)  134 (70.2) 277 (77.8)  
  Yes 136 (24.9)  57 (29.8) 79 (22.2)  
Condom use with casual partners, past 6 monthse  0.24 
  Inconsistent 254 (46.7)  83 (43.9) 171 (48.2)  
  Consistent 190 (34.9)  64 (33.9) 126 (35.5)  
  No casual partners  100 (18.4)  42 (22.2) 58 (16.3)  
History of using hormonal contraceptives    <.01 
  No 15 (2.8)  10 (5.3) 5 (1.4)  
  Yes 524 (97.2)  177 (94.7) 347 (98.6)  
Totals vary because of missing values. 
a. Categories based on self-reported vaccination status. 
b. Based on (parental) country of birth. A women was defined native Dutch if both parents were born in the Netherlands. 
c. High educational level included school of higher general secondary education, pre-university education, university of applied 
sciences, and university. Low/middle educational level included all other levels of education.  
d. Vaginal or anal sex. 
e. Inconsistent included reporting never, rarely and “sometimes I do, sometimes I do not” condom use. Consistent included 
reporting often or always condom use. 
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Only 2 vaccinated women (0.6%) tested positive for anal HPV16, and only 1 (0.3%) for HPV18 
(Supplementary Table 4.2). In comparison, 4.2% and 3.1% of unvaccinated women tested 
positive for anal HPV16 and HPV18, respectively, leading to an adjusted VE of 88.2% (95% 
confidence interval [CI], 41.3%-97.6%) against anal HPV16 and 91.9% (95% CI, 30.5%-99.1%) 
against anal HPV18 (Figure 4.1). The VE against anal HPV16/18 combined was 89.9% (95% 
CI, 63.0%-97.2%). None of the vaccinated women were positive for anal HPV45, compared 
with 3.1% of the unvaccinated women (VE, 100%; unadjusted 95% CI, 66.5%-100%). We also 
observed cross-protection against anal HPV31 (VE, 73.0%; 95% CI, 25.5%-90.2%). The type-
specific VE against anal HPV positivity correlated well with the VE against cervicovaginal 
HPV positivity (Spearman’s ρ= 0.76; p<.01). 
Of the total study population, 251 women (46%) reported any history of anal sex. In this 
subgroup, the anal prevalence of an hrHPV type or HPV6/11 was higher than among women 
who reported no history of anal sex (41% vs 34% respectively), and the VE against anal 
HPV16/18 was 95.5% (95% CI, 63.3%-99.5%) (Supplementary Figure 4.2). Most women 
(n=491 [90%]) were offered vaccination ≥5 years ago (range, 5-8 years). In this subgroup, 
the VE against anal HPV16/18 was comparable to that in the total population, at 90.0% (95% 
CI, 63.3%-97.3%) (Supplementary Figure 4.3). 
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Figure 4.1. A) Anal HPV prevalence by self-reported vaccination status and B) adjusted VE against anal 
HPV for ≥1 dose.  
Note: All 9v types included all types of the 9vHPV vaccine: HPV6/11/16/18/31/33/45/52/58. All hrHPV types included 
HPV16/18/31/33/35/39/45/51/52/56/58/59. VE was estimated as (1 − adjusted odds ratio) × 100%. Odds ratios were adjusted for 
age, education level, history of anal sex, number of sex partners in the past 6 months, STI–related symptoms, and history of 
hormonal contraceptives use. *Unadjusted 95% CI based on score confidence limits for the odds ratio. 
 
Discussion 
 
We demonstrated high effectiveness of the 2vHPV vaccine against anal positivity with 
vaccine types HPV16/18 up to 8 years after vaccination. We also demonstrated cross-
protection against anal HPV45 and HPV31 and a high correlation between anal and 
cervicovaginal VE. These results confirm that HPV vaccination protects against anal HPV 
infection among women in a population-based setting, thereby suggesting that the benefits 
of HPV vaccination will extend to anal cancer prevention. 
To our knowledge, this is the first observational study reporting VE of the 2vHPV vaccine 
against anal HPV positivity. A strength of our study is the population-based design. A 
limitation is the differential sexual risk behavior between vaccinated and unvaccinated 
women who provided an anal swab sample, possibly related to differences in demographics 
between vaccinated and unvaccinated women in general, such as educational level and 
migration background [9]. We adjusted for known differences between vaccinated and 
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unvaccinated women who did provide an anal swab sample, but we cannot rule out residual 
confounding. To mitigate unmeasured confounding, we used mixed models that allow for 
fixed effects of known risk factors as well as random effects in individual risk for HPV 
infection. 
Another limitation is the self-reported vaccination status. However, we previously 
showed that self-reported vaccination status agreed excellently with HPV16 and HPV18 
antibody levels, suggesting limited bias [7]. Moreover, misclassification according to self-
reported vaccination status should lead to an underestimation of the effect of vaccination. 
In addition, the majority of our study population was eligible as part of the catch-up 
program (84%), meaning that most vaccinated women were between 12 and 16 years old 
when offered vaccination. Some women in our study population might have acquired anal 
HPV infection before getting vaccinated, negatively affecting VE [3, 4]. Finally, although we 
had detailed information on sexual risk behavior, this was not specific for anal sex. For 
instance, the number of sex partners included anal sex as well as vaginal sex partners. 
Our VE against anal HPV16/18 positivity was comparable to the vaccine efficacy 
reported against anal HPV16/18 infection in the RCTs, conducted in women for the 2vHPV 
vaccine and in men for the 4vHPV vaccine [3-5]. In the only other observational study, the 
VE against anal HPV6/11/16/18 positivity was somewhat lower (64%), which could be 
related to the relatively high anal HPV prevalence before vaccination in that study [6]. 
Although few effectiveness measures against anal HPV infection are available, the limited 
data, including ours, suggest an equally high VE against anal as against genital HPV infection. 
We also observed cross-protection against anal HPV31 and HPV45, consistently observed 
cross-protective types in 2vHPV vaccine studies with regard to cervicovaginal HPV infections 
[7, 10-13]. Comparable cross-protection is further supported by the high correlation 
between type-specific VE against anal and cervicovaginal HPV infections in our study. 
The mechanism of protection against anal HPV infection is unclear in the current study. 
Many women who reported no history of anal sex tested positive for anal HPV (34%). This 
has also been reported elsewhere [14] and resembles anal chlamydia infection patterns 
[15]. In part, this could be due to underreporting of anal sex, but it is also possible that the 
relatively high positivity rate for anal HPV is partly explained by autoinoculation from genital 
HPV infection sites. In these cases, protection against anal HPV infection would be an 
indirect effect of vaccination, following from the prevention of genital HPV infection. 
However, the VE against anal HPV16/18 positivity was equally high (96%) among women 
who did report a history of anal sex, suggesting undiminished effectiveness with regard to 
direct protection. 
In conclusion, we demonstrated high VE, up to 8 years after vaccination, of the 2vHPV 
vaccine against anal HPV infections, which was comparable to prevention of genital 
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infections. The VE was particularly high against anal HPV16/18 positivity. These findings are 
promising for anal cancer control, given that nearly 90% of all HPV-related anal cancers are 
associated with HPV16/18 [1]. With an increasing incidence of HPV-related anal cancer and 
a current lack of effective screening opportunities, HPV vaccination provides a tremendous 
opportunity for anal cancer prevention. 
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Supplementary Table 4.1. Characteristics of the women included in the PASSYON study who had 
been eligible for HPV vaccination in the Dutch NIP. 
 
 Total (N=2,246)  Unvaccinateda 
(N=855) 
Vaccinateda (≥1 
dose, N=1,391) 
 N Anal swab 
n (%)b 
 N Anal swab 
n (%)b 
N Anal swab 
n (%)b 
Age        
  16-18 years 440 72 (16.4)  176 29 (16.5) 264 43 (16.3) 
  19-21 years 1335 330 (24.7)  512 117 (22.9) 823 213 (25.9) 
  22-24 years 471 146 (31.0)  167 45 (26.9) 304 101 (33.2) 
Migration backgroundc      
  Native Dutch 1764 420 (23.8)  627 139 (22.2) 1137 281 (24.7) 
  Not native Dutch 465 127 (27.3)  221 52 (23.5) 244 75 (30.7) 
Education leveld        
  Low/middle 609 115 (18.9)  294 55 (18.7) 315 60 (19.0) 
  High 1636 433 (26.5)  561 136 (24.2) 1075 297 (27.6) 
History of anal sex        
  No 1582 295 (18.6)  593 91 (15.3) 989 204 (20.6) 
  Yes, past 6 months 280 142 (50.7)  118 63 (53.4) 162 79 (48.8) 
  Yes, ever 369 109 (29.5)  137 36 (26.3) 232 73 (31.5) 
No. of sex partners, past 6 monthse      
  0-1 partners 600 133 (22.2)  265 55 (20.8) 335 78 (23.3) 
  2-3 partners 1084 263 (24.3)  394 93 (23.6) 690 170 (24.6) 
  ≥4 partners 561 151 (26.9)  195 42 (21.5) 366 109 (29.8) 
No. of sex partners, lifetimee      
  ≤3 partners 502 110 (21.9)  215 46 (21.4) 287 64 (22.3) 
  4-6 partners 645 142 (22.0)  244 48 (19.7) 401 94 (23.4) 
  ≥7 partners 1071 288 (26.9)  383 92 (24.0) 688 196 (28.5) 
Age at sexual debute      
  ≤14 years 336 75 (22.3)  146 25 (17.1) 190 50 (26.3) 
  15-16 years 1121 283 (25.2)  418 99 (23.7) 703 184 (26.2) 
  ≥17 years 762 184 (24.1)  278 63 (22.7) 484 121 (25.0) 
History of any STI        
  No 1178 291 (24.7)  421 97 (23.0) 757 194 (25.6) 
  Yes 579 155 (26.8)  241 59 (24.5) 338 96 (28.4) 
  Never tested 482 102 (21.2)  191 35 (18.3) 291 67 (23.0) 
Current anal chlamydia/gonorrhoea infection      
  No  312 173 (55.4)  122 68 (55.7) 190 105 (55.3) 
  Yes 71 32 (45.1)  26 12 (46.2) 45 20 (44.4) 
  Not tested 1863 343 (18.4)  707 111 (15.7) 1156 232 (20.1) 
Notified for STIs        
  No 1913 468 (24.5)  721 161 (22.3) 1192 307 (25.8) 
  Yes 312 80 (25.6)  125 30 (24.0) 187 50 (26.7) 
STI-related symptoms      
  No 1666 411 (24.7)  601 134 (22.3) 1065 277 (26.0) 
  Yes 558 136 (24.4)  245 57 (23.3) 313 79 (25.2) 
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Supplementary Table 4.1. (Continued). 
 
 Total (N=2,246)  Unvaccinateda 
(N=855) 
Vaccinateda (≥1 
dose, N=1,391) 
 N Anal swab 
n (%)b 
 N Anal swab 
n (%)b 
N Anal swab 
n (%)b 
Condom use with casual partners, past 6 monthsf   
  Inconsistent 1088 254 (23.3)  405 83 (20.5) 683 171 (25.0) 
  Consistent 696 190 (27.3)  253 64 (25.3) 443 126 (28.4) 
  No casual partners  450 100 (22.2)  191 42 (22.0) 259 58 (22.4) 
History of using hormonal contraceptives      
  No 74 15 (20.3)  43 10 (23.3) 31 5 (16.1) 
  Yes 2135 524 (24.5)  798 177 (22.2) 1337 347 (26.0) 
Totals vary because of missing values. 
a. Based on self-reported vaccination status. 
b. Percentage who provided an anal swab. 
c. Based on (parental) country of birth. A women was defined native Dutch if both parents were born in the Netherlands. 
d. High educational level included school of higher general secondary education, pre-university education, university of applied 
sciences, and university. Low/middle educational level included all other levels of education.  
e. Vaginal or anal sex. 
f. Inconsistent included reporting never, rarely and “sometimes I do, sometimes I do not” condom use. Consistent included 
reporting often or always condom use. 
 
Supplementary Table 4.2. Anal HPV prevalence by vaccination status. 
 
 Unvaccinateda (N=191)  Vaccinateda (≥1 dose, N=357) 
 n positive % positive (95% CI)  n positive % positive (95% CI) 
HPV6 22 11.5 (7.7 - 16.8)  42 11.8 (8.8 - 15.5) 
HPV11 1 0.5 (0.1 - 2.9)  3 0.8 (0.3 - 2.4) 
HPV16 8 4.2 (2.1 - 8.0)  2 0.6 (0.2 - 2.0) 
HPV18 6 3.1 (1.4 - 6.7)  1 0.3 (0.0 - 1.6) 
HPV31 12 6.3 (3.6 - 10.7)  7 2.0 (1.0 - 4.0) 
HPV33 5 2.6 (1.1 - 6.0)  4 1.1 (0.4 - 2.8) 
HPV35 4 2.1 (0.8 - 5.3)  5 1.4 (0.6 - 3.2) 
HPV39 5 2.6 (1.1 - 6.0)  14 3.9 (2.4 - 6.5) 
HPV45 6 3.1 (1.4 - 6.7)  0 0.0 (0.0 - 1.1) 
HPV51 28 14.7 (10.3 - 20.4)  50 14.0 (10.8 - 18.0) 
HPV52 16 8.4 (5.2 - 13.2)  37 10.4 (7.6 - 14.0) 
HPV56 14 7.3 (4.4 - 11.9)  24 6.7 (4.6 - 9.8) 
HPV58 2 1.0 (0.3 - 3.7)  7 2.0 (1.0 - 4.0) 
HPV59 4 2.1 (0.8 - 5.3)  7 2.0 (1.0 - 4.0) 
a. Based on self-reported vaccination status. 
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Supplementary Figure 4.2. Anal HPV prevalence and adjusted VE, restricted to women who reported 
any history of anal sex. A) Anal HPV prevalence by self-reported vaccination status and B) adjusted VE 
against anal HPV for at least one dose. 
Note: All 9v types included all types of the 9vHPV vaccine: HPV6/11/16/18/31/33/45/52/58. All hrHPV types included: 
HPV16/18/31/33/35/39/45/51/52/56/58/59. VE was estimated as (1- odds ratio)*100% and was adjusted for age, education level, 
anal sex in the past 6 months, number of sex partners in the past 6 months, STI-related symptoms, and history of hormonal 
contraceptives use. 
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Supplementary Figure 4.3. Adjusted VE, restricted to women who were offered vaccination ≥5 years 
ago (range 5-8 years). 
Note: All 9v types included all types of the 9vHPV vaccine: HPV6/11/16/18/31/33/45/52/58. All hrHPV types included: 
HPV16/18/31/33/35/39/45/51/52/56/58/59. VE was estimated as (1- odds ratio)*100% and was adjusted for age, education level, 
anal sex in the past 6 months, number of sex partners in the past 6 months, STI-related symptoms, history of hormonal 
contraceptives use, and age vaccination was offered. 
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Abstract  
 
Data on the impact of human papillomavirus (HPV) vaccination on the population HPV 
prevalence are largely obtained from women. We assessed the impact of the girls-only 
HPV16/18 vaccination program in the Netherlands that started in 2009, on trends in HPV 
prevalence among women and heterosexual men, using data from the PASSYON study. In 
this cross-sectional study, the HPV prevalence among 16- to 24-year-old visitors to sexually 
transmitted infection clinics was assessed in 2009, 2011, 2013, and 2015. We compared the 
genital post-vaccination HPV prevalence with the pre-vaccination prevalence (2009) using 
Poisson GEE models. In total, we included 4,996 women and 1,901 heterosexual men. The 
percentage of women who reported to be vaccinated increased from 2.3% in 2009 to 37% 
in 2015. Among all women, the HPV16/18 prevalence decreased from 23% pre-vaccination 
to 15% in 2015 (adjusted prevalence ratio [aPR] 0.62, ptrend<.01). Among heterosexual men, 
the HPV16/18 prevalence decreased from 17% pre-vaccination to 11% in 2015 (aPR 0.52, 
ptrend<.01). Of the heterosexual men with a steady partner, HPV16/18 prevalence was lower 
among those whose steady partner had been vaccine-eligible in the national immunization 
program (aPR 0.13). Among unvaccinated women, the HPV16/18 prevalence in 2015 was 
not different from pre-vaccination. The decreasing HPV16/18 prevalence among 
heterosexual men and the reduced HPV16/18 prevalence among heterosexual men with a 
vaccine-eligible steady partner strongly suggests herd protection from girls-only 
vaccination. Absence of notable herd effects among unvaccinated women 6 years post-
vaccination may be due to the moderate vaccine uptake among girls in the Netherlands. 
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Introduction 
 
Human papillomavirus (HPV) is a sexually transmitted virus that plays a causal role in the 
development of anogenital and oropharyngeal cancers in both men and women [1]. To 
prevent HPV-related cancers, many countries have included HPV vaccination in their 
national immunization program (NIP), using one of the available vaccines that provide direct 
protection against 2, 4, or 9 HPV types, all including HPV16 and HPV18 [2]. 
In the Netherlands, the bivalent HPV (2vHPV) vaccine (Cervarix®, GSK) is used in the NIP; 
to date, this has been a girls-only program [3]. In 2009, there was a catch-up campaign for 
girls born in 1993-1996 with 52% that completed the 3-dose schedule [4]. Routine HPV 
vaccination was introduced in 2010 for girls in the year they turn 13 years old, with an initial 
3-dose uptake of 56% (birth cohort 1997). The uptake increased to 61% for birth cohort 
2001, but decreased again to 53% for birth cohort 2002. In 2014, routine HPV vaccination 
changed to a 2-dose schedule [5]. 
We previously reported on direct 2vHPV vaccine effectiveness using cross-sectional data 
from female sexually transmitted infection (STI) clinic visitors. We showed high 
effectiveness against the vaccine types HPV16 and HPV18 and cross-protection against 
other oncogenic HPV types [6]. These findings were reiterated in a longitudinal cohort study 
among vaccine-eligible girls [7]. 
The population-level impact of HPV vaccination programs also includes possible indirect 
effects, such as herd protection. So far, the population-level impact of HPV vaccination 
programs on the HPV prevalence has mainly been studied among women. Surveillance 
studies have shown a decrease in the HPV16/18 prevalence since the introduction of 
vaccination [8]. Some studies have also shown decreases in the HPV16/18 prevalence 
among unvaccinated women [9-11]. This decrease among unvaccinated women is 
attributed to herd protection in men, yet there is limited information about trends in HPV 
prevalence among men, especially after 2vHPV vaccination. One study has shown that the 
HPV16/18 prevalence in urine samples from men decreased from 5.0% pre-vaccination to 
1.1% 2-4 years post- girls-only 2vHPV vaccination [12]. However, since the method of 
sample collection had changed, the authors were cautious in drawing conclusions. Because 
HPV16/18 are associated with the majority of HPV-related cancers in men, demonstrating 
herd protection for these types in heterosexual men is important for assessing the overall 
health gain from a girls-only HPV vaccination program [13, 14]. 
We assessed the population-level impact of the girls-only 2vHPV vaccination program in 
the Netherlands by studying trends in the prevalence of HPV vaccine and cross protective 
types from pre-vaccination up to 6 years post-vaccination. We included women as well as 
heterosexual men, and focused on unvaccinated women and heterosexual men with 
vaccine-eligible partners to study herd protection. We used data from the PASSYON 
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(PApillomavirus Surveillance among STI clinic Youngsters in the Netherlands) study, a 
biennial cross-sectional study among visitors to STI clinics that had been designed to 
monitor the HPV vaccination program in the Netherlands. 
 
Methods 
 
Study design and population 
The PASSYON study started in 2009 when HPV vaccination was implemented in the 
Netherlands. Young (16- to 24-year-old) people who visited STI clinics throughout the 
Netherlands were asked to participate in the study. In addition to the routine STI 
consultation, participants were asked to fill out a questionnaire regarding demographics, 
sexual behavior, and vaccination status. Moreover, they were asked to provide a self-
collected genital swab for HPV testing. Women were instructed to insert a swab (Copan 
Diagnostics, Italy) about 4 cm into the vagina until resistance was felt and to turn it around 
along the walls of the vagina. Men were instructed to firmly move the swab up and down 
the entire shaft, the glans, the coronal sulcus, and under the foreskin of the penis. More 
details about the PASSYON study have been published previously [15]. To explore trends in 
the HPV prevalence after implementation of HPV vaccination, the PASSYON study was 
repeated in 2011, 2013, and 2015 using the same study protocol. Participants could be 
included in multiple study rounds, but the probability of repeated consultations is low as 
we sampled for only 2 months in the same period every other year (Figure 5.1). The Dutch 
Medical Research Involving Human Subjects Act (Dutch acronym: WMO) does not apply for 
our study, because only for-the-researchers-anonymized-data were used and there were 
no (medical) interventions other than routine care. The Medical Ethical Committee of the 
University of Utrecht, the Netherlands, provided a waiver for full medical ethical review 
(protocol number 08/397). Data were obtained using a unique code per person and all 
participants gave informed consent. 
 
Laboratory methods 
HPV testing protocols were constant across all years and described in detail elsewhere [15]. 
Briefly, DNA was extracted using the MagnaPure platform (Total Nucleic Acid Isolation Kit, 
Roche, the Netherlands) and HPV DNA was amplified using the SPF10 primer set and 
detected using the DNA enzyme-linked immunoassay (HPV-DEIA, DDL Diagnostics 
Laboratory, the Netherlands). Positive samples were genotyped with line-probe assay (HPV-
LiPA25, DDL Diagnostics Laboratory, the Netherlands), which is able to detect 25 HPV types, 
including HPV16 and HPV18. 
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Figure 5.1. HPV vaccination in the Netherlands and the PASSYON study design. 
 
Statistical analyses 
Only participants with a genital swab were included in the analyses. All analyses were 
performed separately for all women (irrespective of vaccination status), heterosexual men 
(based on self-identified sexual preference), and unvaccinated women (based on self-
reported vaccination status). 
We calculated the prevalence and Wilson score 95% confidence interval (95% CI) of 
HPV16 and HPV18 (combined and separately) for each PASSYON year and performed a 
crude Cochran-Armitage Trend Test. Next, we compared the HPV prevalence of the post-
vaccination periods (2011, 2013, and 2015) with the pre-vaccination period (2009) and 
calculated prevalence ratios (PRs) using a Poisson model with robust error variance. This 
results in comparable estimates as compared to log-binomial regression, and improves 
numerical convergence [16]. Additionally, because we assumed identical effects of 
covariates on the prevalence of HPV types included in the analyses, we made use of a 
generalized estimating equation (GEE) model with an exchangeable correlation structure. 
This allows efficient estimation of coefficients and calculation of the population-averaged 
effect of study year on the HPV prevalence, either type-specific or pooled (as a weighted 
average) [17]. Linear trends over time were assessed by including PASSYON year as a 
continuous variable in the model. These analyses were adjusted for age (16-20 and 21-24 
years) and possible confounders, presented in Table 5.1. The variables age at sexual debut 
and number of sex partners in the past 6 months and lifetime were categorized for analyses 
purposes based on knowledge about the HPV risk and size of each category. The selection 
of confounders was based on the following procedure. First, we explored the association 
with PASSYON year and high-risk HPV (hrHPV) positivity (being positive for HPV16/18/31/ 
33/35/39/45/51/52/56/58/59), using χ2 tests. Using hrHPV instead of HPV16/18 positivity 
for the selection of confounders gave more power to detect possible associations. Variables 
associated with PASSYON year and hrHPV positivity (p<.05) in univariable analyses were 
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selected. Second, because sexual risk behavior variables were highly correlated, we used 
computerized selection models (stepwise with p<.05 as entry and stay criteria) with hrHPV 
positivity as an outcome and the sexual risk behavior variables that were selected as 
independent variables. Variables that were included in the final selection model were 
evaluated as possible confounders to adjust for in the Poisson GEE models for comparing 
HPV prevalence between study rounds. For all women, we also adjusted for self-reported 
vaccination status to assess if possible trends in HPV prevalence over time was explained by 
an increasing proportion of vaccinated women in our study population. Although HPV 
vaccination was not offered to men in the Dutch NIP, it is possible that men were vaccinated 
elsewhere. In sensitivity analyses, we excluded heterosexual men who reported to have 
been HPV vaccinated. To study the population-level impact and herd protection for the 
cross-protective types HPV31/33/45 [9], we repeated the analyses by also including these 
types.  
Because women who were offered vaccination in the Netherlands (women born in 1993 
or later), were aging over the span of the PASSYON study, the vaccination coverage by age 
category differed over the years. We assessed for effect modification by age category by 
including an interaction term between PASSYON year and age category. For all women, we 
again additionally adjusted for self-reported vaccination status to assess if the possible 
difference in trends by age category were explained by differences in vaccination coverage. 
We also calculated the adjusted PRs (aPRs) and the trend for the age categories separately. 
If participants reported being in a relationship, the age of the steady partner was asked. 
For heterosexual men, we assessed if the steady partner had been eligible for HPV 
vaccination in the Dutch NIP based on the reported age of the steady partner. We assumed 
the steady partner had been eligible for vaccination if she was ≤17 years in PASSYON round 
2011, ≤19 years in PASSYON round 2013, and ≤21 years in PASSYON round 2015. If the 
steady partner was older in a specific PASSYON round, we assumed she had not been 
eligible for HPV vaccination in the NIP. Also for all heterosexual men included in PASSYON 
round 2009, we assumed the steady partner had not been eligible for HPV vaccination. To 
consider herd effects, we calculated the combined HPV16/18 prevalence among 
heterosexual men by age of the steady partner and vaccine-eligibility of the steady partner. 
Next, we assessed the difference in HPV16/18 prevalence between heterosexual men with 
or without a vaccine-eligible steady partner by using a GEE model with HPV16/18 as an 
outcome and vaccine-eligibility of the steady partner as an independent variable. This 
analysis was adjusted for age of the men and age of the steady partner. 
All analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC). We used 
a significance level of p<.05. We did complete case analyses, as none of the variables had 
more than 5% missing. 
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Results 
 
Study population 
A total of 7,108 women and heterosexual men participated in the PASSYON study, of whom 
6,897 (4,996 women and 1,901 heterosexual men) delivered a genital swab and were 
included in the current analysis; 1,524 in 2009, 1,775 in 2011, 1,816 in 2013, and 1,782 in 
2015. The proportion of women who had been eligible for vaccination increased from 0.4% 
in 2009 to 5.3% in 2011, 27% in 2013, and 57% in 2015. Of the women who had been eligible 
for vaccination, 55% (n=650) reported to be vaccinated (30 reported to be vaccinated with 
1 dose, 42 with 2 doses, 456 with 3 doses, and 122 an unknow number of doses). The 
proportion of all women reporting to be vaccinated at least once increased from 2.3% in 
2009 to 37% in 2015. In total 27 heterosexual men (1.4%) reported to be HPV vaccinated. 
Characteristics of the study population of all PASSYON years combined are presented in 
Table 5.1. 
 
Table 5.1. Characteristics of the study population of all PASSYON years combined for all women, 
heterosexual men, and unvaccinated women. 
 
 All women Heterosexual men Unvaccinated women 
 N (%) N (%) N (%) 
Total 4996 1901 3594 
Age    
  16-20 years 2012 (40.3) 557 (29.3) 1186 (33.0) 
  21-24 years 2984 (59.7) 1344 (70.7) 2408 (67.0) 
Self-defined ethnicity    
  Dutch 4319 (86.5) 1522 (80.1) 3127 (87.1) 
  Not Dutch 675 (13.5) 377 (19.9) 465 (12.9) 
Education levela    
  Low/middle 1246 (25.1) 591 (31.2) 835 (23.3) 
  High 3719 (74.9) 1303 (68.8) 2745 (76.7) 
Sexual preference   
  Heterosexual 4804 (96.2) 1901 (100) 3457 (96.2) 
  Gay or bisexual  192 (3.8) - 137 (3.8) 
Age at sexual debutb    
  ≤14 years 647 (13.1) 322 (17.1) 439 (12.3) 
  15-16 years 2396 (48.5) 762 (40.5) 1697 (47.7) 
  ≥17 years 1898 (38.4) 799 (42.4) 1423 (40.0) 
No. of sex partners, past 6 monthsc  
  0-1 partners 1627 (32.6) 418 (22.0) 1203 (33.5) 
  2-3 partners 2412 (48.3) 715 (37.6) 1721 (47.9) 
  4-5 partners 687 (13.8) 390 (20.5) 499 (13.9) 
  ≥6 partners 265 (5.3) 378 (19.9) 169 (4.7) 
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Table 5.1. (Continued). 
 
 All women Heterosexual men Unvaccinated women 
 N (%) N (%) N (%) 
No. of sex partners, lifetimec   
  ≤2 partners 570 (11.6) 105 (5.8) 396 (11.2) 
  3-4 partners 973 (19.8) 202 (11.1) 688 (19.4) 
  5-6 partners 966 (19.7) 240 (13.2) 694 (19.6) 
  7-14 partners 1702 (34.7) 585 (32.2) 1245 (35.2) 
  ≥15 partners 693 (14.1) 687 (37.8) 516 (14.6) 
Anal sex past 6 months   
  No 4351 (87.6) 1590 (84.8) 3122 (87.3) 
  Yes 614 (12.4) 284 (15.2) 455 (12.7) 
Notified for STIsd    
  No 4511 (90.6) 1608 (85.0) 3263 (91.1) 
  Yes 467 (9.4) 284 (15.0) 319 (8.9) 
STI-related symptomsd   
  No 3799 (76.5) 1367 (72.4) 2721 (76.1) 
  Yes 1170 (23.5) 521 (27.6) 853 (23.9) 
History of any STI  
  No 2852 (57.4) 1055 (55.7) 2101 (58.7) 
  Yes 1266 (25.5) 377 (19.9) 920 (25.7) 
  Never tested 851 (17.1) 462 (24.4) 558 (15.6) 
Current genital chlamydia infectiond   
  No 4283 (86.1) 1594 (84.4) 3098 (86.5) 
  Yes 694 (13.9) 294 (15.6) 482 (13.5) 
Steady partner    
  No 2961 (60.7) 1037 (56.5) 2127 (60.6) 
  Yes, for 0-6 months 1102 (22.6) 475 (25.9) 801 (22.8) 
  Yes, for ≥6 months 813 (16.7) 324 (17.6) 583 (16.6) 
Condom use with casual partners, past 6 monthse  
  Inconsistent 1950 (39.2) 851 (44.9) 1344 (37.5) 
  Consistent 1806 (36.3) 658 (34.7) 1361 (37.9) 
  No casual partners 1224 (24.6) 385 (20.3) 882 (24.6) 
Totals vary because of missing values. 
a. High educational level included school of higher general secondary education, pre-university education, university of applied 
sciences, and university. Low/middle educational level included all other levels of education. 
b. Categorized for analyses purposes. Minimum-maximum age reported: 9-24 years among (unvaccinated) women and 
heterosexual men. 
c. Categorized for analyses purposes. Maximum no. of partners reported: 540 past 6 months and 900 lifetime among 
(unvaccinated) women; 50 past 6 months and 400 lifetime among heterosexual men. 
d Based on information of the STI clinic visit. 
e. Inconsistent included reporting never, rarely and “sometimes I do, sometimes I do not” condom use. Consistent included 
reporting often or always condom use. 
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In general, the indicators for sexual risk behavior increased over the years among women, 
heterosexual men, and unvaccinated women (Supplementary Tables 5.1, 5.2, 5.3). For 
example, we observed an association between lifetime number of sex partners and 
PASSYON year; with proportions reporting ≥15 lifetime sex partners of 12% in 2009 and 18% 
in 2015 among all women; 31% in 2009 and 44% in 2015 among heterosexual men; and 12% 
in 2009 and 19% in 2015 among unvaccinated women. The genital chlamydia prevalence 
was associated with PASSYON year among heterosexual men only. Supplementary Tables 
5.1, 5.2, 5.3 also show the association between the characteristics and hrHPV positivity. In 
general, people with higher sexual risk behavior were more often hrHPV positive. 
 
HPV prevalence over time 
Figure 5.2 presents the HPV16 and HPV18 prevalence over time and the crude trend test 
among all women, heterosexual men, and unvaccinated women. Among all women, the 
HPV16/18 prevalence decreased from 23% in 2009 to 15% in 2015 (aPR 0.62, Table 5.2). 
Also for HPV16 and HPV18 separately, there was a significant decrease over time (aPR 0.59 
and 0.69 respectively). When we additionally adjusted for vaccination status, the 
prevalences in 2015 were no longer significantly different from 2009. Among heterosexual 
men, the combined HPV16/18 prevalence decreased from 17% in 2009 to 11% in 2015 (aPR 
0.52). Also separately, HPV16 and HPV18 prevalences were significantly lower in 2015 
compared to 2009 (aPR 0.64 and 0.33 respectively). Excluding the 27 heterosexual men who 
reported to be vaccinated did not lead to different results (Supplementary Table 5.4). 
Among unvaccinated women, we observed no declining trends in the HPV16 or HPV18 
prevalence. 
For HPV31, HPV33, and HPV45, we only observed a declining trend in the HPV31 
prevalence among all women (adjusted ptrend 0.01), but not among heterosexual men or 
unvaccinated women. For the other HPV types, no trends were observed except for an 
increasing trend of HPV45 among unvaccinated women (Supplementary Table 5.5). 
The vaccination coverage over time differed by age category; for example in 2013, 40% 
of the 16- to 20-year-old women reported to be vaccinated (≥1 dose), while 4.6% of the 21- 
to 24-year-old women reported to be vaccinated. We observed that the HPV16/18 
prevalence among 16- to 20-year-old women decreased faster as compared to 21- to 24-
year-old women (aPR 0.41 vs 0.74 respectively for 2015 compared to 2009, Supplementary 
Figure 5.1 and Supplementary Table 5.6). The difference in the effect of year by age group 
was statistically significant (p<.01). After additional adjustment for vaccination status, the 
difference between ages was no longer statistically significant. Among heterosexual men 
and unvaccinated women, there was no statistically significant interaction with age. Among 
unvaccinated women, there were no statistically significant trends in the HPV16 or HPV18 
prevalence for both age categories (Supplementary Table 5.6). 
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Figure 5.2. Prevalence of HPV types 16 or 18, HPV16, and HPV18 over time and p values for the crude 
trend test, among A) all women; B) heterosexual men; C) unvaccinated women. 
Note: The p value presents the Cochran-Armitage Trend Test. *Percentage of women and heterosexual men who reported to be 
vaccinated at least once. 
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Vaccine-eligible steady partner 
The proportion of heterosexual men reporting a steady partner who had been eligible for 
HPV vaccination increased from 2.2% in 2011, to 15% in 2013, and 19% in 2015. Figure 5.3 
shows the combined HPV16/18 prevalence among heterosexual men according to the age 
of the steady partner and vaccine-eligibility of the steady partner. Overall, heterosexual 
men whose steady partner had been vaccine-eligible were less often HPV16/18 positive 
compared to heterosexual men whose steady partner had not been vaccine-eligible in the 
NIP (aPR 0.13 [95% CI 0.04-0.41]). 
 
 
Figure 5.3. Prevalence of HPV types 16 or 18 among heterosexual men who reported to have a 
steady partner, by age of the steady partner and vaccine-eligibility of the steady partner.  
Note: *Vaccine-eligibility of the steady partner was based on the reported age of the steady partner in a specific PASSYON study 
round and the Dutch NIP. None of the steady partners of ≥22 years had been eligible according to the NIP in the Netherlands. 
 
Discussion 
 
We estimated the population-level impact of the national girls-only 2vHPV vaccination 
program in the Netherlands by comparing HPV prevalence from pre-vaccination to post-
vaccination periods among male and female visitors to STI clinics. We showed decreasing 
trends in the HPV16 and HPV18 prevalence among all women and heterosexual men, but 
not among unvaccinated women separately. Of the heterosexual men who reported to have 
a steady partner, HPV16/18 prevalence was lower among those whose steady partner had 
been vaccine-eligible. 
Our results provide compelling evidence for herd protection for the vaccine types among 
men in the aftermath of girls-only HPV16/18 vaccination and show that herd effects among 
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heterosexual men will likely precede those among unvaccinated women. Our data offer 
empirical support for the population-level impact of vaccination against the 2 most 
oncogenic HPV types as previously predicted by transmission-dynamic models [18]. 
We do acknowledge some limitations. First, STI clinics became stricter in prioritizing 
high-risk individuals especially since 2015, when the funding of the STI clinics had changed 
[19]. We indeed observed increased sexual risk behavior over time possibly related to 
changes in the access policy of STI clinics. Although we adjusted for known changes, 
unknown changes in the study population may have resulted in changes in the HPV 
prevalence unrelated to HPV vaccination. This could for instance explain the observed 
increase in HPV16 prevalence in 2015 compared to 2013 among heterosexual men. If 
participants in the post-vaccination study periods were at higher HPV risk, we may have 
underestimated the impact of vaccination, including declines in HPV16/18 prevalence 
among unvaccinated women. However, the chlamydia prevalence did not increase among 
(unvaccinated) women, suggesting that unrecorded sexual risk behavior likely did not 
chance that much among female study participants. Analyses restricted to chlamydia 
positive unvaccinated women did not lead to different results (results not shown). Second, 
the use of self-reported vaccination status may have induced bias. Among women, we 
believe the bias will be minimal as we previously showed that the HPV16 and HPV18 
antibody concentrations agreed well with the self-reported vaccination status [6]. Of the 
heterosexual men, 1.4% reported to be HPV vaccinated. If these men were truly vaccinated 
against HPV, this would lead to an overestimation of the herd effects. However, excluding 
the men who reported to be HPV vaccinated did not lead to different results. We also used 
self-reported sexual preference to identify heterosexual men. It might be that some men 
did (also) have sex with men. Such bias would have underestimated the impact of 
vaccination. Third, only 1 pre-vaccination measurement was available. If there were natural 
fluctuations in the HPV prevalence in the absence of vaccination, multiple pre-vaccination 
measurements would have been preferred to obtain an accurate estimate of the average 
pre-vaccination prevalence and to assess possible pre-vaccination trends. Last, we used a 
population of visitors to STI clinics who are at higher HPV risk as compared to the general 
population. The results are therefore not representative of the general Dutch population, 
probably underestimating the impact of vaccination [20]. 
The decrease in the HPV16/18 prevalence among women in our study, coincided with 
an increase in the percentage of women who reported to be vaccinated. After adjustment 
for vaccination status, the HPV16/18 prevalence did not differ in 2015 as compared to 2009, 
indicating that the increasing proportion of vaccinated women explained the decreasing 
HPV prevalence. In other countries, also a decline in the HPV16/18 prevalence among 
women was observed after introduction of 2vHPV vaccination. In England, the HPV16/18 
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prevalence decreased from 18% pre-vaccination to 4.0% 4-5 years post-vaccination among 
16- to 18-year-old sexually active women [21]. In Scotland, the HPV16/18 prevalence 
decreased from 30% pre-vaccination to 4.5% 7 years post-vaccination among 20- to 21-year-
old women who underwent their first cervical screening. The larger declines in these 
countries as compared to our study could be explained by an overall lower percentage of 
women vaccinated in our study (37% ≥1 dose in 2015). This reflects both a lower percentage 
of women who had been eligible for vaccination (57% in 2015) and a lower vaccination 
uptake among vaccine-eligible women (55% ≥1 dose). Among 16- to 20-year-old women, 
with a higher percentage vaccinated, we observed larger declines in the HPV16/18 
prevalence. 
We also observed a decrease in the HPV16/18 prevalence among heterosexual men 
since the introduction of girls-only 2vHPV vaccination. Our results are comparable to 
Australia where a declining trend in the HPV16/18 prevalence among heterosexual men was 
observed after girls-only quadrivalent HPV vaccination [22]. In Australia, also a decline in 
the HPV16/18 prevalence was observed among foreign-born heterosexual men who had 
arrived from countries with a 2vHPV vaccination program within 2 years of study inclusion. 
However, effects of exposure within those countries might have been negligible because 
the majority of the HPV16/18 infections clear within 2 years [23]. 
While the decreasing HPV16/18 prevalence among heterosexual men in our study 
strongly suggests herd protection, causality cannot be concluded based on ecological 
analyses. Nonetheless, the decreasing prevalence in combination with a lower HPV16/18 
prevalence among men whose steady partner had been vaccine-eligible strongly indicates 
that heterosexual men receive indirect protection. With most HPV-related penile cancers 
attributed to HPV16 [24], cancer reductions are also expected to occur for heterosexual 
men in the aftermath of girls-only HPV vaccination. Among men who have sex with men, 
large reductions in HPV-related cancers are not expected, because they benefit less from 
herd protection after girls-only vaccination [25]. While it is anticipated that HPV prevalence 
will also decline at other anatomical sites among heterosexual men, this has not yet been 
demonstrated. Given that oropharyngeal cancers constitute the largest HPV-related burden 
in men [26], showing herd effects against oral HPV is valuable to acknowledge the ultimate 
impact of HPV vaccination. 
Among heterosexual men, the decline in HPV prevalence was larger for HPV18 than for 
HPV16, which is in line with data from Finland where also larger herd effects were observed 
for HPV18 [10]. Higher herd effects for HPV18 could be explained by a lower basic 
reproduction number (as a consequence of a higher clearance relative to HPV16) [23, 27, 
28]. Even though HPV31/33/45 could also be expected to have a lower basic reproduction 
number than HPV16, there were no signs of herd effects for these types. This could be 
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related to a relatively low background prevalence in combination with reduced vaccine 
effectiveness, resulting in limited power to detect herd effects against cross-protective 
types compared to the vaccine types. 
Because the vaccination coverage of completed schedule among vaccine-eligible 
women in the Netherlands is 50%-60% [5], herd protection will not have reached its full 
potential [13, 14]. This is particularly true for herd protection in unvaccinated heterosexual 
women, which is derived from herd protection in heterosexual men, and thus constitutes a 
second-order effect. With suboptimal girls-only vaccination coverage, vaccinating boys 
along with girls will not only protect boys themselves, but could also increase herd 
protection to unvaccinated women [29, 30]. Based on modeling studies, 80% vaccination 
coverage in both men and women, but not in either sex, could eradicate the vaccine types 
[18]. 
We did not find signs of herd effects among unvaccinated women, also not when 
stratified by age. Nonetheless, other studies have observed a declining prevalence of the 
HPV vaccine types among unvaccinated women suggestive of herd protection. In Scotland, 
unvaccinated women born in 1995 were less often HPV16/18 positive at their first cervical 
screening compared to women born in 1988 who were not eligible for vaccination (5.3% vs 
30%) [9]. Also in Australia and the United States, decreases in the vaccine-type prevalence 
have been recorded among unvaccinated women [31, 32]. There are several possible 
explanations for the absence of a declining trend among unvaccinated women in our study. 
First, in high-risk populations with frequent changes in sex partners, people are more likely 
to encounter a HPV-positive man or women, limiting herd effects [20]. However, in Australia 
declines in vaccine-type prevalence were also observed among the high-risk group of 
chlamydia-positive unvaccinated women [33]. Second, in Australia and Scotland, the 
vaccination initiation rate was much higher: >80% in Australia and >90% in Scotland [2]. 
Third, the time horizon of our study (6 years post-vaccination) might be too short to observe 
second-order herd effects. In the United States, where vaccination coverage was also 
limited, decreases in vaccine-type prevalence among unvaccinated women were noted 5-8 
years after vaccine introduction and not yet after 3-6 years [32, 34]. 
In conclusion, the declining HPV16/18 prevalence among women is consistent with 
previous studies, but our findings also provide evidence for herd protection in heterosexual 
men after girls-only HPV16/18 vaccination. Due to the reduction in the HPV16/18 
prevalence among women and heterosexual men, HPV-related cancers are expected to 
decline in both sexes after girls-only HPV vaccination. The absence of measurable herd 
effects among unvaccinated women 6 years post-vaccination highlights once again the 
importance of high vaccination coverage to optimally reduce HPV-related cancer morbidity. 
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Supplementary information to Chapter 5 
 
Supplementary Table 5.1. Characteristics over time and relation with hrHPV positivity among all 
women. 
 
 
2009 
(n=1,110) 
2011 
(n=1,274) 
2013 
(n=1,294) 
2015 
(n=1,318)  hrHPVa 
 N (%) N (%) N (%) N (%) 
p 
valueb 
n positive 
(%) 
p 
valueb 
Age     <.01  <.01 
  16-20 years 480 (43.2) 465 (36.5) 539 (41.7) 528 (40.1)  1071 (53.2)  
  21-24 years 630 (56.8) 809 (63.5) 755 (58.3) 790 (59.9)  1921 (64.4)  
Self-defined ethnicity     0.67  0.30 
  Dutch 964 (87.0) 1093 (85.8) 1113 (86.0) 1149 (87.2)  2599 (60.2)  
  Not Dutch 144 (13.0) 181 (14.2) 181 (14.0) 169 (12.8)  392 (58.1)  
Education levelc    <.01  0.79 
  Low/middle 232 (21.2) 335 (26.4) 349 (27.2) 330 (25.1)  750 (60.2)  
  High 863 (78.8) 933 (73.6) 936 (72.8) 987 (74.9)  2223 (59.8)  
Sexual preference    <.01  0.76 
  Heterosexual 1079 (97.2) 1235 (96.9) 1241 (95.9) 1249 (94.8)  2875 (59.9)  
  Gay/bisexual  31 (2.8) 39 (3.1) 53 (4.1) 69 (5.2)  117 (60.9)  
Age at sexual debut    0.07  0.09 
  ≤14 years 118 (10.7) 158 (12.6) 193 (15.0) 178 (13.7)  403 (62.3)  
  15-16 years 539 (48.8) 614 (48.9) 606 (47.2) 637 (49.1)  1456 (60.8)  
  ≥17 years 447 (40.5) 484 (38.5) 485 (37.8) 482 (37.2)  1103 (58.1)  
No. of sex partners, past 6 months   <.01  <.01 
  0-1 partner 391 (35.3) 476 (37.4) 421 (32.6) 339 (25.7)  820 (50.4)  
  2-3 partners 528 (47.7) 599 (47.1) 649 (50.2) 636 (48.3)  1486 (61.6)  
  4-5 partners 141 (12.7) 152 (12.0) 156 (12.1) 238 (18.1)  481 (70.0)  
  ≥6 partners 48 (4.3) 45 (3.5) 67 (5.2) 105 (8.0)  203 (76.6)  
No. of sex partners, lifetime    <.01  <.01 
  ≤2 partners 138 (12.6) 183 (14.6) 128 (10.1) 121 (9.4)  202 (35.4)  
  3-4 partners 235 (21.5) 257 (20.5) 265 (20.9) 216 (16.7)  489 (50.3)  
  5-6 partners 224 (20.5) 239 (19.1) 249 (19.6) 254 (19.7)  543 (56.2)  
  7-14 partners 360 (32.9) 414 (33.1) 458 (36.1) 470 (36.4)  1166 (68.5)  
  ≥15 partners 136 (12.4) 159 (12.7) 169 (13.3) 229 (17.8)  534 (77.1)  
Anal sex, past 6 months    0.09  0.06 
  No 964 (87.5) 1138 (89.5) 1119 (87.1) 1130 (86.4)  2583 (59.4)  
  Yes 138 (12.5) 133 (10.5) 165 (12.9) 178 (13.6)  389 (63.4)  
Notified for STIsd   <.01  0.02 
  No 1027 (92.8) 1167 (91.9) 1169 (90.5) 1148 (87.6)  2677 (59.3)  
  Yes 80 (7.2) 103 (8.1) 122 (9.5) 162 (12.4)  303 (64.9)  
STI-related symptomsd   0.19  0.73 
  No 847 (76.9) 993 (78.3) 962 (74.7) 997 (76.0)  2268 (59.7)  
  Yes 254 (23.1) 276 (21.7) 326 (25.3) 314 (24.0)  705 (60.3)  
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Supplementary Table 5.1. (Continued). 
 
 
2009 
(n=1,110) 
2011 
(n=1,274) 
2013 
(n=1,294) 
2015 
(n=1,318)  hrHPVa 
 N (%) N (%) N (%) N (%) 
p 
valueb 
n positive 
(%) 
p 
valueb 
History of any STI    <.01  <.01 
  No 715 (65.1) 741 (58.4) 715 (55.5) 681 (51.9)  1644 (57.6)  
  Yes 238 (21.7) 313 (24.7) 335 (26.0) 380 (29.0)  902 (71.3)  
  Never tested 146 (13.3) 215 (16.9) 239 (18.5) 251 (19.1)  433 (50.9)  
Current genital chlamydia infectiond   0.47  <.01 
  No 959 (86.7) 1090 (85.9) 1095 (84.9) 1139 (86.8)  2507 (58.5)  
  Yes 147 (13.3) 179 (14.1) 195 (15.1) 173 (13.2)  472 (68.0)  
Steady partner     <.01  <.01 
  No  634 (58.1) 728 (58.7) 744 (58.9) 855 (66.7)  1836 (62.0)  
  Yes, for 0-6m 249 (22.8) 288 (23.2) 298 (23.6) 267 (20.8)  674 (61.2)  
  Yes, for ≥6m 208 (19.1) 225 (18.1) 221 (17.5) 159 (12.4)  404 (49.7)  
Condom use with casual partners, past 6 monthse  <.01  <.01 
  Inconsistent 382 (34.5) 408 (32.1) 538 (41.7) 622 (47.4)  1281 (65.7)  
  Consistent 421 (38.0) 492 (38.7) 446 (34.5) 447 (34.1)  1087 (60.2)  
  No casual 
partners 304 (27.5) 371 (29.2) 307 (23.8) 242 (18.5)  614 (50.2)  
Totals vary because of missing values. Sexual risk behavior variables that were associated with PASSYON study year (p<.05) and 
hrHPV (p<.05) were considered in a computerized stepwise selection model, to select confounders to adjust for. The variables that 
were selected in the stepwise model were: lifetime sex partners, history of any STI, steady partner, and condom use with casual 
partners. 
a. Being positive for HPV16/18/31/33/35/39/45/51/52/56/58 or HPV59. 
b. Calculated using Chi-square tests. 
c. High educational level included school of higher general secondary education, pre-university education, university of applied 
sciences, and university. Low/middle educational level included all other levels of education. 
d. Based on information of the STI clinic visit. 
e. Inconsistent included reporting never, rarely and “sometimes I do, sometimes I do not” condom use. Consistent included reporting 
often or always condom use. 
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Supplementary Table 5.2. Characteristics over time and relation with hrHPV positivity among 
heterosexual men. 
 
 
2009 
(n=414) 
2011 
(n=501) 
2013 
(n=522) 
2015 
(n=464) 
 hrHPVa 
 N (%) N (%) N (%) N (%) 
p 
valueb 
n positive 
(%) 
p 
valueb 
Age     0.34  <.01 
  16-20 years 118 (28.5) 139 (27.7) 169 (32.4) 131 (28.2)  144 (25.9)  
  21-24 years 296 (71.5) 362 (72.3) 353 (67.6) 333 (71.8)  559 (41.6)  
Self-defined ethnicity     0.75  0.21 
  Dutch 332 (80.6) 397 (79.2) 414 (79.3) 379 (81.7)  574 (37.7)  
  Not Dutch 80 (19.4) 104 (20.8) 108 (20.7) 85 (18.3)  129 (34.2)  
Education levelc     0.19  0.12 
  Low/middle 129 (31.2) 161 (32.3) 174 (33.5) 127 (27.4)  204 (34.5)  
  High 284 (68.8) 337 (67.7) 345 (66.5) 337 (72.6)  498 (38.2)  
Age at sexual debut    0.05  0.03 
  ≤14 years 65 (15.9) 95 (19.0) 92 (17.8) 70 (15.3)  128 (39.8)  
  15-16 years 147 (36.0) 192 (38.5) 230 (44.4) 193 (42.1)  302 (39.6)  
  ≥17 years 196 (48.0) 212 (42.5) 196 (37.8) 195 (42.6)  268 (33.5)  
No. of sex partners, past 6 months   <.01  <.01 
  0-1 partner 121 (29.2) 113 (22.6) 101 (19.3) 83 (17.9)  115 (27.5)  
  2-3 partners 168 (40.6) 198 (39.5) 196 (37.5) 153 (33.0)  221 (30.9)  
  4-5 partners 66 (15.9) 111 (22.2) 108 (20.7) 105 (22.6)  179 (45.9)  
  ≥6 partners 59 (14.3) 79 (15.8) 117 (22.4) 123 (26.5)  188 (49.7)  
No. of sex partners, lifetime    <.01  <.01 
  ≤2 partners 34 (8.5) 31 (6.5) 25 (5.0) 15 (3.4)  12 (11.4)  
  3-4 partners 50 (12.5) 58 (12.2) 63 (12.6) 31 (7.0)  40 (19.8)  
  5-6 partners 70 (17.5) 67 (14.1) 62 (12.4) 41 (9.3)  58 (24.2)  
  7-14 partners 121 (30.2) 151 (31.8) 154 (30.8) 159 (35.9)  197 (33.7)  
  ≥15 partners 126 (31.4) 168 (35.4) 196 (39.2) 197 (44.5)  360 (52.4)  
Anal sex, past 6 months    0.25  <.01 
  No 351 (85.4) 427 (85.9) 441 (86.0) 371 (81.9)  559 (35.2)  
  Yes 60 (14.6) 70 (14.1) 72 (14.0) 82 (18.1)  130 (45.8)  
Notified for STIsd   <.01  0.07 
  No 366 (89.1) 427 (85.7) 442 (84.7) 373 (80.9)  582 (36.2)  
  Yes 45 (10.9) 71 (14.3) 80 (15.3) 88 (19.1)  119 (41.9)  
STI-related symptomsd   0.94  0.04 
  No 295 (72.3) 363 (72.9) 373 (71.5) 336 (73.0)  488 (35.7)  
  Yes 113 (27.7) 135 (27.1) 149 (28.5) 124 (27.0)  212 (40.7)  
History of any STI  <.01  <.01 
  No 286 (69.8) 265 (53.1) 263 (50.5) 241 (51.9)  379 (35.9)  
  Yes 64 (15.6) 99 (19.8) 103 (19.8) 111 (23.9)  187 (49.6)  
  Never tested 60 (14.6) 135 (27.1) 155 (29.8) 112 (24.1)  133 (28.8)  
Current genital chlamydia infectiond   <.01  <.01 
  No 365 (89.2) 421 (84.7) 435 (83.5) 373 (80.9)  567 (35.6)  
  Yes 44 (10.8) 76 (15.3) 86 (16.5) 88 (19.1)  133 (45.2)  
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Supplementary Table 5.2. (Continued). 
 
 
2009 
(n=414) 
2011 
(n=501) 
2013 
(n=522) 
2015 
(n=464) 
 hrHPVa 
 N (%) N (%) N (%) N (%) 
p 
valueb 
n positive 
(%) 
p 
valueb 
Steady partner     <.01  0.02 
  No  206 (51.1) 253 (53.0) 284 (55.8) 294 (65.8)  383 (36.9)  
  Yes, for 0-6m 108 (26.8) 134 (28.1) 142 (27.9) 91 (20.4)  192 (40.4)  
  Yes, for ≥6m 89 (22.1) 90 (18.9) 83 (16.3) 62 (13.9)  100 (30.9)  
Condom use with casual partners, past 6 monthse  <.01  <.01 
  Inconsistent 146 (35.4) 211 (42.4) 240 (46.1) 254 (55.0)  345 (40.5)  
  Consistent 152 (36.8) 179 (35.9) 181 (34.7) 146 (31.6)  249 (37.8)  
  No casual 
partners 
115 (27.8) 108 (21.7) 100 (19.2) 62 (13.4)  105 (27.3)  
Totals vary because of missing values. Sexual risk behavior variables that were associated with PASSYON study year (p<.05) and 
hrHPV (p<.05) were considered in a computerized stepwise selection model, to select confounders to adjust for. The variables that 
were selected in the stepwise model were: lifetime sex partners, history of any STI, and steady partner. 
a. Being positive for HPV16/18/31/33/35/39/45/51/52/56/58 or HPV59. 
b. Calculated using Chi-square tests. 
c. High educational level included school of higher general secondary education, pre-university education, university of applied 
sciences, and university. Low/middle educational level included all other levels of education. 
d. Based on information of the STI clinic visit. 
e. Inconsistent included reporting never, rarely and “sometimes I do, sometimes I do not” condom use. Consistent included reporting 
often or always condom use. 
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Supplementary Table 5.3. Characteristics over time and relation with hrHPV positivity among 
unvaccinated women. 
 
 
2009 
(n=929) 
2011 
(n=1,060) 
2013 
(n=896) 
2015 
(n=709) 
 hrHPVa 
 N (%) N (%) N (%) N (%) 
p 
valueb 
n positive 
(%) 
p 
valueb 
Age     <.01  <.01 
  16-20 years 373 (40.2) 345 (32.5) 283 (31.6) 185 (26.1)  665 (56.1)  
  21-24 years 556 (59.8) 715 (67.5) 613 (68.4) 524 (73.9)  1561 (64.8)  
Self-defined ethnicity     0.60  0.05 
  Dutch 816 (88.0) 919 (86.7) 771 (86.0) 621 (87.6)  1956 (62.6)  
  Not Dutch 111 (12.0) 141 (13.3) 125 (14.0) 88 (12.4)  269 (57.8)  
Education levelc     <.01  0.80 
  Low/middle 172 (18.8) 261 (24.6) 226 (25.2) 176 (24.8)  514 (61.8)  
  High 743 (81.2) 799 (75.4) 670 (74.8) 533 (75.2)  1703 (62.0)  
Sexual preference    0.02  0.57 
  Heterosexual 901 (97.0) 1027 (96.9) 860 (96.0) 669 (94.4)  2138 (61.9)  
  Gay/bisexual  28 (3.0) 33 (3.1) 36 (4.0) 40 (5.6)  88 (64.2)  
Age at sexual debut    0.20  0.01 
  ≤14 years 95 (10.3) 122 (11.7) 125 (14.0) 97 (13.9)  289 (65.8)  
  15-16 years 447 (48.3) 508 (48.6) 411 (46.2) 331 (47.4)  1073 (63.2)  
  ≥17 years 383 (41.4) 416 (39.8) 354 (39.8) 270 (38.7)  843 (59.2)  
No. of sex partners, past 6 months   <.01  <.01 
  0-1 partner 330 (35.6) 395 (37.3) 288 (32.1) 190 (26.8)  618 (51.4)  
  2-3 partners 440 (47.4) 496 (46.8) 446 (49.8) 339 (47.8)  1111 (64.6)  
  4-5 partners 122 (13.1) 131 (12.4) 116 (12.9) 130 (18.3)  359 (71.9)  
  ≥6 partners 36 (3.9) 37 (3.5) 46 (5.1) 50 (7.1)  138 (81.7)  
No. of sex partners, lifetime    <.01  <.01 
  ≤2 partners 104 (11.4) 150 (14.3) 82 (9.3) 60 (8.6)  142 (35.9)  
  3-4 partners 200 (21.8) 205 (19.6) 163 (18.5) 120 (17.2)  354 (51.5)  
  5-6 partners 195 (21.3) 198 (18.9) 163 (18.5) 138 (19.8)  399 (57.5)  
  7-14 partners 303 (33.1) 360 (34.4) 339 (38.5) 243 (34.9)  885 (71.1)  
  ≥15 partners 114 (12.4) 134 (12.8) 133 (15.1) 135 (19.4)  409 (79.3)  
Anal sex, past 6 months    0.02  0.02 
  No 813 (87.8) 945 (89.2) 770 (86.7) 594 (84.4)  1908 (61.1)  
  Yes 113 (12.2) 114 (10.8) 118 (13.3) 110 (15.6)  305 (67.0)  
Notified for STIsd   <.01  0.11 
  No 861 (92.9) 975 (92.3) 810 (90.6) 617 (87.5)  2008 (61.5)  
  Yes 66 (7.1) 81 (7.7) 84 (9.4) 88 (12.5)  211 (66.1)  
STI-related symptomsd   0.21  0.53 
  No 710 (77.0) 821 (77.8) 668 (74.9) 522 (74.0)  1677 (61.6)  
  Yes 212 (23.0) 234 (22.2) 224 (25.1) 183 (26.0)  536 (62.8)  
History of any STI  <.01  <.01 
  No 613 (66.5) 620 (58.6) 505 (56.6) 363 (51.3)  1249 (59.4)  
  Yes 199 (21.6) 258 (24.4) 232 (26.0) 231 (32.7)  668 (72.6)  
  Never tested 110 (11.9) 180 (17.0) 155 (17.4) 113 (16.0)  300 (53.8)  
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Supplementary Table 5.3. (Continued). 
 
 
2009 
(n=929) 
2011 
(n=1,060) 
2013 
(n=896) 
2015 
(n=709) 
 hrHPVa 
 N (%) N (%) N (%) N (%) 
p 
valueb 
n positive 
(%) 
p 
valueb 
Current genital chlamydia infectiond   0.16  <.01 
  No 798 (86.1) 913 (86.5) 760 (85.1) 627 (88.9)  1878 (60.6)  
  Yes 129 (13.9) 142 (13.5) 133 (14.9) 78 (11.1)  339 (70.3)  
Steady partner     <.01  <.01 
  No  537 (58.8) 606 (58.5) 521 (59.4) 463 (67.6)  1363 (64.1)  
  Yes, for 0-6m 206 (22.6) 246 (23.7) 214 (24.4) 135 (19.7)  506 (63.2)  
  Yes, for ≥6m 170 (18.6) 184 (17.8) 142 (16.2) 87 (12.7)  301 (51.6)  
Condom use with casual partners, past 6 monthse  <.01  <.01 
  Inconsistent 306 (33.0) 343 (32.4) 374 (41.8) 321 (45.4)  927 (69.0)  
  Consistent 371 (40.0) 420 (39.7) 316 (35.3) 254 (35.9)  850 (62.5)  
  No casual 
partners 
250 (27.0) 296 (28.0) 204 (22.8) 132 (18.7)  443 (50.2)  
Totals vary because of missing values. Sexual risk behavior variables that were associated with PASSYON study year (p<.05) and 
hrHPV (p<.05) were considered in a computerized stepwise selection model, to select confounders to adjust for. The variables that 
were selected in the stepwise model were: lifetime sex partners, history of any STI, and condom use with casual partners. 
a. Being positive for HPV16/18/31/33/35/39/45/51/52/56/58 or HPV59. 
b. Calculated using Chi-square tests. 
c. High educational level included school of higher general secondary education, pre-university education, university of applied 
sciences, and university. Low/middle educational level included all other levels of education. 
d. Based on information of the STI clinic visit. 
e. Inconsistent included reporting never, rarely and “sometimes I do, sometimes I do not” condom use. Consistent included reporting 
often or always condom use. 
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 Supplementary Table 4.5. Comparing post-vaccination HPV prevalence with pre-
vaccination prevalence (2009) and assessing the trend among heterosexual men, excluding 
the men who reported to be HPV vaccinated. 
 
 
Heterosexual men 
not reporting to be HPV vaccinated 
 % positive (95% CI) aPR (95% CI)a 
HPV16/18b   
  2009 17.0 (13.6 - 20.9) Reference 
  2011 12.8 (10.1 - 16.0) 0.73 (0.52 - 1.02) 
  2013 8.0 (5.9 - 10.7) 0.44 (0.30 - 0.64) 
  2015 10.8 (8.3 - 14.0) 0.51 (0.36 - 0.74) 
ptrend valuec <.01 <.01 
HPV16   
  2009 11.3 (8.6 - 14.7) Reference 
  2011 6.7 (4.8 - 9.3) 0.57 (0.36 - 0.88) 
  2013 5.8 (4.1 - 8.2) 0.49 (0.31 - 0.78) 
  2015 8.4 (6.2 - 11.3) 0.63 (0.41 - 0.97) 
ptrend valuec 0.13 0.05 
HPV18   
  2009 7.1 (5.0 - 10.0) Reference 
  2011 7.1 (5.2 - 9.7) 0.97 (0.60 - 1.58) 
  2013 2.5 (1.5 - 4.3) 0.35 (0.18 - 0.66) 
  2015 2.8 (1.7 - 4.8) 0.33 (0.17 - 0.64) 
ptrend valuec <.01 <.01 
a. Adjusted for: age, lifetime sex partners, history of any STI, and steady partner. 
b. Defined as positive for HPV16 or HPV18 in the percentage positive, and as a pooled estimate to calculate the aPR. 
c. The crude ptrend values were calculated using the Cochran-Armitage Trend Test. The adjusted ptrend values were 
calculated by including PASSYON year as a continuous variable. 
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Supplementary Figure 5.1. Prevalence of HPV types 16 or 18, HPV16, and HPV18 over time and p vales 
for the crude trend test, among: A) 16- to 20-year-old women; B) 21- to 24-year-old women; C) 16- to 
20-year-old heterosexual men; D) 21- to 24-year-old heterosexual men; E) 16- to 20-year-old 
unvaccinated women; F) 21- to 24-year-old unvaccinated women. 
Note: The p value presents the Cochran-Armitage Trend Test. * Percentage of women and heterosexual men who reported to be 
vaccinated at least once. 
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Abstract 
 
Introduction: In 2009, girls-only HPV16/18 vaccination was introduced in the Netherlands 
which has achieved 46%-61% uptake. Heterosexual men have benefitted from herd 
protection, but it is unknown whether men who have sex with men (MSM) also benefit from 
herd effects of the girls-only HPV16/18 vaccination program. Because MSM bear a high 
HPV-related disease burden, countries might consider targeted vaccination for MSM. To 
study possible herd effects and prior HPV exposure at a potential moment of vaccination, 
we assessed trends in the HPV prevalence and proportions (sero)negative for the various 
vaccine types among young MSM visiting sexual health centers (SHCs). 
 
Methods: We used data from MSM included in PASSYON study years 2009-2017. In this 
biennial cross-sectional study among visitors of SHCs aged 16-24 years, MSM provided a 
penile and anal swab for HPV DNA testing (including vaccine types HPV6/11/16/18/31/33/ 
45/52/58) and blood for HPV antibody testing (HPV16/18/31/33/ 45/52/58). 
 
Results: In total 575 MSM were included, with a median of 22 years of age and 15 lifetime 
sex partners and 3.5% HIV positive. Trends in penile or anal HPV prevalence during 2009-
2017 were statistically non-significant for all vaccine types. Of the 455 MSM with a penile 
and anal swab, 360 (79%), 283 (62%), and 242 (53%) were HPV DNA negative at both 
anatomical sites for HPV16/18, HPV6/11/16/18, and HPV6/11/16/18/31/33/45/52/58 
respectively. Among MSM who were HPV16/18 and HPV16/18/31/33/45/52/58 DNA 
negative and were tested for serology (n=335 and 279 respectively), 82% and 71% were also 
seronegative for the respective types. 
 
Discussion: There were no significant declines in the HPV prevalence among MSM up to 8 
years after introduction of girls-only HPV16/18 vaccination, indicating that MSM are 
unlikely to benefit largely from herd effects from girls-only vaccination. Most MSM were 
vaccine-type DNA negative and seronegative, suggesting that vaccination of young MSM 
visiting SHCs could still be beneficial. 
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Introduction 
 
Sexually transmitted human papillomavirus (HPV) can cause anogenital warts (AGWs) and 
various cancers in both men and women: cervical, vaginal, vulvar, anal, and oropharyngeal 
cancer in women; and penile, anal, and oropharyngeal cancer in men [1]. Many different 
HPV types have been identified, which are classified into high-risk HPV (hrHPV) or low-risk 
HPV (lrHPV) based on their oncogenic potential. Currently, 3 prophylactic vaccines against 
HPV are on the European market and all are licensed for both males and females [2-4]; a 
bivalent HPV (2vHPV), quadrivalent HPV (4vHPV), and nonavalent HPV (9vHPV) vaccine. All 
vaccines target hrHPV types 16/18. The 4vHPV and 9vHPV vaccines also target lrHPV types 
6/11, the most important types causing AGWs [5]. The 9vHPV vaccine targets 5 additional 
hrHPV types: HPV31/33/45/52/58. As of May 2018, nearly half of the countries worldwide 
have implemented HPV vaccination in their national immunization program (NIP) [6]. 
Studies of high-income countries have shown declines in the HPV infection prevalence and 
the burden of AGWs and pre-malignant disease within a decade after HPV vaccination 
implementation [7]. 
Although sex-neutral HPV vaccination has been implemented in a diverse array of 
countries (e.g. Argentina, Australia, Austria, Brazil, Canada, Croatia, Israel, Panama) to 
prevent HPV-related cancers in both men and women, many countries still offer vaccination 
to girls only [8]. Also in the Netherlands, HPV vaccination is still a girls-only program as of 
2020. 2vHPV vaccination was introduced in 2009 with the main aim to prevent cervical 
cancer. It started with a catch-up campaign for 12- to 16-year-old girls and in 2010 HPV 
vaccination was implemented in the Dutch NIP for girls in the calendar year they turn 13 
years old. The vaccination uptake has ranged between 46% and 61% in vaccine-eligible 
cohorts [9]. 
Among heterosexual men, declines in the HPV vaccine-type prevalence have been 
observed after introduction of girls-only HPV vaccination, indicating that heterosexual men 
benefit from herd protection [10, 11]. It is unknown whether men who have sex with men 
(MSM) also experience decreases in the HPV16/18 prevalence as observed among 
heterosexual men. In Australia, AGWs (mostly caused by HPV6/11) nearly disappeared in 
young Australian heterosexual men within 7 years of girls-only 4vHPV vaccination, whereas 
only a small decline in AGWs was observed among MSM [12]. Accordingly, herd protection 
for hrHPV types among MSM is expected to be less than for heterosexual men, even though 
MSM are at much higher risk of HPV-related diseases than heterosexual men, especially for 
anal cancer. In meta-analyses published in 2012, the anal cancer incidence was estimated 
at 5.1 per 100,000 among HIV negative MSM and at 45.9 per 100,000 among HIV positive 
MSM [13]. This is about 17-30 times more frequent compared to heterosexual men [14, 15], 
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highlighting the importance of extending the protection afforded by prophylactic HPV 
vaccination to MSM. 
Additional to (pre)adolescent sex-neutral vaccination, countries might consider targeted 
vaccination for MSM. When combined with sex-neutral vaccination in (pre)adolescence, 
additional vaccination of MSM, even when previously exposed to HPV, is predicted to 
accelerate penile and anal cancer prevention, compensate for low-uptake among 
(pre)adolescents and protect previously unvaccinated MSM [16, 17]. A randomized 
controlled trial (RCT) carried out in MSM aged up to 26 years with 1-5 lifetime sex partners, 
showed that vaccination is effective in preventing genital and anal lesions, especially in 
those DNA negative and seronegative for the HPV vaccine type under study and at the 
anatomical site under study [18, 19]. Because it is difficult to target MSM from the general 
population and before sexual debut, an option would be to offer vaccination to MSM visiting 
sexual health centers (SHCs), comparable to targeted hepatitis B vaccination [20]. This is 
already being implemented in for example the United Kingdom after a successful pilot 
program with nearly 50% uptake [21]. However, the effectiveness of HPV vaccination 
targeting sexually active MSM visiting SHCs might be hampered by prior exposure to HPV 
vaccine types. 
Here, we assessed the scope of targeted HPV vaccination for MSM attending SHCs. First, 
we assessed trends in the penile and anal HPV prevalence among MSM visiting SHCs in the 
Netherlands from pre-vaccination up to 8 years post-vaccination, to study possible herd 
effects from girls-only vaccination. Second, we assessed the proportions HPV DNA negative 
at the penile and anal site and seronegative for the various vaccine-targeted types, to study 
prior exposure and the occurrence of prevalent infections at a potential moment of targeted 
vaccination, i.e. directed at MSM upon SHC visits. 
 
Methods 
 
Study design and population 
We used data from the PASSYON (PApillomavirus Surveillance among STI clinic YOungsters 
in the Netherlands) study, a biennial cross-sectional survey among 16- to 24-year-old 
visitors to SHCs in the Netherlands that started in 2009 when girls-only 2vHPV vaccination 
was implemented [22]. In the current analysis we used data from MSM included in the 
PASSYON study. MSM were classified as men who indicated to be homosexual or bisexual 
in the questionnaire. In addition to routine sexually transmitted infection (STI) testing, MSM 
were asked to provide a self-collected penile and anal swab for HPV testing. For the penile 
swab, men were instructed to firmly move the swab up and down the entire penile shaft, 
the glans, the coronal sulcus, and under the foreskin. For the anal swab, men were 
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instructed to insert the swab about 3 cm into the anus and circle it around. From 
participants who provided blood for routine syphilis and HIV testing, serum was collected 
to assess their HPV serology-status. Because MSM are at higher risk for syphilis and HIV, 
testing is usually indicated. The PASSYON study was repeated in 2011, 2013, 2015, and 2017 
using the same study protocol during which the proportion of women who had been offered 
HPV vaccination increased to almost 90% (of whom almost 60% reported to be HPV 
vaccinated with ≥1 dose). Participants could be included in multiple study rounds, but the 
probability of repeat consultations is low as we sampled for only 2 months in the same 
period (i.e. February-March) every other year. The Medical Ethical Committee of the 
University of Utrecht, the Netherlands, approved this study (protocol number 08/397). Data 
was obtained using a unique code per person and all participants gave informed consent. 
 
Laboratory methods 
Swabs were tested using the SPF10-DEIA-LiPA25 assay (DDL Diagnostics Laboratory, the 
Netherlands) as published in detail previously [22]. This sensitive broad-spectrum 
polymerase chain reaction (PCR) is able to detect DNA of 25 HPV types, including the 
vaccine-targeted HPV types 6/11/16/18/31/33/45/52/58 and the non-vaccine hrHPV types 
35/39/51/56/59. 
HPV serum IgG antibodies were assessed using a virus-like particle (VLP) based multiplex 
immunoassay against the vaccine-targeted hrHPV types 16/18/31/33/45/52/58 as 
published in detail previously [23, 24]. GSK (GlaxoSmithKline, Rixensart, Belgium) and MSD 
(Merck&Co, Kenilworth, NJ, USA) produced the VLPs that were used in the study. Serum 
samples were considered antibody seropositive at the following previously determined cut-
offs: 9, 13, 27, 11, 19, 14, and 31 Luminex Units (LU)/mL for HPV types 16, 18, 31, 33, 45, 
52, and 58, respectively [24]. 
 
Statistical analyses 
We explored the association between characteristics of the MSM and hrHPV DNA positivity 
(being positive for HPV types 16/18/31/33/35/39/45/51/52/56/58 or 59) using χ2 tests, for 
penile and anal HPV separately. To study trends in the vaccine types over time, we 
calculated the penile and anal HPV DNA prevalence for each PASSYON study year and 
performed crude Cochran-Armitage Trend Tests. Changes in the characteristics of the study 
population by study year were explored using χ2 tests. 
Because RCTs showed that vaccine efficacy among women was substantial even if a 
woman was seropositive when vaccinated (>66% against persistent infection with the 
vaccine types) [25, 26], we first calculated the proportion DNA negative for the vaccine-
targeted HPV types in the penile and anal swab, irrespective of serostatus. We did this 
among MSM with both swabs available, for the vaccine-targeted HPV types separately as 
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well as combined for the types included in the currently licensed vaccines (HPV16/18, 
HPV6/11/16/18, and HPV6/11/16/18/31/33/45/52/58). 
Next, we calculated the proportion DNA negative (both swabs) and seronegative. This 
was done for the vaccine-targeted hrHPV types only, because serum antibodies against 
HPV6/11 were not determined, again for each type separately as well as combined 
(HPV16/18 and HPV16/18/31/33/45/52/58). MSM were considered negative if they were 
DNA negative for all types in both swabs and seronegative for all types. 
Last, to explore the value of seropositivity as a marker of prior exposure to HPV, we 
studied the HPV antibody concentration by age and number of lifetime sex partners 
(categorized into 5 categories based on percentiles). The associations between log 
transformed antibody concentration and age/lifetime sex partners were studied using 
linear regression. All analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, 
NC) with a significance level of p<.05. 
 
Results 
 
Study population 
There were 587 MSM in the PASSYON study of which 575 (98%) provided a penile and/or 
anal swab and were included in the current analyses; 71 in round 2009, 110 in round 2011, 
136 in round 2013, 130 in round 2015, and 128 in round 2017. In total, 455 (78%) provided 
a penile and anal swab, 112 provided only a penile swab, and 8 provided only an anal swab. 
We had serum available of 531 MSM (92%) and 421 (73%) men provided both swabs and 
serum. 
Characteristics of the study population and the association with hrHPV DNA positivity 
are presented in Table 7.1. The median age of the MSM was 22 years (range 16-24) and the 
median reported number of lifetime sex partners was 15 (interquartile range: 6-30). Of all 
MSM, 3.5% were HIV positive. Overall, 20.3% and 36.7% of the MSM were positive for 
hrHPV at the penile and anal site respectively. In general, higher sexual risk behavior (like a 
higher number of lifetime sex partners and a history of STIs) was associated with hrHPV 
positivity. Receptive anal sex in the past 6 months was associated with anal hrHPV and 
insertive anal sex in the past 6 months with penile hrHPV. 
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Table 7.1. Characteristics of the MSM over all PASSYON study years and the relation with hrHPV 
DNA positivity. 
 
 Total study 
population 
(N=575) 
Penile hrHPVa (N=567) Anal hrHPVa (N=463) 
 N (%) % positive (95% CI) p value % positive (95% CI) p value 
Overall  20.3 (17.2 - 23.8)  36.7 (32.5 - 41.2)  
Age   0.09  0.11 
  16-18 years 51 (8.9) 8.0 (3.2 - 18.8)  30.2 (18.6 - 45.1)  
  19-20 years 143 (24.9) 18.0 (12.5 - 25.2)  28.9 (21.4 - 37.9)  
  21-22 years 177 (30.8) 22.2 (16.7 - 28.9)  42.3 (34.4 - 50.7)  
  23-24 years 204 (35.5) 23.3 (18.0 - 29.6)  39.1 (32.0 - 46.6)  
Self-defined ethnicity   0.53  <.01 
  Dutch 476 (82.9) 19.8 (16.5 - 23.7)  33.1 (28.6 - 37.9)  
  Not Dutch 98 (17.1) 22.7 (15.5 - 32.0)  55.1 (44.1 - 65.7)  
Education levelb   0.83  <.01 
  Low/middle 190 (33.1) 19.8 (14.7 - 26.1)  45.7 (38.0 - 53.6)  
  High 384 (66.9) 20.6 (16.8 - 24.9)  32.5 (27.5 - 37.9)  
Sexual preference  0.70  0.56 
  Homosexual 483 (84.0) 20.0 (16.6 - 23.8)  37.2 (32.6 - 42.0)  
  Bisexual 92 (16.0) 21.7 (14.5 - 31.2)  33.3 (22.7 - 45.9)  
Age at sexual debut  0.76  0.02 
  ≤14 yearsc 85 (14.9) 21.4 (14.0 - 31.3)  31.9 (22.1 - 43.6)  
  15-16 years 202 (35.4) 22.1 (16.9 - 28.4)  40.6 (33.4 - 48.2)  
  17-18 years 184 (32.2) 19.3 (14.2 - 25.7)  41.7 (33.9 - 49.8)  
  19-24 years 100 (17.5) 17.2 (11.0 - 25.8)  23.2 (15.4 - 33.4)  
No. of sex partners, past 6 months  0.08  0.07 
  0-1 partners 106 (18.5) 15.5 (9.8 - 23.8)  28.6 (20.0 - 39.0)  
  2-3 partners 191 (33.3) 18.1 (13.2 - 24.2)  35.4 (28.1 - 43.5)  
  4-6 partners 148 (25.8) 19.9 (14.2 - 27.1)  35.4 (27.7 - 44.1)  
  ≥7 partnersc 129 (22.5) 27.9 (20.9 - 36.2)  46.7 (37.6 - 56.1)  
No. of sex partners, lifetime  <.01  <.01 
  ≤5 partners 111 (19.8) 10.2 (5.8 - 17.3)  16.3 (10.0 - 25.5)  
  6-9 partners 85 (15.1) 11.8 (6.5 - 20.3)  33.3 (23.2 - 45.3)  
  10-19 partners 128 (22.8) 23.0 (16.5 - 31.1)  42.9 (33.5 - 52.7)  
  20-39 partners 124 (22.1) 22.0 (15.5 - 30.1)  38.1 (29.4 - 47.6)  
  ≥40 partnersc 114 (20.3) 29.2 (21.6 - 38.2)  49.0 (39.3 - 58.7)  
Insertive anal sex, past 6 months  0.02  0.05 
  No 154 (26.9) 14.0 (9.3 - 20.5)  29.3 (22.0 - 37.8)  
  Yes 419 (73.1) 22.7 (18.9 - 26.9)  39.3 (34.3 - 44.6)  
Receptive anal sex, past 6 months  0.79  <.01 
  No 143 (25.0) 19.6 (13.9 - 26.8)  24.7 (16.9 - 34.6)  
  Yes 430 (75.0) 20.6 (17.0 - 24.7)  39.5 (34.7 - 44.6)  
Notified for STIsd   0.75  0.22 
  No 479 (83.6) 20.6 (17.2 - 24.5)  35.5 (30.9 - 40.5)  
  Yes 94 (16.4) 19.1 (12.5 - 28.3)  42.7 (32.5 - 53.5)  
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Table 7.1. (Continued). 
 
 Total study 
population 
(N=575) 
Penile hrHPVa (N=567) Anal hrHPVa (N=463) 
 N (%) % positive (95% CI) p value % positive (95% CI) p value 
STI-related symptomsd  0.92  0.03 
  No 451 (78.7) 20.3 (16.8 - 24.3)  34.3 (29.6 - 39.3)  
  Yes 122 (21.3) 20.7 (14.4 - 28.7)  46.0 (36.6 - 55.7)  
History of any STI  <.01  <.01 
  No 269 (46.9) 15.8 (11.9 - 20.7)  27.2 (21.6 - 33.6)  
  Yes 229 (39.9) 28.2 (22.7 - 34.4)  48.4 (41.5 - 55.5)  
  Never tested 76 (13.2) 12.2 (6.5 - 21.5)  31.3 (21.2 - 43.4)  
Current STId,e   0.72  <.01 
  No 478 (83.4) 20.1 (16.7 - 23.9)  33.2 (28.7 - 38.1)  
  Yes 95 (16.6) 21.7 (14.5 - 31.2)  53.8 (42.9 - 64.3)  
HIV infectiond   0.23  <.01 
  No 502 (96.5) 19.8 (16.5 - 23.5)  34.0 (29.5 - 38.8  
  Yes 18 (3.5) 33.3 (16.3 - 56.3)  83.3 (60.8 - 94.2)  
Condom use with casual partners, past 6 monthsf 0.66  0.28 
  Inconsistent 124 (21.6) 17.4 (11.6 - 25.1)  35.1 (26.3 - 45.0)  
  Consistent 382 (66.4) 21.2 (17.3 - 25.6)  38.9 (33.6 - 44.5)  
  No casual partners 69 (12.0) 20.6 (12.7 - 31.6)  28.3 (18.5 - 40.8)  
Totals vary because of missing values.  
a. Being DNA positive for HPV16/18/31/33/35/39/45/51/52/56/58/59. 
b. High educational level included school of higher general secondary education, pre-university education, university of applied 
sciences, and university. Low/middle educational level included all other levels of education. 
c. The minimum reported age at sexual debut was 8. The maximum number of reported sex partners in the past 6 months was 
100 and lifetime 900. 
d. Based on the visits at the SHC. 
e. Including chlamydia, gonorrhea, and syphilis. 
f. Inconsistent included reporting never, rarely and “sometimes I do, sometimes I do not” condom use. Consistent included 
reporting often or always condom use. 
 
Prevalence of vaccine-targeted HPV types over time 
No statistically significant declining trends were observed in the penile (Figure 7.1A) or anal 
(Figure 7.1B) HPV DNA prevalence among MSM for any of the vaccine-targeted types up to 
8 years after the introduction of girls-only 2vHPV vaccination. Also for the pooled outcome 
HPV16/18, no statistically significant declining trend was observed (ptrend=0.75 for penile 
and ptrend=0.50 for anal HPV). The prevalence of AGWs decreased from 7.1% in 2009 to 0.8% 
in 2017 (ptrend=0.03) (Figure 7.1C). Changes over time in the characteristics of the MSM 
included in the PASSYON study are presented in Supplementary Table 7.1. Only sexual 
preference and a history of STIs were associated with PASSYON study year (p<.05). The 
proportion reporting no history of STIs was 57% in 2009 and 41% in 2017. 
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Figure 7.1. Prevalence of penile and anal HPV DNA and anogenital warts among MSM over time and 
the crude trend. 
Note: The p value presents the Cochran-Armitage Trend Test. The y-axis differs for the different outcomes. For A) penile HPV, in 
total 567 MSM were included; 69 in 2009, 109 in 2011, 135 in 2013, 129 in 2015, and 125 in 2017. For B) anal HPV, in total 463 
MSM were included; 53 in 2009, 80 in 2011, 113 in 2013, 104 in 2015, and 113 in 2017. For C) anogenital warts, in total 575 MSM 
were included; 71 in 2009, 110 in 2011, 136 in 2013, 130 in 2015, and 128 in 2017. 2vHPV include HPV16/18; 4vHPV include 
HPV6/11/16/18; 9vHPV include HPV6/11/16/18/31/33/45/52/58. 
 
Proportion negative for the vaccine-targeted HPV types 
The percentage of MSM negative for HPV DNA at the penile and anal site was the smallest 
for HPV6 (83%) and the largest for HPV58 (99%) (Figure 7.2A). For HPV16, 88% was negative, 
8.6% was positive only at the anal site, 2.2% was positive only at the penile site, and 1.5% 
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was positive at both sites. For HPV18, 89% was negative, 6.8% was positive only at the anal 
site, 2.0% was positive only at the penile site, and 1.8% was positive at both sites. In total, 
79%, 62%, and 53% were HPV DNA negative at both anatomic sites for HPV16/18, 
HPV6/11/16/18, and HPV6/11/16/18/31/33/45/52/58, respectively (Figure 7.2B). Of the 
MSM infected with  at least one of the 9 vaccine-targeted types at either anatomical site 
(n=213), the majority was infected with 1 type (n=136, 64%). Nobody was positive for all 
vaccine-targeted types; the maximum number of types present at either anatomic site was 
6 (n=1). Nobody was positive for both HPV16 and HPV18 at both anatomic sites. 
 
 
Figure 7.2. Percentage of MSM who were DNA negative (panel A and B) and seronegative (panel C 
and D) for the vaccine-targeted HPV types. 
Note: For panel A and B, all MSM with both swabs available were included (n=455). For panel C and D, all MSM with both swabs 
and serum available were included (n=421). 2vHPV include HPV16/18; 4vHPV include HPV6/11/16/18; 9vHPV include 
HPV6/11/16/18/31/33/45/52/58. 9v hrHPV include HPV16/18/31/33/45/52/58. 1 Negative was defined as being negative for all 
the types. Positivity was defined as being positive for ≥1 type. 2 DNA negative was defined as being negative in the penile as well 
as the anal swab, DNA positive was defined as being positive in ≥1 swab. Seropositivity was based on the predefined type-specific 
cut-off levels. 3 DNA negative was defined as being negative for all the types in the penile as well as the anal swab, DNA positive 
was defined as being positive for ≥1 type in ≥1 swab. Seronegative was defined as being seronegative for all types, seropositivity 
was defined as being seropositive for ≥1 type based on the predefined type-specific cut-off levels. 
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Also including serology, 76% of the MSM were HPV16 negative (DNA negative in both swabs 
and seronegative) and 79% were HPV18 negative (Figure 7.2C). For the other vaccine-
targeted hrHPV, the percentage HPV DNA negative and seronegative was even higher and 
up to 94% for HPV58. Among MSM HPV16/18 and HPV16/18/31/33/45/52/58 DNA 
negative, 82% and 71% were also seronegative for the respective vaccine types. In total, 
65% and 47% were HPV DNA negative and seronegative for HPV16/18 and 
HPV16/18/31/33/45/52/58 respectively (Figure 7.2D). 
 
HPV antibody concentration  
The HPV16 and HPV18 log antibody concentration increased both with age and number of 
lifetime sex partners (p<.05). However, even in the highest categories of 23-to 24–year-olds 
and ≥40 lifetime sex partners, the majority of the MSM were not seropositive (Figure 7.3). 
These patterns were comparable to the other hrHPV types (data not shown). 
 
 
Figure 7.3. Log antibody concentration for HPV16 and HPV18 by age and number of lifetime sex 
partners. 
Note: The dashed line represents the type-specific predefined cut-off level for seropositivity. The maximum number of reported 
lifetime sex partners was 900. The error bars represent the 2.5th and 97.5th percentiles. 
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Discussion 
 
We assessed the scope for targeted HPV vaccination for sexually active MSM, by studying 
trends in the HPV prevalence over time and by studying the proportions (sero)negative for 
the various vaccine-targeted HPV types among young sexually active MSM who visited SHCs 
in the Netherlands. We did not discern trends for any of the vaccine types up to 8 years 
after the introduction of girls-only vaccination, and the majority of the MSM in our study 
population were HPV DNA negative and seronegative for the various vaccine types. Our 
study provides important baseline measurements in case male HPV vaccination will be 
implemented in the Netherlands. Moreover, because young MSM visiting SHCs are a natural 
target population for a selective vaccination program, our study may provide relevant input 
for countries considering targeted HPV vaccination for MSM. 
We do acknowledge some limitations. First, MSM definition was based on self-
identification of sexual preference instead of behavior, because information on the sex of 
the sex partners was unavailable. Second, relatively small numbers of MSM were included 
per PASSYON study round, resulting in limited power to detect possible trends. Last, we only 
had data from young MSM up to 24 years of age with 3.5% being HIV positive. We cannot 
extrapolate the results to older MSM visiting SHCs or MSM populations with a higher HIV 
prevalence. Whether prophylactic HPV vaccination of HIV positive MSM would be effective 
is still unclear; an RCT to study the vaccine efficacy among HIV infected adults aged 27 years 
or older was ended prematurely due to lack of effectiveness [27]. 
No significant declining trends were observed in the HPV16/18 prevalence among MSM 
in the aftermath of girls-only HPV16/18 vaccination. Given that a declining trend in the 
HPV16/18 prevalence was observed among heterosexual men in the PASSYON study (35% 
decline in a 6-year period) [11], the lack of a noticeable trend among MSM in an 8-year 
period indicates that MSM are unlikely to benefit to a large extent from herd protection 
from girls-only vaccination. We did observe a declining trend in the AGW prevalence, 
presumably as a result of changes in the policy of the SHCs; persons with AGWs were more 
often referred to the general practitioner in recent years [28]. The declining trend is likely 
not a result of herd protection as the current vaccination program for girls does not include 
vaccination against HPV6/11, the main causes of AGWs [5]. 
In contrast to what is often assumed, our study shows that many young MSM visiting 
SHCs are HPV DNA negative and seronegative for the vaccine-targeted types, at least until 
the age of 24 years. For two-thirds of the MSM there was no evidence of current or past 
infection with both HPV16 and HPV18 at the penile as well as the anal site, suggesting that 
vaccination could still be beneficial. Note that this definition of negativity based on DNA and 
serostatus (negative for all measures for both HPV vaccine types) is more stringent than 
used in the RCT’s per-protocol definition where negativity was defined as being DNA 
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negative at the anatomic site and HPV type under study and seronegative for the HPV type 
under study [18, 19]. Therefore, the proportion of MSM to experience vaccine-induced 
protection similar to the per-protocol efficacy demonstrated in RCTs will likely exceed two-
thirds of 16- to 24-year-old MSM. If someone is positive at 1 anatomical site, vaccination 
could possibly still prevent infections at the other site and if someone is positive for only 1 
type included in the vaccine, vaccination could still be effective in preventing infections with 
the other type(s) [29]. All MSM were negative for at least one of the 2vHPV types at one or 
more anatomical sites, indicating that all MSM could derive at least partial benefit from 
vaccination. Focusing on HPV16, by far the most oncogenic type in men, 98% of the MSM 
were DNA negative at one or more anatomical sites. Moreover, although vaccination does 
not have a therapeutic effect on infections prevalent at the time of vaccination, it might still 
prevent future infections [30]. In contrast to women, where the peak of infection is before 
the mid-twenties, many MSM will keep being exposed and infected during many years of 
their lifetime [31]. Thus, as the risk of HPV acquisition does not diminish with age, 
vaccinating MSM at older age is still likely to be beneficial. 
One of the inclusion criteria of the RCT where efficacy of HPV vaccination among MSM 
has been demonstrated, was having 1-5 lifetime sex partners [18, 19]. Of the MSM in our 
study, 80% had 6 or more partners and 20% even 40 or more. Despite these high numbers 
of partners, we observed a low type-specific (sero)prevalence for the various vaccine types. 
It could be that MSM without evidence of HPV exposure were previously infected but 
cleared the infection without seroconversion [32] or had a latent infection [33]. Prophylactic 
vaccination probably has no effect on latent infections and one could argue that MSM who 
previously cleared an infection are able to also clear a future infection, diminishing an 
additional benefit of vaccination. However, chance could play an important role in clearance 
[34] and build-up of (long lasting) natural immunity in men is not apparent from 
epidemiological data [35, 36]. Moreover, viral persistence and oncogenic potential might 
differ between different variants of the same HPV type [37]. Therefore, even if an MSM 
already cleared an infection, there is still a risk of acquiring a persistent infection in the 
future. Future research should focus on the role of latency and of clearance in relation to 
prior exposure, and how these factors could affect vaccine effectiveness (VE) when offering 
HPV vaccination to MSM with high numbers of lifetime sex partners. 
The antibody concentration among MSM increased only slightly with age and number 
of lifetime partners; even among those with ≥40 partners, the majority was not yet 
seropositive. The median HPV16- and HPV18-specific antibody concentrations among MSM 
with ≥40 partners were also considerably lower than among vaccinated women in the 
PASSYON study (0.62 and 1.41 , compared to 7.61 and 6.94 Ln LU/mL, respectively) [38]. In 
another study among MSM with a median age of 40 years, HPV16/18 antibody 
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concentrations of over 6.2 Ln LU/mL (i.e. >500 LU/mL) were not associated with a lower 
acquisition of anal or penile HPV infections over a 12-month period [35]. Vaccination could 
increase the antibody concentration of MSM, even among those previously exposed, up to 
levels affording protection against subsequent infections. 
Taken together, even though the VE among MSM with a high number of sex partners is 
not clear-cut, it is likely that many young MSM visiting SHCs in the Netherlands could still 
benefit from HPV vaccination given the high proportions of HPV (sero)negativity for the 
relevant vaccine types and the likely limited build-up of natural immunity. This was also 
suggested in previous research [39-42]. Various modeling studies have indicated that 
targeted prophylactic vaccination for sexually active MSM could also be a (cost-) effective 
strategy on a population-level [17, 43], including a recent study using the context of the 
Netherlands [16]. The HPV16 prevalence in our study was in line with the predicted penile 
and anal HPV16 prevalence among MSM in that modeling study. However, projected 
reductions in HPV16 prevalence were strongly reduced if no effectiveness was assumed in 
MSM with prevalent infection at the time of vaccination. Because vaccination is most 
effective before HPV exposure and HPV positivity increases with lifetime number of 
partners, it is desirable to vaccinate MSM as early as possible. While our data suggest that 
vaccination might be effective for the population of 16- to 24-year-old MSM who visit a SHC, 
vaccination is preferably offered at the initial SHC visit. In our study, 13% reported never 
being tested for STIs indicating this was their first visit; the other MSM (87%) had possibly 
visited the SHC in the past. HPV vaccination may also be beneficial for MSM not visiting 
SHCs; those are more difficult to target, but might be reached via the general practitioner 
or snowball sampling through MSM who do visit SHCs. 
In conclusion, this study did not find evidence for declines in the prevalence of HPV 
vaccine types among MSM, indicating that they are unlikely to benefit to a large extent from 
herd effects from girls-only vaccination. Moreover this study shows that many young MSM 
visiting SHCs are HPV DNA negative and seronegative for the relevant vaccine types, 
indicating they could still benefit from HPV vaccination. Targeted MSM vaccination might 
be considered and SHCs could play an important role in promoting HPV vaccination to young 
MSM. 
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Supplementary information to Chapter 7 
 
Supplementary Table 7.1. Characteristics of the MSM over the PASSYON study years. 
 
 2009 2011 2013 2015 2017  
 N (%) N (%) N (%) N (%) N (%) p value 
Total 71 110 136 130 128  
Age      0.29 
  16-18 years 7 (9.9) 9 (8.2) 17 (12.5) 6 (4.6) 12 (9.4)  
  19-20 years 18 (25.4) 27 (24.5) 37 (27.2) 26 (20.0) 35 (27.3)  
  21-22 years 15 (21.1) 35 (31.8) 42 (30.9) 49 (37.7) 36 (28.1)  
  23-24 years 31 (43.7) 39 (35.5) 40 (29.4) 49 (37.7) 45 (35.2)  
Self-defined ethnicity      0.82 
  Dutch 57 (81.4) 88 (80.0) 115 (84.6) 107 (82.3) 109 (85.2)  
  Not Dutch 13 (18.6) 22 (20.0) 21 (15.4) 23 (17.7) 19 (14.8)  
Education levela      0.12 
  Low/middle 25 (35.7) 38 (34.5) 55 (40.4) 39 (30.0) 33 (25.8)  
  High 45 (64.3) 72 (65.5) 81 (59.6) 91 (70.0) 95 (74.2)  
Sexual preference     0.05 
  Homosexual 60 (84.5) 82 (74.5) 117 (86.0) 113 (86.9) 111 (86.7)  
  Bisexual 11 (15.5) 28 (25.5) 19 (14.0) 17 (13.1) 17 (13.3)  
Age at sexual debut      0.62 
  ≤14 yearsb 14 (20.0) 18 (16.4) 15 (11.1) 18 (13.8) 20 (15.9)  
  15-16 years 22 (31.4) 42 (38.2) 54 (40.0) 49 (37.7) 35 (27.8)  
  17-18 years 20 (28.6) 31 (28.2) 46 (34.1) 39 (30.0) 48 (38.1)  
  19-24 years 14 (20.0) 19 (17.3) 20 (14.8) 24 (18.5) 23 (18.3)  
No. of sex partners, past 6 months      0.21 
  0-1 partners 15 (21.4) 17 (15.5) 32 (23.5) 29 (22.3) 13 (10.2)  
  2-3 partners 26 (37.1) 37 (33.6) 46 (33.8) 43 (33.1) 39 (30.5)  
  4-6 partners 16 (22.9) 31 (28.2) 32 (23.5) 32 (24.6) 37 (28.9)  
  ≥7 partnersb 13 (18.6) 25 (22.7) 26 (19.1) 26 (20.0) 39 (30.5)  
No. of sex partners, lifetime     0.41 
  ≤5 partners 15 (21.1) 22 (21.0) 32 (24.4) 20 (15.6) 22 (17.3)  
  6-9 partners 7 (9.9) 13 (12.4) 25 (19.1) 19 (14.8) 21 (16.5)  
  10-19 partners 18 (25.4) 26 (24.8) 25 (19.1) 34 (26.6) 25 (19.7)  
  20-39 partners 10 (14.1) 23 (21.9) 29 (22.1) 31 (24.2) 31 (24.4)  
  ≥40 partnersb 21 (29.6) 21 (20.0) 20 (15.3) 24 (18.8) 28 (22.0)  
Insertive anal sex, past 6 months     0.69 
  No 15 (21.1) 30 (27.3) 37 (27.6) 33 (25.4) 39 (30.5)  
  Yes 56 (78.9) 80 (72.7) 97 (72.3) 97 (74.6) 89 (69.5)  
Reseptive anal sex, past 6 months     0.94 
  No 17 (23.9) 30 (27.3) 33 (24.6) 34 (26.2) 29 (22.7)  
  Yes 54 (76.1) 80 (72.7) 101 (75.4) 96 (73.8) 99 (77.3)  
Notified for STIsc      0.30 
  No 62 (88.6) 95 (86.4) 115 (85.2) 102 (78.5) 105 (82.0)  
  Yes 8 (11.4) 15 (13.6) 20 (14.8) 28 (21.5) 23 (18.0)  
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Supplementary Table 7.1. (Continued). 
 
 2009 2011 2013 2015 2017  
 N (%) N (%) N (%) N (%) N (%) p value 
STI-related symptomsc     0.82 
  No 54 (77.1) 88 (80.0) 104 (77.0) 100 (76.9) 105 (82.0)  
  Yes 16 (22.9) 22 (20.0) 31 (23.0) 30 (23.1) 23 (18.0)  
History of any STI    0.03 
  No 40 (57.1) 55 (50.0) 63 (46.3) 58 (44.6) 53 (41.4)  
  Yes 24 (34.3) 44 (40.0) 45 (33.1) 61 (46.9) 55 (43.0)  
  Never tested 6 (8.6) 11 (10.0) 28 (20.6) 11 (8.5) 20 (15.6)  
Current STIc,d      0.16 
  No 55 (78.6) 89 (80.9) 120 (88.9) 112 (86.2) 102 (79.7)  
  Yes 15 (21.4) 21 (19.1) 15 (11.1) 18 (13.8) 26 (20.3)  
HIV infectionc      0.27 
  No 69 (98.6) 108 (98.2) 130 (95.6) 121 (93.8) 74 (98.7)  
  Yes 1 (1.4) 2 (1.8) 6 (4.4) 8 (6.2) 1 (1.3)  
Condom use with casual partners, past 6 monthse    0.33 
  Inconsistent 10 (14.1) 24 (21.8) 28 (20.6) 27 (20.8) 35 (27.3)  
  Consistent 53 (74.6) 73 (66.4) 87 (64.0) 85 (65.4) 84 (65.6)  
  No casual partners 8 (11.3) 13 (11.8) 21 (15.4) 18 (13.8) 9 (7.0)  
Totals vary because of missing values. 
a. High educational level included school of higher general secondary education, pre-university education, university of applied 
sciences, and university. Low/middle educational level included all other levels of education. 
b. The minimum reported age at sexual debut was 8. The maximum number of reported sex partners in the past 6 months was 
100 and lifetime 900. 
c. Based on the visits at the SHC. 
d. Including chlamydia, gonorrhea, and syphilis.  
e. Inconsistent included reporting never, rarely and “sometimes I do, sometimes I do not” condom use. Consistent included 
reporting often or always condom use. 
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Abstract  
 
Introduction: Data from a vaccine trial and from post-vaccine surveillance in the United 
Kingdom have suggested that the bivalent HPV16/18 vaccine offers cross-protection against 
HPV6/11 and protection against anogenital warts (AGWs). We studied the effect of the 
bivalent vaccine on genital HPV6/11 positivity and AGWs in the Netherlands. 
 
Methods: We included all vaccine-eligible women from the PASSYON study, a biennial 
cross-sectional study among 16- to 24-year-old sexually transmitted infection (STI) clinic 
attendants. Cervicovaginal self-swabs were analyzed for type-specific HPV and AGWs were 
diagnosed at the STI clinic. Prevalence of HPV6 and/or HPV11 and AGWs were compared 
between self-reported vaccinated and unvaccinated women by log-binomial regression 
analysis, adjusted for demographics and risk behavior. 
 
Results: Of the 1,198 women included, 56% reported to be vaccinated at least once. Relative 
to unvaccinated women, the adjusted prevalence ratio (PR) for HPV6/11 was 1.03 (95% 
confidence interval [CI] 0.74-1.43) for women vaccinated at least once. The crude PR for 
AGWs was 0.67 (95% CI 0.22-2.07) for women vaccinated at least once. Adjustment did not 
change these results. 
 
Discussion: We observed no cross-protective effect of the bivalent vaccine on genital 
HPV6/11 positivity and a non-significant partially protective effect on AGWs. 
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Introduction 
 
Human papillomavirus (HPV) is a sexually transmitted virus of which many different types 
exist. Types 16 and 18 are responsible for approximately 70% of all cervical cancers [1] and 
types 6 and 11 are responsible for approximately 90% of all anogenital warts (AGWs) [2]. 
Currently, 3 different vaccines against HPV are available: (A) the bivalent (2vHPV) 
vaccine (Cervarix®) which protects against HPV types 16 and 18 [3]; (B) the quadrivalent 
(4vHPV) vaccine (Gardasil®) which protects against HPV types 16, 18, 6, and 11 [4]; (C) the 
nonavalent (9vHPV) vaccine (Gardasil9®) which protects against HPV types 16, 18, 6, 11, 31, 
33, 45, 52, and 58 [5]. 
Although the 2vHPV vaccine is not indicated to prevent HPV6/11, some studies have 
suggested a cross-protective effect against HPV6/11 and a protective effect against AGWs. 
In post-hoc analyses of a 2vHPV vaccine trial (PATRICIA trial) a vaccine efficacy of 35% (95% 
confidence interval [CI] 11%-52%) against 6-month persistent HPV6 and/or HPV11 infection 
was estimated among women who were HPV seronegative at baseline [6]. Moreover, data 
from post-vaccine surveillance in the United Kingdom suggested that the 2vHPV vaccine 
offers protection against AGWs. They observed a decline in AGWs among young girls and 
heterosexual men after introduction of the 2vHPV vaccine in 2008, while such a decline was 
not observed among older women or men who have sex with men [7, 8]. The vaccine 
effectiveness (VE) against AGWs was calculated to be 34% (95% CI 29%-38%) [7]. In 2012, 
the United Kingdom switched to the 4vHPV vaccine in their national immunization program 
(NIP) and a further drop in AGWs is expected due to direct protection against HPV6/11. 
The Netherlands is one of the few industrialized countries using the 2vHPV vaccine in 
the NIP. In 2009, there was a one-off catch-up campaign for girls born in 1993-1996 (12-16 
years old). From 2010 onwards, girls are offered vaccination in the year they turn 13 years 
old, starting with birth cohort 1997 in 2010 [9]. The vaccination coverage for the catch-up 
cohorts was 52% [10]. The vaccination coverage of the routine vaccination was 56% for birth 
cohort 1997 and increased to 61% for birth cohort 2001 [11]. 
From a public health perspective, monitoring of the effect of the HPV vaccination 
program includes its possible effect on non-vaccine HPV types. For this reason, a biennial 
cross-sectional study among young sexually transmitted infection (STI) clinic attendants was 
initiated in the Netherlands in 2009, the year of HPV vaccine introduction in the 
Netherlands. 
In this paper, we explore the effects of the 2vHPV vaccine on genital HPV6 and/or HPV11 
positivity and AGWs by comparing vaccinated and unvaccinated women with similar 
exposure, using data from STI clinics from 2011 to 2015. 
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Methods 
 
Study design and population 
We used data from the PASSYON (PApillomavirus Surveillance among STI clinic YOungsters 
in the Netherlands) study. The study design is described in detail elsewhere [12]. Briefly, the 
PASSYON study is a biennial cross-sectional study among 16- to 24-year-old attendants of 
STI clinics located throughout the Netherlands. It started in 2009 and was repeated in 2011, 
2013, and 2015 (Figure 8.1). Additional to the routine STI consultation, participants were 
asked to provide a genital self-swab for HPV testing and to fill-in a questionnaire including 
self-reported vaccination status. From participants who provided blood for routine STI 
diagnostics, serum was collected for HPV serology. AGWs were diagnosed during the 
routine STI consultation, based on clinical presentation. The Medical Ethical Committee of 
the University of Utrecht, the Netherlands approved this study (protocol number 08/397). 
Data were obtained using a unique code per person and all participants gave informed 
consent. 
To study the effect of the 2vHPV vaccine on HPV6/11 and AGWs, we included from the 
PASSYON study years 2011, 2013, and 2015 all women born in 1993 or later, i.e. those who 
were eligible for vaccination in the catch-up campaign or the NIP (Figure 8.1). 
 
 
 
Figure 8.1. PASSYON study design and the study population selection. 
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Laboratory methods 
Swabs were stored at −20°C until analyses [12]. DNA was extracted using the MagnaPure 
platform (Total Nucleic Acid Isolation Kit, Roche, the Netherlands) and eluted in 100-
microliter elution buffer. HPV DNA was amplified using the SPF10 primer set. Subsequently, 
HPV specific amplicons were detected using the DNA enzyme-linked immunoassay (HPV-
DEIA, DDL Diagnostics Laboratory, the Netherlands). Amplicons of positive samples were 
genotyped with Line probe assay (HPV-LiPA, DDL Diagnostics Laboratory, the Netherlands) 
which is able to detect 25 HPV types including types 6 and 11 [12]. 
Serum samples were stored at −80°C until analyses [13]. HPV antibodies against L1 virus-
like particles (VLPs) for 7 serotypes including types 16 and 18 were assessed using a 
multiplex immunoassay [14]. Cut-off levels for seropositivity were previously determined 
and were 9 Luminex Units (LU)/ml for HPV16 and 13 LU/ml for HPV18 [14]. 
 
Statistical analyses 
First, we checked for differences in demographics and risk behavior between vaccinated 
and unvaccinated women. We compared women who reported to be vaccinated (≥1 dose) 
with unvaccinated women and women who reported to be fully vaccinated (3 doses 
according guidelines prevailing at the time of vaccination for women eligible for this study 
[15]) with unvaccinated women. Women with an unknown vaccination status were 
analyzed separately. 
We considered the demographic variables age, migration background, and education 
level. Migration background was based on (parental) country of birth. A woman was defined 
as native Dutch if both parents were born in the Netherlands [16]. Education level was self-
reported and categorized as high and low/middle. High educational level included school of 
higher general secondary education, pre-university education, university of applied 
sciences, and university. Low/middle educational level included all other forms of 
education. 
For risk behavior, we considered number of sex partners in the past 6 months, number 
of lifetime sex partners, age at sexual debut, history of STIs, condom use with casual 
partners in the past 6 months, hormonal contraceptives use, and current genital chlamydia 
or gonorrhea infection. The latter was based on diagnoses during the routine STI 
consultation. The other variables were self-reported and categorized (Table 8.1). 
Prevalence of genital HPV6 and/or HPV11 positivity and AGWs were calculated by self-
reported vaccination status. We calculated prevalence ratios (PR) using log-binomial 
regression analyses. For the outcome genital HPV6 and/or HPV11 positivity, we first 
calculated the crude PR. Second, we adjusted for age and demographic variables that were 
associated with vaccination status. Third, we further adjusted for risk behavior variables 
that were associated with vaccination status to measure the adjusted effect of vaccination 
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on HPV6/11. For the outcome AGWs, we calculated the crude PR. Due to low numbers of 
AGWs in our study, we could not adjust for potential confounders all at once, so we adjusted 
for potential confounders in bivariable analyses only. Moreover, we described the genital 
HPV types that were found among women diagnosed with AGWs. 
All analyses were performed using SAS version 9.3 (SAS Institute Inc., Cary, NC) with a 
significance level of p<.05. The records with missing data were excluded from the analyses, 
as these represented less than 5% of the study population. 
 
Sensitivity analyses 
HPV16 and HPV18 antibody concentrations were compared between self-reported 
vaccinated and unvaccinated women with serum available. Since all women vaccinated with 
the 2vHPV vaccine have an antibody response against HPV16 and HPV18 up to 9.4 years 
after vaccination [17], it is unlikely that vaccinated women are seronegative for HPV16/18. 
We repeated the analyses excluding women who reported to be vaccinated, but were 
seronegative for HPV16 or HPV18. 
 
Results 
 
Study population 
In the PASSYON study, 1,198 women were eligible for HPV vaccination (born in 1993 or 
later) and included in the current study (Figure 8.1). Of these women, 666 (56%) reported 
to be vaccinated at least once and 450 (38%) reported not to be vaccinated. The remaining 
did not know or did not report their vaccination status. 467 women (39%) reported to be 
fully vaccinated. Of the women who reported to be vaccinated at least once, the majority 
(94%) was vaccinated during the catch-up campaign (birth cohorts 1993-1996). Of the total 
1,198 women included, 1,168 women (97.5%) had a genital swab taken and 1,193 women 
(99.6%) provided information about the STI consult including diagnoses of AGWs. 
In Table 8.1, the characteristics of the study population are presented, stratified by 
vaccination status. There were some differences between vaccinated and unvaccinated 
women. Vaccinated women were more often native Dutch and highly educated. They less 
often had a history of STIs and used hormonal contraceptives more often. Women 
vaccinated at least once had more partners in the past 6 months and were older at sexual 
debut, but these factors did not differ statistically significant between fully vaccinated and 
unvaccinated women. 
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Table 8.1. Characteristics of the study population and a comparison between vaccinated and unvaccinated 
women. 
 
 Total Unvaccinated Vaccinated (≥1 dose) Fully vaccinateda Unknown  
 N (%) N (%) N (%) p 
valueb 
N (%) p 
valueb 
N (%) 
Total 1198 450 666  467  82 
Age    0.47  0.69  
  16-18 years 353 (29.5) 138 (30.7) 191 (28.7)  149 (31.9)  24 (29.3) 
  19-22 years 845 (70.5) 312 (69.3) 475 (71.3)  318 (68.1)  58 (70.7) 
Migration background   <.01  <.01  
  Native Dutch 938 (78.3) 323 (71.8) 557 (83.6)  397 (85.0)  58 (70.7) 
  Not native Dutch 255 (21.3) 125 (27.8) 107 (16.1)  69 (14.8)  23 (28.0) 
Education level    <.01  <.01  
  Low/middle 386 (32.2) 176 (39.1) 174 (26.1)  126 (27.0)  36 (43.9) 
  High 809 (67.5) 274 (60.9) 491 (73.7)  341 (73.0)  44 (53.7) 
No. of sex partners, past 6 months  0.01  0.08  
  0-1 partners 349 (29.1) 151 (33.6) 169 (25.4)  127 (27.2)  29 (35.4) 
  2-3 partners 578 (48.2) 207 (46.0) 339 (50.9)  245 (52.5)  32 (39.0) 
  ≥4 partners 271 (22.6) 92 (20.4) 158 (23.7)  95 (20.3)  21 (25.6) 
No. of sex partners, lifetime   0.23  0.95  
  ≤3 partners 317 (26.5) 130 (28.9) 164 (24.6)  132 (28.3)  23 (28.0) 
  4-6 partners 370 (30.9) 140 (31.1) 215 (32.3)  150 (32.1)  15 (18.3) 
  ≥7 partners 486 (40.6) 172 (38.2) 280 (42.0)  180 (38.5)  34 (41.5) 
Age at sexual debut   0.04  0.15  
  ≤14 years 210 (17.5) 93 (20.7) 102 (15.3)  76 (16.3)  15 (18.3) 
  15-16 years 616 (51.4) 227 (50.4) 346 (52.0)  240 (51.4)  43 (52.4) 
  ≥17 years 353 (29.5) 124 (27.6) 213 (32.0)  148 (31.7)  16 (19.5) 
History of any STI  0.02  <.01  
  No 625 (52.2) 221 (49.1) 373 (56.0)  273 (58.5)  31 (37.8) 
  Yes 269 (22.5) 116 (25.8) 129 (19.4)  78 (16.7)  24 (29.3) 
  Never tested 296 (24.7) 111 (24.7) 162 (24.3)  114 (24.4)  23 (28.0) 
Current genital chlamydia/gonorrhea infection  0.93  0.57  
  No  980 (81.8) 366 (81.3) 547 (82.1)  389 (83.3)  67 (81.7) 
  Yes 212 (17.7) 80 (17.8) 118 (17.7)  77 (16.5)  14 (17.1) 
Condom use with casual partners, past 6 monthsc  0.22  0.47  
  Inconsistent 567 (47.3) 204 (45.3) 322 (48.3)  221 (47.3)  41 (50.0) 
  Consistent 356 (29.7) 134 (29.8) 207 (31.1)  145 (31.0)  15 (18.3) 
  No casual 
partners  
267 (22.3) 111 (24.7) 135 (20.3)  99 (21.2)  21 (25.6) 
History of using hormonal contraceptives  0.01  0.01  
  No 52 (4.3) 26 (5.8) 18 (2.7)  12 (2.6)  8 (9.8) 
  Yes 1125 (93.9) 416 (92.4) 641 (96.2)  448 (95.9)  68 (82.9) 
Totals vary because of missing values. 
a. Fully vaccinated women reported to be vaccinated 3 times. 
b. Comparing women vaccinated (≥1 dose) and women fully vaccinated with unvaccinated women. 
c. Inconsistent included reporting never, rarely and “sometimes I do, sometimes I do not” condom use. Consistent included reporting 
often or always condom use. 
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HPV6/11 
In total, 122 women (10%) were positive for HPV6, 18 women (1.5%) for HPV11, and 2 
women (0.2%) for both. Among unvaccinated women, 12% was positive for genital HPV6 
and/or HPV11. Among women who reported to be vaccinated (≥1 dose), this was 13% 
(Figure 8.2). After adjustment for demographics and risk behavior, the PR of women 
vaccinated (≥1 dose) was 1.03 (95% CI 0.74-1.43) relative to unvaccinated women (Table 
8.2). Of the fully vaccinated women, 11% was positive for genital HPV6 and/or HPV11. 
Comparing fully vaccinated women with unvaccinated women, the PR was 0.91 (95% CI 
0.63-1.31) adjusted for demographics and risk behavior. 
 
Anogenital warts 
In total, only 13 (1.1%) out of 1,193 vaccine-eligible women with information of the STI 
consult were diagnosed with AGWs. Among unvaccinated women, 1.3% were diagnosed 
with AGWs and among vaccinated women (≥1 dose) this was 0.9% (Figure 8.2), resulting in 
a PR of 0.67 (95% CI 0.22-2.07) (Table 8.2). Adjustment for demographics or risk behavior in 
bivariable analyses did not lead to other PRs; ranging from 0.66 adjusted for education level 
to 0.69 adjusted for number of partners in the past 6 months. Among fully vaccinated 
women, 0.9% were diagnosed with AGWs, giving a PR of 0.64 (95% CI 0.18-2.25) relative to 
unvaccinated women. Adjustment resulted in PRs ranging from 0.63 adjusted for hormonal 
contraceptives use to 0.65 adjusted for number of partners in the past 6 months. 
 
 
Figure 8.2. A) prevalence of genital HPV6 and/or HPV11 positivity and B) anogenital warts, by 
vaccination status. 
Note: * Fully vaccinated women reported to be vaccinated 3 times. Note the different scale of the y-axes. 
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Table 8.2. Prevalence and prevalence ratios of genital HPV6 and/or HPV11 positivity and anogenital 
warts by vaccination status. 
 
 N n Events 
(%) 
Crude PR  
(95% CI) 
Adjusted PR  
(95% CI)b 
Adjusted PR  
(95% CI)c 
Genital HPV6 and/or HPV11    
  Unvaccinated 438 52 (11.9) Reference Reference Reference 
  Vaccinated (≥1 dose) 649 85 (13.1) 1.10 (0.80 - 1.52) 1.04 (0.75 - 1.45) 1.03 (0.74 - 1.43) 
  Fully vaccinateda 456 52 (11.4) 0.96 (0.67 - 1.38) 0.91 (0.63 - 1.31) 0.91 (0.63 - 1.31) 
  Unknown 81 5 (6.2) 0.52 (0.21 - 1.26) 0.43 (0.16 - 1.16) 0.45 (0.17 - 1.21) 
Anogenital warts      
  Unvaccinated 447 6 (1.3) Reference - - 
  Vaccinated (≥1 dose) 665 6 (0.9) 0.67 (0.22 - 2.07) - - 
  Fully vaccinateda 466 4 (0.9) 0.64 (0.18 - 2.25) - - 
  Unknown 81 1 (1.2) 0.92 (0.11 - 7.54) - - 
a. Fully vaccinated women reported to be vaccinated 3 times. 
b. Corrected for demographic variables (age, migration background, and education level). 
c. Corrected for demographic variables (age, migration background, and education level) and risk behavior (no. of sex partners 
in the past 6 months, age at sexual debut, history of any STI, and history of hormonal contraceptives use). 
 
Table 8.3 shows the genital HPV types that were found among women diagnosed with 
AGWs, by vaccination status. All women with AGWs were HPV positive and all 6 vaccinated 
women were positive for HPV6. Of the 6 unvaccinated women, 3 were positive for HPV6. 
HPV11 was not found among women diagnosed with AGWs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8.3. Genital HPV types of women with anogenital warts, by vaccination status. 
 
Sample Self-reported vaccination status Genital HPV types isolated 
1 Unvaccinated 6, 18, 31, 53, 56, 59 
2 Unvaccinated 6, 31, 33, 52 
3 Unvaccinated 6, 39, 51, 56 
4 Unvaccinated 16 
5 Unvaccinated 31 
6 Unvaccinated 51 
7 Fully vaccinateda 6, 51, 66 
8 Fully vaccinateda 6, 51 
9 Fully vaccinateda 6 
10 Fully vaccinateda 6 
11 Vaccinated at least once 6 
12 Vaccinated at least once 6 
13 Unknown  31, 52, 58 
a. Fully vaccinated women reported to be vaccinated 3 times. 
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Sensitivity analyses 
Of the total study population, 43% had serum available for HPV antibody testing. Of the 268 
women who reported to be vaccinated (≥1 dose) with serum available, only 11 (4.1%) were 
seronegative for either HPV16 or HPV18. Excluding these 11 women from the analyses did 
not change the results. Of the 194 women who reported to be fully vaccinated with serum 
available, 8 (4.1%) were seronegative for HPV16 or HPV18. Excluding these 8 women from 
the analyses comparing fully vaccinated with unvaccinated women did also not change the 
results (Supplementary Table 8.1). 
 
Discussion 
 
We estimated the effect of the HPV16/18 vaccine on genital HPV6 and/or HPV11 positivity 
and AGWs among vaccine-eligible women attending STI clinics in the Netherlands. We 
observed no cross-protective effect of the 2vHPV vaccine on genital HPV6/11 positivity and 
a non-significant partially protective effect on AGWs. 
To our knowledge, this is the first study to directly estimate the protective effect of the 
2vHPV vaccine on both genital HPV6/11 positivity and AGWs among vaccine-eligible 
women. However, we do acknowledge some limitations. First, we had very low numbers of 
AGWs in our study population leading to insufficient power to robustly assess an effect of 
vaccination on AGW diagnoses. The low number of AGWs is partly because most AGWs in 
the Netherlands are diagnosed by the general practitioner [18]. Another reason is that 
among women, physical examination and thus diagnosis of AGWs is performed in case of 
reported symptoms only. Likely, some diagnoses of AGWs were missed in our study and the 
true prevalence of AGWs was probably higher. While it is unlikely that the effect estimate 
is biased for this reason, as the rate of underdiagnoses is probably not related to vaccination 
status, the low occurrence of AGWs influenced the precision of our effect estimate. Second, 
vaccination status was self-reported, which is prone to recall bias. However, only 4% of the 
women who reported to be vaccinated were seronegative for HPV16 or HPV18. We 
performed sensitivity analyses, excluding women who likely incorrectly reported to be 
vaccinated, but this did not change the results. Third, there were some differences between 
vaccinated and unvaccinated women in our study. Vaccinated women were often native 
Dutch and highly educated, which is in line with earlier findings [19]. Moreover, we 
observed some differences in sexual behavior between vaccinated and unvaccinated 
women. Although there is no evidence that HPV vaccination leads to other/higher sexual 
risk behavior [20], it is possible that sexual behavior was indirectly associated with 
vaccination, meaning that girls who chose to get vaccinated were a different population 
than girls who chose not to get vaccinated, and therefore developed another sexual risk 
8
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profile. While we adjusted for demographics and risk behavior, we cannot rule out residual 
confounding. Last, our study population consisted of women who visited the STI clinic 
(suggesting high sexual risk behavior) and who were primarily vaccinated during the catch-
up campaign. Based on the reported age at sexual debut in the questionnaire and the 
scheduled vaccinations by birth cohort [19], about 7.7%-25% of the vaccinated women in 
our study were possibly already exposed to HPV before vaccination. 
There is a possibility that the 2vHPV vaccine offers protection against AGWs, whilst not 
providing cross-protective effectiveness against HPV6/11. In many AGWs, multiple HPV 
types have been found, including types 16 and 18 [21, 22]. HPV16/18 could play a role in 
the development of AGWs, either indirectly by interaction with HPV6/11 or directly. Indeed, 
in some AGWs HPV16 was pointed out to be the probable type causing the wart [23, 24]. 
Although surface swabbing does not necessarily indicate the causative HPV type [23], in our 
study we found 1 women with AGWs who was positive for HPV16 only. 
HPV6 and HPV11 (both from the α-10 species), are phylogenetically not closely related 
to the vaccine types HPV16 (α-9 species) and HPV18 (α-7 species) [25]. Nevertheless, in the 
PATRICIA trial, a vaccine efficacy of the 2vHPV vaccine of 35% against 6-month persistent 
HPV6/11 infection was reported among women who were HPV seronegative at baseline [6]. 
Adjusted for demographics and risk behavior, we calculated a PR of 0.91 (95% CI 0.63-1.31) 
against HPV6/11 positivity for fully vaccinated women. This estimate corresponds to a VE 
of 9% (95% CI −31% to 37%) [26]. Although this suggests no effect, the confidence interval 
includes the 35% efficacy reported from the vaccine trial. In our cross-sectional study, we 
did not have information on duration of infection hampering a direct comparison. 
The cross-protective effect of the 2vHPV vaccine on HPV6/11 positivity has so far not 
been replicated in post-vaccine surveillance studies. In England, where the 2vHPV vaccine 
was used until 2012, the prevalence of HPV6 and/or HPV11 among 16- to 18-year-old 
women increased from 5.8% in the pre-vaccination period to 8.3% in the post-vaccination 
period [27]. In Scotland, where the 2vHPV vaccine was also used until 2012, there were no 
differences in HPV6/11 positivity among vaccinated and unvaccinated women who 
underwent their first cervical screening [28]. However, these analyses were unadjusted for 
confounders and not all women were eligible for vaccination. 
Interestingly, we calculated a crude PR of 0.64 for AGWs for fully vaccinated women, 
corresponding to a VE of 36%. Although non-significant, this point estimate is almost 
identical to the VE against AGWs calculated by Howell-Jones and colleagues in an ecological 
study in the United Kingdom (34%) [7]. However, in a study conducted in the Czech 
Republic, no effect of the 2vHPV vaccine on AGWs prevalence was observed among 16- to 
40-year-old women [29]. 
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In conclusion, our study neither supports nor excludes cross-protection from the 2vHPV 
vaccine against HPV6/11. We also could not confirm a protective effect of the 2vHPV 
vaccine against AGWs, 6 years after introduction of vaccination. For a more definite 
outcome, larger and longer duration studies would be needed. We are currently working 
on a research proposal to investigate the effect of the 2vHPV vaccine on AGWs using data 
from a large general practice network in the Netherlands where more diagnoses of AGWs 
are anticipated. 
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Supplementary information to Chapter 8 
 
Supplementary Table 8.1. Sensitivity analyses: prevalence ratios of genital HPV6 and/or HPV11 
positivity and anogenital warts by vaccination status, excluding women reported to be vaccinated 
without an HPV16 or HPV18 antibody response. 
 
 Crude PR (95% CI) aPR (95% CI)b aPR (95% CI)c 
Genital HPV6 and/or HPV11    
  Unvaccinated Reference Reference Reference 
  Vaccinated (≥1 dose)a 1.07 (0.77 - 1.48) 1.00 (0.72 - 1.40) 0.99 (0.71 - 1.38) 
  Fully vaccinateda 0.92 (0.64 - 1.33) 0.86 (0.60 - 1.25) 0.86 (0.59 - 1.26) 
  Unknown 0.52 (0.21 - 1.26) 0.43 (0.16 - 1.16) 0.46 (0.17 - 1.23) 
Anogenital warts    
  Unvaccinated Reference - - 
  Vaccinated (≥1 dose)a 0.68 (0.22 - 2.11) - - 
  Fully vaccinateda 0.65 (0.18 - 2.29)   
  Unknown 0.92 (0.11 - 7.54) - - 
a. Women who were seronegative for HPV16 or HPV18 were excluded from the analyses. Fully vaccinated reported to be 
vaccinated 3 times. 
b. Corrected for demographic variables (age, migration background, and education level). 
c. Corrected for demographic variables (age, migration background, and education level) and risk behavior (no. of sex 
partners in the past 6 months, age at sexual debut, history of any STI, and history of hormonal contraceptives use). 
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Summary 
 
An infection with sexually transmitted human papillomavirus (HPV) is usually asymptomatic 
but can sometimes cause anogenital warts (AGWs) and various anogenital and head-and-
neck cancers in men and women. Girls-only bivalent HPV (2vHPV) vaccination was 
introduced in the Netherlands in 2009 to prevent the most oncogenic HPV types 16 and 18. 
After implementation of vaccines in national immunization programs (NIPs), observational 
studies are needed to assess the (long-term) effects of vaccination on the occurrence of the 
infection in a population at large. 
 
Chapter 1 provides an introduction to HPV, HPV-related diseases, the available HPV 
vaccines, and the implementation of HPV vaccination in the Netherlands. Moreover, it 
describes a theoretical framework by which different effects of vaccination can be 
distinguished and how these effects can be measured in post-vaccine surveillance. We 
highlight the direct vaccine effectiveness (VE) and impact of vaccination. The VE is related 
to the direct protection of the vaccine itself in a vaccinated person (individual-level effect), 
while the impact is related to the effects of a vaccination program in the total population 
(population-level effects). To measure the different effects of HPV vaccination, the 
PASSYON (PApillomavirus Surveillance among STI clinic YOungsters in the Netherlands) 
study was set-up. In this cross-sectional study that started in 2009 and was repeated every 
other year, 16- to 24- year-old men and women visiting sexual health centers (SHCs) 
throughout the Netherlands were tested for type-specific HPV positivity. The studies 
described in this thesis aimed to measure the VE of 2vHPV vaccination against HPV positivity 
and AGWs and to measure the impact of the HPV vaccination program in the Netherlands 
on the HPV prevalence. 
 
Part 1: Direct vaccine effectiveness against HPV positivity 
The first part of this thesis focuses on the VE of 2vHPV vaccination against HPV positivity, 
among women in the PASSYON study who had been eligible for HPV vaccination in the 
Netherlands, i.e. women born in 1993 or later. In Chapter 2, we estimated the VE of the 
2vHPV vaccine against genital oncogenic HPV positivity. We compared HPV positivity 
between self-reported vaccinated (≥1 dose) and unvaccinated women, and estimated VE by 
a logistic mixed model. The adjusted pooled VE against the vaccine types HPV16/18 was 
high (90%, 95% confidence interval [CI] 82%-94%). Moreover, we calculated significant VE 
against non-vaccine types HPV45 (91%), HPV35 (57%), HPV31 (50%), and HPV52 (37%). In 
Chapter 3, we updated the analyses of Chapter 2 using more data and including low-risk 
HPV types. Moreover, we evaluated the VE against type-specific HPV positivity as a function 
of phylogenetic distance to vaccine types HPV16/18. 2vHPV was predicted to provide partial 
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cross-protection against HPV types 31, 33, 35, 45, 52, and possibly 58; all oncogenic types 
with close phylogenetic relationships to HPV16 or HPV18. Cross-protection and protection 
against HPV16/18 was sustained up to 8 years post-vaccination. In Chapter 4, type-specific 
VE against HPV positivity at the anal site was measured using the same methods as in 
Chapter 2. VE against the vaccine types HPV16/18 was high (90%, 95% CI, 63%-97%). 
Moreover, we calculated significant VE against non-vaccine types HPV45 (100%) and HPV31 
(73%). Type-specific VE against anal HPV correlated well with VE against genital HPV 
(Spearman’s ρ = 0.76), suggesting comparable effectiveness of 2vHPV vaccination against 
genital and anal infections. 
 
Part 2: Population-level impact on HPV positivity 
The second part of this thesis focuses on the impact of the HPV vaccination program in the 
Netherlands on the HPV prevalence, using data from the PASSYON study. In Chapter 5, we 
assessed trends in HPV16 and HPV18 prevalence among women and heterosexual men, 
using data up to 6 years post-vaccination. We compared the genital post-vaccination HPV 
prevalence with the pre-vaccination prevalence (year 2009) using Poisson GEE models. We 
observed significantly decreasing trends in the HPV16/18 prevalence among women (from 
23% pre-vaccination to 15% in 2015) and heterosexual men (from 17% pre-vaccination to 
11% in 2015), but not among unvaccinated women. Of the heterosexual men with a steady 
partner, the HPV16/18 prevalence was lower among those men whose steady partner had 
been vaccine-eligible in the NIP. The results strongly suggest that heterosexual men benefit 
from herd protection from girls-only vaccination. In Chapter 6, we updated the analyses of 
Chapter 5 and assessed trends in prevalence of 25 HPV types in the period 2009-2017 (up 
to 8 years post-vaccination). The HPV16/18 prevalence decreased among women (with 
12.6% annually), heterosexual men (with 13.0% annually), and unvaccinated women (with 
5.4% annually). Moreover, decreases in HPV31 and HPV45 were observed among women 
and heterosexual men. Increases were observed in HPV56 among women and in HPV52 
among unvaccinated women. The results suggest herd effects among heterosexual men for 
vaccine and cross-protective HPV types. Additionally, the results suggest second-order herd 
effects for the vaccine types among unvaccinated women. In Chapter 7, we studied possible 
herd effects among men who have sex with men (MSM), by assessing trends in HPV 
prevalence in the period 2009-2017. No declining trends in penile or anal HPV prevalence 
were observed, indicating that MSM are unlikely to benefit largely from herd effects from 
girls-only vaccination. Moreover, in this chapter we studied prior exposure to HPV among 
MSM, by assessing the presence of HPV DNA at the anal and penile site and presence of 
HPV antibodies. The majority of the MSM were HPV DNA negative at the penile as well as 
the anal site for all types included in the bivalent (79%), quadrivalent (62%), and nonavalent 
vaccine (53%). Among MSM who were HPV16/18 and HPV16/18/31/33/45/52/58 DNA 
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negative, 82% and 71% were also seronegative for the respective types. Because many MSM 
were vaccine-type DNA negative and seronegative, vaccination of young MSM visiting SHCs 
could still be beneficial. 
 
Part 3: Direct vaccine effectiveness against anogenital warts 
The third part of this theses focuses on the VE of 2vHPV vaccination against AGWs among 
women who had been eligible for HPV vaccination in the Netherlands. In Chapter 8, we 
studied the effect of the 2vHPV vaccine on genital HPV6/11 positivity and AGWs, using data 
from the PASSYON study. Prevalence of HPV6 and/or HPV11 and AGWs were compared 
between self-reported vaccinated and unvaccinated women by log-binomial regression 
analysis. We observed no cross-protective effect of the 2vHPV vaccine on genital HPV6/11 
positivity (VE=9%, 95% CI −31%-37%) and a non-significant partially protective effect against 
AGWs (VE=36%, 95% CI −107%-78%). In Chapter 9 we assessed the effect of 2vHPV 
vaccination on AGWs using data from general practices, where the vast majority of the 
AGWs are being diagnosed in the Netherlands. By linking general practice data to the Dutch 
national immunization registry, we performed a retrospective registry-based open cohort 
study. Adjusted incidence rate ratios (aIRRs) were estimated using Poisson regression with 
vaccination status as a time-dependent exposure. AGW incidence was lower after ≥1 dose 
versus 0 doses (aIRR 0.75, 95% CI 0.64-0.88), which corresponds to a VE of 25%. The effect 
of vaccination was stronger after full vaccination (VE=28%) and for women who were 
offered vaccination at 12-13 years of age (VE=31%). Although we were unable to adjust for 
sexual risk behavior in this study, the results seem to suggest that 2vHPV vaccination 
partially protects against AGWs. 
 
Last, in Chapter 10 the main findings of this thesis are summarized and discussed. Future 
perspectives for measuring the individual- and population-level effects of HPV vaccination 
are given, keeping in mind upcoming changes in the HPV vaccination program, like a lower 
age at vaccine-initiation, sex-neutral vaccination, and multi-cohort catch-up vaccination. 
The results of this thesis add to the growing body of evidence on the highly beneficial effects 
of HPV vaccination, on an individual- as well as a population-level. The PASSYON study has 
proven to be valuable in measuring several aspects of HPV vaccination effects and should 
be continued to keep on monitoring the effects of HPV vaccination following upcoming 
changes in the program. 
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Nederlandse samenvatting 
 
Een infectie met het seksueel overdraagbare humaan papillomavirus (HPV) verloopt in de 
meeste gevallen asymptomatisch, maar kan in sommige gevallen leiden tot anogenitale 
wratten (AGW), anogenitale kanker, en hoofd-hals kanker in mannen en vrouwen. In 
Nederland wordt sinds 2009 HPV vaccinatie aangeboden aan meisjes. Hiervoor wordt 
gebruik gemaakt van het bivalente HPV (2vHPV) vaccin dat bescherming biedt tegen HPV16 
en HPV18; de HPV types die de meeste kanker veroorzaken. Na de invoering van vaccinatie 
in het Rijksvaccinatieprogramma (RVP) zijn observationele studies nodig om het (lange 
termijn) effect van vaccinatie te meten op het voorkomen van de infectie in de algehele 
populatie. 
 
Hoofdstuk 1 geeft een introductie over HPV, HPV-gerelateerde ziektes, de verschillende 
HPV vaccins, en de toevoeging van HPV aan het RVP in Nederland. Daarnaast wordt in 
Hoofdstuk 1 een theoretisch kader beschreven waarmee verschillende effecten van 
vaccinatie kunnen worden onderscheiden en hoe deze effecten kunnen worden gemeten 
in post-vaccinatie surveillance. We bespreken de directe vaccin effectiviteit (VE) en de 
impact van vaccinatie. De VE is gerelateerd aan de directe bescherming van het vaccin zelf 
voor een gevaccineerd persoon (individueel effect). De impact is gerelateerd aan de 
effecten van het gehele vaccinatieprogramma in de bevolking (populatie-effect). Om de 
verschillende HPV vaccinatie-effecten te meten, werd in 2009 de PASSYON (PApillomavirus 
Surveillance among STI clinic YOungsters in the Netherlands) studie opgezet. In deze studie 
wordt eens in de 2 jaar een dwarsdoorsnedeonderzoek uitgevoerd naar de prevalentie van 
type-specifieke HPV bij 16 t/m 24 jarige bezoekers van de centra seksuele gezondheid (CSG). 
Het doel van de studies in dit proefschrift was het meten van de VE van het 2vHPV vaccin 
tegen HPV positiviteit en AGW en het meten van de impact van het HPV 
vaccinatieprogramma in Nederland op de HPV prevalentie. 
 
Deel 1: Directe vaccinatie effectiviteit tegen HPV positiviteit 
In het eerste deel van dit proefschrift wordt de VE tegen HPV positiviteit onderzocht binnen 
vrouwen die in aanmerking kwamen voor HPV vaccinatie in Nederland, namelijk vrouwen 
geboren in 1993 of later. Er werd gebruik gemaakt van data van de PASSYON studie. In 
Hoofdstuk 2 hebben we de VE berekend tegen genitale oncogene HPV types. Dit hebben 
we gedaan door de HPV prevalentie te vergelijken tussen vrouwen die zelf rapporteerden 
gevaccineerd (≥1 dosis) of niet gevaccineerd te zijn. De VE was hoog tegen de vaccintypes 
HPV16/18 (90%, 95% betrouwbaarheidsinterval [BI] 82%-94%). Daarnaast was er 
significante kruisbescherming tegen niet-vaccintypes, namelijk 91% tegen HPV45, 57% 
tegen HPV35, 50% tegen HPV31, en 37% tegen HPV52. In Hoofdstuk 3 hebben we de 
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analyses van Hoofdstuk 2 herhaald met meer gegevens en met niet-oncogene HPV types. 
Daarnaast hebben we de type-specifieke VE afgezet tegen de fylogenetische afstand naar 
de vaccintypes HPV16/18. De analyses wezen erop dat het 2vHPV vaccin gedeeltelijke 
bescherming biedt tegen HPV types 31, 33, 35, 45, 52, en mogelijk 58. Dit zijn allemaal 
oncogene HPV types die nauw verwant zijn aan HPV16 of HPV18. De kruisbescherming en 
de bescherming tegen de vaccintypes bleven hoog tot 8 jaar na vaccinatie. In Hoofdstuk 4 
is de type-specifieke VE gemeten tegen anale HPV. De VE was hoog tegen de vaccintypes 
HPV16/18 (90%, 95% BI 63%-97%). Daarnaast was er significante kruisbescherming tegen 
HPV45 (VE=100%) en tegen HPV31 (VE=73%). De type-specifieke VE tegen anale HPV 
correleerde goed met de VE tegen genitale HPV (Spearman’s ρ = 0,76), wat wijst op 
vergelijkbare effectiviteit tegen anale als tegen genitale HPV infectie. 
 
Deel 2: Populatie impact op het voorkomen van HPV 
In het tweede deel van dit proefschrift wordt de impact van het HPV vaccinatieprogramma 
onderzocht op de prevalentie van HPV in de populatie. Hiervoor werden de gegevens van 
de PASSYON studie gebruikt. In Hoofdstuk 5 zijn de trends over tijd in de prevalentie van 
HPV16 en HPV18 onderzocht, tot 6 jaar na de invoering van vaccinatie. De HPV16/18 
prevalentie daalde bij vrouwen (van 23% in 2009 naar 15% in 2015) en heteroseksuele 
mannen (van 17% in 2009 naar 11% in 2015), maar niet bij ongevaccineerde vrouwen. Bij 
heteroseksuele mannen wiens vaste partner in aanmerking was gekomen voor HPV 
vaccinatie, was de HPV16/18 prevalentie lager dan bij heteroseksuele mannen wiens vaste 
partner niet in aanmerking was gekomen voor HPV vaccinatie. De resultaten wijzen op 
groepsbescherming bij heteroseksuele mannen door HPV vaccinatie van meisjes. In 
Hoofdstuk 6 zijn de analyses van Hoofdstuk 5 uitgebreid met gegevens van 25 HPV types en 
tot 8 jaar na vaccinatie. In de periode 2009-2017 daalde de HPV16/18 prevalentie ieder jaar 
met 12,6% bij vrouwen en met 13,0% bij heteroseksuele mannen. Met data tot 8 jaar na 
vaccinatie daalde de HPV16/18 prevalentie ook bij ongevaccineerde vrouwen (met 5,4% per 
jaar). Daarnaast daalde de HPV31 en HPV45 prevalentie bij vrouwen en heteroseksuele 
mannen en steeg de HPV56 prevalentie bij vrouwen en de HPV52 prevalentie bij 
ongevaccineerde vrouwen. De resultaten wijzen op groepsbescherming bij heteroseksuele 
mannen voor HPV16/18 en de HPV types waarvoor kruisbescherming is aangetoond. 
Bovendien wijzen de resultaten erop dat er ook groepsbescherming is voor de vaccintypes 
bij ongevaccineerde vrouwen. In Hoofdstuk 7 hebben we onderzoek gedaan naar mogelijke 
groepsbescherming bij mannen die seks hebben met mannen (MSM). In de periode 2009-
2017 was er geen daling in de HPV prevalentie bij MSM. Dit wijst erop dat MSM niet of 
nauwelijks baat hebben bij HPV vaccinatie van meisjes. Daarnaast hebben we in dit 
hoofdstuk gekeken naar eerdere blootstelling aan HPV bij MSM, door de aanwezigheid van 
HPV DNA op de penis en in de anus, en de aanwezigheid van HPV antistoffen te bestuderen. 
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Het merendeel van de MSM testte negatief voor HPV DNA; 79% testte negatief voor alle 
types in het 2vHPV vaccin, 62% testte negatief voor alle types in het 4vHPV vaccin, en 53% 
testte negatief voor alle types in het 9vHPV vaccin. Van de MSM die negatief testten voor 
HPV16/18 en HPV16/18/31/33/45/52/58 DNA, had 82% respectievelijk 71% ook geen 
meetbare HPV antistoffen tegen deze types. Omdat veel MSM negatief testten voor HPV 
DNA en HPV antistoffen, zou HPV vaccinatie van jonge MSM die de CSG bezoeken zinvol 
kunnen zijn. 
 
Deel 3: Directe vaccinatie effectiviteit tegen anogenitale wratten 
In deel 3 van dit proefschrift wordt de VE tegen AGW onderzocht binnen vrouwen die in 
aanmerking kwamen voor HPV vaccinatie in Nederland. In Hoofdstuk 8 is hiervoor gebruik 
gemaakt van de PASSYON studie. We hebben gekeken naar het effect van het 2vHPV vaccin 
tegen AGW en tegen genitale HPV6/11, de belangrijkste types die AGW veroorzaken. In 
deze studie was er geen effect van 2vHPV vaccinatie tegen HPV6/11 (VE=9%, 95% BI −31%-
37%). Het effect van 2vHPV vaccinatie tegen AGW was niet statistisch significant (VE=36%, 
95% BI −107%-78%). In Hoofdstuk 9 hebben we onderzoek gedaan naar het effect van 
2vHPV vaccinatie tegen AGW door gebruik te maken van huisartsendata, omdat hier 
verreweg de meeste AGW diagnoses worden gesteld in Nederland. Door de gegevens van 
huisartsen te koppelen aan het Nederlandse vaccinatieregister, konden we de AGW 
incidentie vergelijken tussen 2vHPV gevaccineerde en niet-gevaccineerde vrouwen. The 
AGW incidentie was lager na ≥1 dosis vaccinatie ten opzichte van geen vaccinatie (VE=25%, 
95% BI 12%-36%). De VE was groter na volledige vaccinatie met 2 of 3 doses (VE=28%) en 
wanneer de vrouwen 12-13 jaar oud waren op het moment dat ze gevaccineerd werden 
(VE=31%). Hoewel we in deze studie niet konden corrigeren voor seksueel risicogedrag, lijkt 
het op basis van deze resultaten dat 2vHPV vaccinatie deels bescherming biedt tegen AGW.  
 
Tot slot, in Hoofdstuk 10 worden de belangrijkste resultaten van dit proefschrift 
samengevat en bediscussieerd. Daarnaast werpt dit hoofdstuk een blik op de toekomst voor 
het meten van individuele en populatie-effecten van HPV vaccinatie, rekening houdend met 
de aanstaande veranderingen in het HPV vaccinatieprogramma, zoals het verlagen van de 
leeftijd van de start van vaccinatie, vaccinatie van zowel jongens als meisjes, en de 
mogelijkheid tot vaccinatie op latere leeftijd. De studies in dit proefschrift dragen bij aan de 
wetenschappelijke onderbouwing van de effectiviteit van het HPV vaccinatieprogramma, 
zowel op individueel als op populatieniveau. De PASSYON studie is waardevol gebleken in 
het meten van verschillende vaccinatie-effecten van HPV vaccinatie en kan ook in de 
toekomst waardevol zijn in het meten van de effecten van veranderingen in het 
programma. 
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Valorization 
 
Of all infectious diseases, human papillomavirus (HPV) infections are associated with the 
highest disease burden in the Netherlands. Sexually transmitted HPV can cause anogenital 
warts, recurrent respiratory papillomatosis, and various anogenital and head-and-neck 
cancers in both men and women. Cancers with an established HPV etiology include cervical, 
vaginal, vulvar, anal, and oropharyngeal cancer in women; and penile, anal, and 
oropharyngeal cancer in men. The estimated yearly number of cancer diagnoses attributed 
to HPV in the Netherlands was over twelve hundred in the period 2008-2017 and almost 
fifteen hundred in 2019. The estimated yearly number of anogenital warts diagnoses was 
over forty-three thousand in the period 2017-2018. Sexually transmitted HPV infections are 
very prevalent in the general population and the vast majority of the sexually active people 
will acquire an HPV infection at least once during lifetime. Infections are not restricted to 
specific groups at high risk of infection, making the prevention of HPV infections of public 
health importance. Prophylactic vaccination is viewed to be best possible prevention 
strategy and historically vaccination programs have achieved major public health benefits. 
Prophylactic HPV vaccination was introduced in the Netherlands in 2009 for young girls 
using the bivalent HPV vaccine that targets the most oncogenic types HPV16 and HPV18. 
Each year all 12-year-old girls are invited for HPV vaccination. From 2021 onwards, even the 
entire cohort of boys and girls will be invited for HPV vaccination annually. This highlights 
that the effects of HPV vaccination are of societal relevance. In this thesis, we assessed the 
individual- as well as the population-level effects of HPV vaccination on HPV positivity and 
anogenital warts. 
At the time of HPV vaccine introduction in the Netherlands in 2009, there were some 
uncertainties regarding the effectiveness of HPV vaccination, for example about the direct 
vaccine effectiveness in a “real-life” setting among the target population of 
(pre)adolescents, the duration of protection, the level of cross-protection, or the possible 
occurrence of type-replacement. This thesis has given insight into many of these questions. 
Lessons learned from this thesis, that are relevant for public health, include: 
 
- The vaccine effectiveness of bivalent HPV vaccination is high against the most 
oncogenic vaccine-targeted HPV types 16 and 18; 
- There is relevant cross-protection against non-vaccine oncogenic HPV types; 
- The vaccine effectiveness is high at least up to 7/8 years after vaccination, with no 
signs of reduced effectiveness over time; 
- The vaccine effectiveness against anal HPV positivity is comparably high as against 
genital HPV positivity; 
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- The HPV vaccination program has reduced the transmission of HPV in the 
population, leading to less infections among those unvaccinated, with the 
exception of men who have sex with men; 
- There are no indications for type-replacement up to 8 years after the introduction 
of the HPV vaccination program; 
- The bivalent HPV vaccine might provide partial protection against anogenital 
warts. 
 
The lessons learned in this thesis have already contributed to the intended changes in the 
HPV vaccination policy. The Dutch Health Council valued our research in recommending 
about the new HPV vaccination program. For example, the sustained high VE, was taken 
into consideration in the recommendation to lower the age at which vaccination should be 
offered from 12 to 9 years of age. Moreover, our finding that herd effects are measurable 
within 6 to 8 years after HPV vaccine introduction, was an important observation for the 
Health Council to recommend extension of the vaccination program to boys. They viewed 
our observed herd effects as evidence that adding boys to the program will not only result 
in the individual prevention of boys themselves, but will also add to the protection of 
unvaccinated women through herd protection. 
The results of this thesis are also relevant for the choice of vaccine to be used in the HPV 
vaccination program, as demonstrated by the acknowledgement of our results in the 
tendering procedure of 2020 to contract an HPV vaccine for the restructured vaccination 
program starting in 2021. Up to date, there are 3 prophylactic vaccines that target HPV; a 
bivalent vaccine that targets the most oncogenic HPV types 16 and 18; a quadrivalent 
vaccine that targets HPV types 6 and 11 (that cause the majority of the anogenital warts) in 
addition to HPV types 16 and 18; a nonavalent vaccine that targets the oncogenic HPV types 
31, 33, 45, 52, and 58 in addition to HPV types 16, 18, 6, and 11. The 3 vaccines are all 
licensed for men and women and indicated to prevent genital (cervical, vulvar, and vaginal) 
and anal (pre)cancers caused by the HPV vaccine types. The quadrivalent and nonavalent 
HPV vaccines are also indicated to prevent anogenital warts. The cross-protection of the 
bivalent vaccine against non-vaccine oncogenic HPV types as found in our studies is higher 
than that generally observed for the quadrivalent vaccine, making the bivalent vaccine 
superior in terms of cancer prevention. The cross-protection of the bivalent vaccine also 
diminishes the difference in cancer prevention between the bivalent and the nonavalent 
vaccine. The differences between the bivalent and nonavalent vaccine are even further 
diminished with the apparent partial protection of the bivalent HPV vaccine against 
anogenital warts. Taken together, the results of this thesis underscore the necessity to 
conduct proper cost-effectiveness analyses to compare the different HPV vaccines, taking 
into account cross-protection against the different HPV types and possible protection 
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against anogenital warts. Because the HPV vaccination program is publicly funded, it is 
important to have good value for money. 
By studying the individual- and population-level effects of HPV vaccination, we 
demonstrated the benefits of HPV vaccination. We estimated a vaccine effectiveness of 90% 
against the most oncogenic HPV types HPV16/18 and a reduction of 13% each year in the 
HPV16/18 prevalence among women and heterosexual men. With the observed cross-
protection and protection against anal HPV, the benefits of bivalent HPV vaccination even 
go beyond initial indications of the registration of the vaccine. These results are useful to 
create public awareness about HPV infections and the importance of HPV vaccination, for 
example via media attention. These results are also useful to inform the general public and 
health care providers. Previous studies indicated that health care providers play an 
important role in the decision-making process to vaccinate. Informing both the general 
public and health care providers about the effectiveness of HPV vaccination, could possibly 
increase the HPV vaccination coverage. Currently, there is a lot of misinformation about 
HPV vaccination, mainly concerning side effects. Moreover, there are misperceptions about 
the effectiveness of HPV vaccination. The bivalent HPV vaccine that is used in the 
Netherlands might be conceived to protect only against the 2 HPV vaccine types, while 
broad cross-protection against multiple HPV types has been clearly demonstrated in our 
studies as well as in others. Another misperception is that HPV vaccination is believed to be 
ineffective once someone has had sexual intercourse. Our results show it is not necessarily 
too late to vaccinate after sexual debut. Even in a highly sexually active population of visitors 
of sexual health centers, many individuals seem to be still unexposed to the HPV vaccine 
types, indicating the vaccine effectiveness could be high. 
The results of this thesis give rise to targeted HPV vaccination of men who have sex with 
men (MSM) visiting sexual health centers, as we showed that MSM have not yet benefitted 
from the girls-only vaccination program to a large extent and many MSM seem to be 
susceptible to HPV when visiting the sexual health center. An HPV vaccination program 
targeting MSM has the potential to have a major impact on the HPV prevalence among 
MSM who are at high risk for anal and oropharyngeal cancer; with the current girls-only 
HPV vaccination program about 566 life years are lost due to vaccine-preventable HPV-
related cancer among MSM each year. However, the HPV vaccine effectiveness in the target 
population of MSM visiting sexual health centers is unknown. This thesis has contributed to 
an innovative ZonMw research proposal to assess the vaccine effectiveness among MSM 
aged ≤26 years who visit the sexual health center of Amsterdam, HPV-ECSTASE (Human 
Papillomavirus Vaccine EffeCtiveness STudy Among men who have SEx with men). Results 
of this study can inform policy on the desirability to roll out a targeted vaccination program 
nationally. 
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Next to the lessons learned about the vaccine effectiveness among women and the 
population-level impact of the current girls-only HPV vaccination program, we also provided 
a framework to monitor the effects of the upcoming changes in the HPV vaccination 
program. Because in the PASSYON study the HPV prevalence is measured among both men 
and women, the PASSYON study can be used the measure the vaccine effectiveness among 
men after sex-neutral vaccination is implemented. Moreover, in the PASSYON study there 
is information available of the HPV prevalence from pre- girls-only vaccination and pre- sex-
neutral vaccination, enabling to study the additional population-level impact after switching 
to a sex-neutral vaccination program. With the unique design of the PASSYON study, 
different effects of the upcoming changes in the HPV vaccination program can be studied. 
In close collaboration with policy makers and observations from other studies, this research 
can direct the future of the HPV vaccination program in the Netherlands. 
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List of abbreviations 
 
2v  Bivalent 
4v  Quadrivalent 
9v  Nonavalent 
AA Amino acid 
ATC Anatomical Therapeutic Chemical Classification System 
AGW Anogenital wart 
aIRR Adjusted incidence rate ratio 
aOR Adjusted odds ratio 
aPR Adjusted prevalence ratio 
AUC Area under the curve 
BP Buffer period 
CI Confidence interval 
CIN Cervical intraepithelial neoplasia 
DALY Disability-adjusted life-year 
DEIA DNA enzymelinked immunoassay 
GEE Generalized estimating equation 
GP General practitioner 
HPV Human papillomavirus 
Hr High-risk 
ID Identifier 
ICPC International Classification of Primary Care 
ITT Intention-to-treat 
LCR Long control region 
LiPA Line probe assay 
Lr Low-risk 
LU Luminex Units 
MSM Men who have sex with men 
NIP National immunization program 
Nivel-PCD Nivel Primary Care Database 
OR Odds ratio 
PASSYON PApillomavirus Surveillance among STI clinic YOungsters in the 
Netherlands 
PCR Polymerase chain reaction 
PP Per-protocol 
PR Prevalence ratio 
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Præventis National immunization registry 
RCT Randomized controlled trial 
ROC Receiver operating characteristic 
SHC Sexual health center 
STI Sexually transmitted infection 
VE Direct vaccine effectiveness 
VLP Virus-like particle 
WGS Whole-genome sequences 
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